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ABSTRACT 
Multiple sclerosis (MS) is a chronic, neuroinflammatory demyelinating disease of the 
central nervous system (CNS). Typical white matter lesions (WML) in MS are 
surrounded by areas of non-demyelinated normal appearing white matter (NAWM) with 
complex subtle pathology, including blood brain barrier (BBB) dysfunction, axonal 
damage and glial activation. Astrocytes, the most abundant cell type within the CNS, 
are known to support neuronal function, maintain homeostasis within the CNS and 
regulate neurotransmission. Yet conversely, can promote an inflammatory response, 
inhibit myelin repair and support the production of autoreactive T cells in MS. This 
thesis aimed to investigate the transcriptomic and proteomic profile of astrocytes in MS 
NAWM to determine whether specific astroglial changes exist, which may 
contribute/prevent disease progression in MS. 
Initial data presented in this thesis demonstrated a change in astrocyte phenotype within 
different pathological regions of the CNS in MS, as observed by the distinct 
immunoprofile of a variety of known astrocyte markers. Being able to isolate cell types 
from human tissue is fundamental in beginning to define a particular cell’s role in 
disease pathogenesis. An immuno-laser capture microdissection (LCM) method was 
developed to enable the isolation of glial cells from human post mortem (PM) CNS 
tissue. In the current study glial fibrillary acidic protein (GFAP) positive astrocytes 
were isolated from MS NAWM and control WM via immuno-LCM and microarray 
analysis completed to compare their transcriptome. Significantly differentially 
expressed genes were associated with the immune response, cell signaling, cytoskeletal 
changes and regulation of homeostasis which relate to the distinct roles of astrocytes. 
Interestingly, from the top 20 significant differentially upregulated genes, six of them 
were related to the regulation of iron homeostasis and oxidative stress, including 
metallothionein I-II (MT-I+II), ferritin light chain (FTL) and transferrin (TF). 
Subsequent transcriptomic and proteomic investigations were carried out on candidate 
genes using polymerase chain reaction, immunohistochemistry, western blotting and 
mass spectrometry to investigate the neuroprotective role of astrocytes in regulating iron 
homeostasis and oxidative stress in MS NAWM. 
Evidence presented in this thesis demonstrates the importance of astrocytes in the 
pathogenesis of MS. The results indicate that further investigations into the protective 
roles of astrocytes in regulating iron and oxidative stress in MS NAWM are warranted.  
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1.1 Multiple Sclerosis (MS) 
Multiple Sclerosis (MS) is traditionally regarded as an inflammatory, demyelinating 
disease affecting both the brain and spinal cord of the central nervous system (CNS). 
Demyelination of axons and the formation of inflammatory lesions (plaques) leads to 
the disruption of nerve conduction within the CNS typically associated with the 
symptoms displayed by the patient (Compston & Coles 2008). 
MS is a complex disease displaying several pathological features including 
demyelination, inflammation, axonal/neuronal damage, gliosis, oxidative stress, 
excitotoxicity, changes in the immune system and blood brain barrier (BBB) 
dysfunction (Stables et al 2010). The disease mainly affects the white matter (WM) in 
the CNS but recent pathological and magnetic resonance imaging (MRI) studies have 
also shown significant cortical involvement (Barnett et al 2009b).  In the majority of 
patients, MS is characterised by a variety of symptoms depending on the anatomical 
location of the demyelinated lesions; these can include visual impairment, limb 
weakness, sensory disturbance, balance and postural problems, sphincter dysfunction, 
cognitive impairments, pain and fatigue (Milo & Kahana 2010).  
More recently there has been recognition that MS is more than an inflammatory 
condition with the involvement of neurodegenerative processes. The degenerative 
component of the disease is commonly unresponsive to immunosuppressant therapy, 
with neurodegeneration driving the progressive neurological impairment associated 
with the disease (Hauser & Oksenberg 2006).  
The exact aetiology of MS is unknown, but most probably involves the interplay 
between both environmental and genetic factors. The disease is more predominant in 
particular races and geographical locations (Milo & Kahana 2010) and is generally more 
prominent in females (in a 3:1 ratio) indicative of possible hormonal involvement in its 
pathogenesis (Barnett et al 2009a, Dunn & Steinman 2013). Typically, MS presents in 
adults between 20-50 years of age, with a general peak onset age of 30 years old 
(Compston 2006), with the disease said to affect 2.5 million people worldwide (Antel et 
al 2012).  
1.2 Clinical features and disease course in MS 
MS presents with a range of symptoms that depend on lesion location in the CNS. For 
example, optic neuritis, a classical symptom of MS occurs when lesions reside on the 
optic nerve. Other symptoms can include numbness, muscle weakness, fatigue, speech 
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impairment, cognitive disturbances, bladder and bowel disruptions and ataxia (Shivane 
& Chakrabarty 2007). A definitive diagnosis of MS is given when one or more of these 
symptoms occurs on more than one occasion, in separate incidents known as a clinically 
isolated syndrome (CIS) (Stables et al 2010) which cannot be justified by any other 
CNS disorder. As well, diagnosis can also be supported by laboratory testing including 
the sampling of cerebrospinal fluid (CSF) for the presence of oligoclonal bands (OCB) 
recognising an immune reaction within the brain and the use of MRI for lesion 
identification (Baranzini et al 2009). 
The disease course of MS can be characterised into separate clinical subtypes (Figure 
1.1). Primarily in most early cases, around 80% of patients present with relapse-
remitting MS (RRMS), characterised by sudden acute attacks followed by complete or 
partial recovery (Antel et al 2012, Compston & Coles 2008) thought to be as a result of 
inflammatory demyelinating lesions. Around 50-60% of patients who present with 
RRMS subsequently develop secondary-progressive MS (SPMS), where neurological 
disability occurs more frequently and for longer periods of time without or between 
relapses. A general progression and worsening of symptoms (Antel et al 2012) as a 
result of widespread WM atrophy and cortical demyelination is apparent in patients 
with SPMS (Kremenchutzky et al 2006). 
Around 10-15% of patients present with primary progressive MS (PPMS), where 
neurological disability steadily develops over time from disease onset, without distinct 
relapses or improvement of symptoms (Antel et al 2012). Generally patients will 
present with PPMS 10 years later than patients presenting with RRMS with little 
evidence of BBB disruption or presence of inflammatory, actively demyelinating 
lesions within the WM. Instead, inflammation in progressive MS is more diffuse and 
present behind an intact BBB, said to be compartmentalised inflammation proving 
challenging for study and investigation (Farrell 2013, Reynolds et al 2011). Patients 
who display constant disease progression with distinct disease relapses with or without 
full recovery are classified as having  progressive-relapsing MS (PRMS) (Sobel & 
Moore 2008). MS can be classified as benign where patients present with little or no 
neurological impairment over a period of 15 years from disease onset. In contrast, 
malignant MS involves a short, rapid disease course with huge neurological impairment 





Figure 1.1 A summary of the clinical classification of MS subtypes                                 
Around 80% of patients will present with relapse-remitting (RRMS) with periods of 
varying neurological impairment (relapse) interspersed with periods of stability 
(remission) (a). Around half of patients with RRMS will go onto secondary-progressive 
MS (SPMS) where the periods of remission are shorter and the disease takes on a more 
progressive phenotype with little improvement in symptoms (b). Around 10-20% of 
patients will present with primary-progressive MS (PPMS) where the patients 
experience neurological decline and progression of disease from onset, with very little 
improvement (c). A small proportion of patients may present with progressive-relapsing 
MS (PRMS). In comparison to PPMS, a PRMS patient will experience periods of 
relapses over a general progression of disease, with minor improvements between 
relapses (d). Figure adapted from Zuvich et al 2009.
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1.3 Pathological hallmarks of MS – lesion type  
The affected areas of CNS tissue in MS are known as white matter lesions (WML) or 
plaques which are usually centred around several vessels (Shivane & Chakrabarty 
2007). Pathological features of MS lesions include: BBB leakage, demyelination, 
oligodendrocyte (OLG) damage, axonal damage and loss, glial scar formation and the 
presence of inflammatory infiltrates that mainly consist of lymphocytes and 
macrophages (Sospedra & Martin 2005). There are several different types of lesion that 
differ based on the stage and subtype of the patient’s MS, as well as the age and 
location of the lesion within the CNS (Lassmann 2011). The classical active MS lesion 
contains activated macrophages, containing myelin debris as a result of the 
demyelinating process (Lassmann 2011). The typical active lesion can be sub divided 
into different types;   
Acute MS plaque – referred to as the early active (EA) lesion, contain an even 
distribution of  macrophages throughout the whole lesion, with the same stage of 
digested myelin products (Lassmann 2011).  
Chronic active MS plaque – referred to as the late active (LA) lesion, contain 
macrophages at the lesion edge with early stages of myelin product digestion, while 
macrophages containing more degraded myelin products are found in the lesion core, or 
have already been removed from the lesion centre (Lassmann 2011).  
Due to the nature of MS as a disease, lesion classification is quite difficult to fully 
define. There have been various attempts to classify lesion types in studies by 
Lucchinetti et al 2000 who defined lesions based on aggressiveness, ranging from 
slowly developing to rapidly developing severe chronic lesions. While Bruck et al 1995 
classified the initial stages of MS lesions as containing macrophages with the earliest 
stages of myelin digestion, failing to appreciate that the uptake of myelin into 
macrophages follows a period of myelin destruction. As well, it is known that the 
typical chronic MS lesion is divided into various subtypes involving a complicated set 
of molecular mechanisms involved in tissue destruction and repair (Lassmann 2011). In 
addition to WML, demyelination also occurs in the cerebral cortex and grey matter 
(GM), these GM lesions (GML) are associated with neuronal loss in the absence of 
inflammation, complement deposition and BBB breakdown, yet are probably driven by 
meningeal inflammatory infiltrates (Choi et al 2012, Gardner et al 2013, Popescu & 
Lucchinetti 2012). GML accumulation has been suggested as a factor in the transition 
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from RRMS to SPMS in patients (Stadelmann 2011). The pathology behind these types 
of lesion is relatively unknown and most probably reflects an immune response to the 
sparse myelin present in the region or to neuronal antigens (Weissert 2013). 
1.4 MS normal appearing white matter 
Adjacent to WML in MS is the area of tissue known as the normal appearing white 
matter tissue (NAWM). Despite its name, there is increasing evidence that NAWM is 
abnormal with regards to several biochemical and histological features (Lund et al 
2013). The cause and pathological mechanisms affecting NAWM remain unclear, but 
have been suggested to be a result of diffuse factors dependent on the macroscopic 
pathology within the tissue, or the result of discrete lesions beyond the sensitivity of 
current imaging instrumentation, or as a result of damage to axons within the lesions 
(Mistry et al 2011). However, these explanations fail to account for the NAWM 
abnormalities present in PPMS patients, which do not typically display inflammatory 
lesions to the same extent as in patients with SPMS. Evidence that cytokines can induce 
the typical symptoms of MS, without the presence of inflammatory lesions, along with 
the upregulation of pro- and anti-inflammatory cytokines in MS NAWM may account 
for these subtle differences (Mistry et al 2011, Zeis et al 2008). Evidence of NAWM 
abnormalities have been obtained from various histological and neuroimaging data. An 
increased level of gliosis, microglial activation, BBB breakdown, cellular infiltration, 
reduced myelin density, and axonal loss have been observed (Allen & McKeown 1979, 
Allen et al 2001, Kutzelnigg et al 2005, Lund et al 2013). Neuroimaging studies have 
shown NAWM alterations, using proton-magnetic resonance spectroscopy (MRS), N-
acetyl-aspartate (NAA) levels in MS NAWM were reduced in comparison to healthy 
controls (Aboul-Enein et al 2010, Sarchielli et al 1999). NAA is a specific marker of 
functional neurons, therefore lower levels of NAA in the NAWM indicate a reduction in 
axonal density. A decrease in axonal density in NAWM brain tissue was confirmed also 
by a reduced magnetization transfer ratio (MTR) in the area, which reflects the transfer 
of magnetization between protons in macromolecules and in the surrounding water 
(Davies et al 2005, Filippi et al 1998). Consequently, MS NAWM has shown to be both 
structurally and functionally different from neurological control tissue. As well from 
MTR studies, around 50% of new WML in MS have shown to develop in the NAWM 
(Allen et al 2001). It is in these areas of NAWM where pre-lesional changes occur, 
which have been termed pre-active lesions, where the tissue is primed with clusters of 
activated microglia in the absence of active demyelination or lymphocyte infiltration in 
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the first instance (van der Valk & Amor 2009). In the majority of these pre-active 
lesions, the initial pathology resolves and only a small number progress into 
demyelinating WML associated with MS (van der Valk & Amor 2009, van Noort et al 
2011). Investigations into the cellular phenotype and interactions in NAWM will 
ultimately help gain a better understanding of MS pathology. 
1.5 Proposed mechanisms underlying the aetiology of MS 
Understanding the aetiology of MS is a hugely debatable topic, and a definitive answer 
is unknown. The disease is believed to occur due to an interplay between both genetic 
and environmental factors in certain predisposed individuals. There are a number of 
theories as to the cause of MS which will be discussed. 
1.5.1 Influence of genetics on MS 
A genetic susceptibility to MS is clear, with initial work conducted on familial 
aggregation identifying a genetic link with human leukocyte antigen (HLA) class I 
antigens (Jersild et al 1972, Naito et al 1972). Across the many MS genome wide 
association studies (GWAS) carried out to date, in the Caucasian population, the 
strongest genetic association with MS has been linked with HLA-DR2 (HLA-
DRB1*15) (Ramagopalan et al 2009). Other HLA alleles have been reported to be 
associated with MS, yet due to the complexity of the major histocompatibility complex 
(MHC) and the disease itself having specific variants and associations it is continuingly 
challenging to identify specific genetic associations (Fernando et al 2008, Ramagopalan 
et al 2009).  It has been shown that a higher susceptibility of disease is apparent in first, 
second and third degree relatives of people with MS, compared with the general 
population (Sadovnick et al 1988). Also, MS twin studies have shown a 25-30% 
concordance level in monozygotic (MZ) twins compared to 2-5% in dizygotic (DZ) 
twins (Hawkes & Macgregor 2009). Consequently, due to the relatively low 
concordance level in MZ twins, additional factors other than purely genetics must be 
apparent in the pathogenesis of the disease (Handel et al 2010b, Sadovnick 2013). 
Despite a known increase incidence of MS in females compared to males, no genetic 
link to the X chromosome has been defined (International Multiple Sclerosis Genetics et 
al 2011), suggesting that sex hormones may exert an active role in disease pathogenesis 
(Correale et al 2013).  
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1.5.2 Environmental factors associated with MS 
A number of environmental factors have been proposed as risks for developing MS, 
including bacterial and viral infections (Handel et al 2010a), vitamin D deficiency 
(Nessler & Bruck 2010), smoking (Hedstrom et al 2013, Ramagopalan et al 2013) and 
obesity (Hedstrom et al 2012, Munger 2013). Evidence has shown these factors to be 
population and geographical based rather than intra-familial (Sadovnick 2013). Such 
examples of infectious pathogens proposed as being involved in the 
development/exacerbation of MS include the bacteria, Mycoplasma pneumoniae and 
Chlamydia pneumoniae, along with viruses including the herpes virus and Epstein-Barr 
virus (EBV). Viral involvement in the disease has been proposed as being a major 
contributor in MS due to the increased number of CD8+ (positive) cytotoxic T cells 
observed within MS lesions, which function to clear viral infections (Babbe et al 2000). 
The way in which infectious agents could lead to an increase in MS susceptibility is 
through molecular mimicry, epitope spreading and bystander activation. Superantigens 
are proteins produced by bacteria (or viruses) that potently activate CD4+ T cells, 
inducing a rapid increase in cellular proliferation and cytokine production, most 
probably involved in MS.  Staphylococcal enterotoxins were identified as superantigens 
capable of reactivating autoreactive T cells in asymptomatic experimental autoimmune 
encephalomyelitis (EAE), the animal model of MS, suggesting a role of bacteria and 
superantigens in the development and progression of MS (Brocke et al 1993, 
Schiffenbauer et al 1993). In a lot of examples however, as with EBV, the mechanisms 
responsible for these bacterial/viral agents in increasing disease susceptibility and 
possible development are unclear (Tselis 2012). Exposure to EBV has been suggested to 
increase the risk of developing MS especially if an individual contracts the virus as a 
young adult. However, children who contract EBV infection have a reduced risk of 
developing MS later in life (Milo & Kahana 2010).  
Vitamin D has been shown to have immunomodulatory actions on T and B cells, with a 
limited vitamin D exposure in early life shown to increase an individual’s risk of 
developing MS (Goldacre et al 2004). The first study on MS patients with regard to 
vitamin D and its association with the disease identified an increased release of the 
cytokine tumour necrosis factor beta 1 (TNFβ1), responsible for inhibiting T cells, in 
patients treated with vitamin D (Mahon et al 2003). Complementary studies have 
identified the anti-inflammatory and neuroprotective properties of vitamin D (Ascherio 
et al 2010, Correale et al 2009, Pierrot-Deseilligny 2009). Conversely low levels of 
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Vitamin D3 were shown to increase MS risk, severity and progression (Ascherio et al 
2010). 
Both the duration and intensity of smoking have been shown to be associated with an 
increased risk of developing MS. However, contrary to many other environmental 
factors where an individual’s exposure to these factors at a specific age increases their 
risk of developing MS, smoking does not follow this trend (Hedstrom et al 2013). The 
mechanism by which smoking increases an individual’s risk of developing MS is 
suggested to occur initially in the lung. In response to smoking, oxidative stress and 
inflammatory responses occur in the cells of the lung. As well, post-translational 
modifications may affect certain proteins and their antigenicity (Hedstrom et al 2013). 
Within the immune system of MS animal models including their innate immunity, B 
and T cells have shown to be affected by exposure to smoking (Fusby et al 2010). 
Therefore, the possibility that autoimmunity occurs against proteins modified in the 
lung that cross-react with CNS proteins is evident (Odoardi et al 2012). As well, the 
presence of memory T cells in the lung could potentially be a factor linked to 
autoimmunity in MS. Memory T cells may rapidly proliferate and migrate into the CNS 
contributing to the initiation of MS (Odoardi et al 2012).  
Obesity in late adolescence/early adulthood has been shown to increase the risk of 
developing MS, with one study showing a 40% increased risk of developing MS in 
obese late adolescent individuals (Munger et al 2009). Another study identified that 
obese individuals at the age of 20 had a two-fold increased risk of developing MS 
(Hedstrom et al 2012). The link between being obese in earlier life and an increased risk 
of developing MS later in life is unknown. Yet studies have identified low levels of 
vitamin D in the blood of obese people, and therefore the risk may in part be related to 
the vitamin D pathway (Wortsman et al 2000). Alternatively, an increased release of 
adipokines, such as leptin from surplus adipose tissue in obese individuals as shown to 
alter the immune system, promoting inflammatory T cell responses (Lord et al 1998) 
and decreasing regulatory T cells (De Rosa et al 2007). Supporting this theory in 
relation to MS, leptin deficient mice have shown to be protected against EAE (Matarese 
et al 2001a, Matarese et al 2001b). 
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1.6 Proposed pathophysiology of MS – an inflammatory or degenerative 
disease? 
MS lesions are characterised histopathologically by inflammation, demyelination, 
partial remyelination, damage to axons and gliosis (Kuhlmann et al 2009). The MS 
lesion is proposed to develop through the breakdown of immune tolerance and passage 
of immune cells across the BBB. Destructive effects follow such as the release of toxic 
oxygen species, and cytokines that lead to an inflammatory response, demyelination and 
neurodegenerative processes typical of MS (Sospedra & Martin 2005).  
MS has generally been considered a T cell mediated autoimmune disease, where T cells 
recognise myelin peptides and induce tissue damage by activating macrophages and 
microglia leading to demyelination resulting in inefficient nerve signal conduction 
throughout the nervous network (Lassmann 1999). Over time it is believed that 
neurodegeneration becomes independent of the inflammatory response continuing on 
into the progressive stage of the disease (Trapp & Nave 2008).   
In contrast to the generally accepted autoimmunity aetiology of MS is the concept that 
MS disease progression and neurodegeneration work independently from the 
neuroinflammatory component of the disease (Stys et al 2012). This mechanism favours 
an unidentified degenerative factor possibly targeting the oligodendrocyte, whether this 
be a virus or other foreign agent is still to be determined. As a result, demyelination 
occurs which over time initiates an immunological response, which is associated with 
the varying degree of inflammatory activity represented in the relapse and remitting 
clinical phenotype of the disease, while neurodegeneration progressively occurs in the 
background resulting in increasing disability (Stys et al 2012). Supporting this 
alternative view on MS pathogenesis is the knowledge that the neuroinflammatory 
component of the disease can be controlled to an extent by the currently available 
therapy, while neurodegeneration continues regardless (Stys et al 2012).  
It is clear that inflammation and degeneration are constant contributors to MS 
pathogenesis yet the initiating factor has eluded researchers. At present the majority of 
research on MS has focussed on the immunological influence on MS lesions and 
potential mechanism of disease which has led to the currently accepted concept that MS 
is an autoimmune disease. Supporting this are the numerous studies that have 
discovered known pathology, mechanisms, and therapeutics for the early relapsing 
disease course. Currently available clinical data and the known genetic associations of 
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MS also support the autoimmune hypothesis. Yet despite many years of research there 
is still no definite cause of MS, nor has there been any definitive CNS autoantigen 
identified (Chaudhuri 2013). As well, very limited therapy for the progressive stage of 
the disease has been developed, which is arguably the most disabling element of the 
disease. More importantly, no cure for the disease has been discovered. These are all 
questions that ultimately indicate that further work addressing the pathogenesis of the 
disease is needed (Bar-Or 2008, Chaudhuri 2013, Stys et al 2012).  
1.6.1 The blood brain barrier (BBB) 
The BBB is a term used to describe a set of discrete properties of blood vessels in the 
CNS that regulate the movement of molecules, ions and cells between the blood and 
CNS tissue (Abbott et al 2010, Begley 2003). In the brain and spinal cord the BBB is 
comprised of specialised endothelial cells (EC) that line the walls of blood capillaries 
held together by tight junctions (TJ) and adherens junctions (AJ) (Begley 2003). This 
lining of endothelium surrounding blood capillaries is closely associated with pericyte 
cells enclosed in the basal lamina, an extracellular matrix (ECM), composed of 
collagen, laminins, and heparin (Luissint et al 2012). The extended processes of 
astrocytes ensheath the blood vessels, as well as directly contacting neurons and axons. 
Also, perivascular macrophages are held in close proximity to this neurovascular unit 
providing an immune surveillance to the vessels. These cells help to support BBB 
maintenance and function (Abbott et al 2010, Abbott et al 2006), (Figure 1.2). The 
major role of the BBB is to act as a physical barrier to diffusion, but also as a transport 
barrier and metabolic barrier (Begley 2003) to maintain homeostasis throughout the 
CNS. As a physical barrier to diffusion, the TJ proteins between the EC of the BBB 
prevents the passive diffusion of solutes from the blood into the brain (Begley 2003). As 
a transport barrier, the BBB mediates the passage of nutrients, oxygen, vitamins, 
proteins and peptides to the CNS (Bundgaard & Abbott 2008).  Functioning as a 
metabolic barrier, the BBB also limits the entry of toxins, pathogens and immune cells 
into the CNS tissue, while aiding in the removal of toxic metabolites from the CNS 
(Abbott et al 2010). 
1.6.2 BBB dysfunction in MS 
An intact BBB is vital in the physiology of the CNS and evidence has shown that BBB 
dysfunction contributes to lesion formation and expansion in MS (McQuaid et al 2009). 






Figure 1.2 The major cellular components of the BBB                                           
Endothelial cells (EC) form a capillary tube in which blood can flow, the cells fold on 
themselves and adhere to one and other through the formation of tight junctions (TJ). 
Pericytes are found adhered to the abluminal side of the EC that is surrounded by 
extracellular matrix (ECM), with astrocyte end feet ensheathing the whole blood 
vessels. Figure adapted from Abbott et al 2010.
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Dysfunctional changes to the BBB exist in neuroinflammatory conditions as seen in MS 
when defective TJ and AJ allow the passage of molecules normally excluded from the 
CNS (Persidsky et al 2006). Alterations in the BBB are believed to be an early 
pathological event in MS, preceding lesion formation (Larochelle et al 2011) that can be 
identified through histology at post mortem and also through MRI both at post-mortem 
and during life (Alvarez et al 2011a). It is proposed that peripheral immune cells and 
antigen presenting cells (APC) enter the CNS through the altered BBB leading to 
demyelination, along with the infiltration of autoreactive T cells that causes oedema, 
axonal loss and gliosis (Klegeris & McGeer 2005). Activated cells of the BBB 
including EC, astrocytes and pericytes release an array of cytokines and chemokines 
that aid in the recruitment and survival of immune cells entering the CNS (Alvarez et al 
2011a). There are many proposed causes of BBB breakdown in MS including the 
involvement of vascular endothelial growth factors (VEFGs), matrix metalloproteinases 
(MMPs), cytokines and reactive oxygen species (ROS) (Daneman 2012, Minagar & 
Alexander 2003). The release of inflammatory agents can directly affect the 
permeability of the BBB. For example, tumour necrosis factor alpha (TNFα) released by 
EC weaken the AJ between the tightly connected EC of the BBB due to a loss of VE-
cadherin (Wojciak-Stothard et al 1998). Expression of interleukin (IL)-1β by infiltrating 
macrophages has been shown to induce the expression of MMP-9, an enzyme 
responsible for the cleavage of the TJ proteins occludin, ZO-1 and claudin 5, 
destabilising the BBB further (Lleo et al 2007, Yang et al 2007). BBB permeability in 
MS is also seen as an advantage in promoting self-repair, allowing the movement of 
anti-inflammatory T helper (Th)2 cells and regulatory T cells (Tregs) into the CNS to 
reduce inflammation (Larochelle et al 2011). Yet prolonged BBB breakdown can lead 
to oedema, and increase in brain volume due to the movement of water into the brain 
causing an altered cellular architecture, myelin degradation, astrocyte activation and 
neuronal dysfunction (Daneman 2012). Whether BBB breakdown is a consequence of a 
primary pathological event in MS is continuously questioned (Correale & Villa 2007). 
1.6.3 Inflammation in MS – the autoimmune hypothesis.  
MS has long since been regarded as an inflammatory disorder of the brain and spinal 
cord, with a complex autoimmune association. Immune cell involvement in MS 
pathogenesis has been suggested from many animal studies showing the involvement of 
both Th17 and Th1 cells (Gilgun-Sherki et al 2005). T cells can be divided into CD4+ 
Th cells or CD8+ cytotoxic T cells (TC), with Th cells further divided into Th1, Th2, 
Th17 and Tregs, distinguished based on the cytokines they produce and their effector 
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functions. Th1 cells release an array of proinflammatory cytokine such as TNFα and 
interferon gamma (IFNγ), designed to eliminate pathogens but also heighten the 
autoimmune responses in the body (Bar-Or 2008). Th2 cells release cytokines designed 
to support antibody production by B cells (Haider et al 2011). In comparison, during 
inflammation the physiologically low number of TC cells in the CNS is increased 
providing direct killing of cells through release of perforin and granzymes (Gravano & 
Hoyer 2013). 
In MS, autoreactive T cells in the periphery become activated as a result of the 
interaction with chemoattractant factors displayed on the surface of EC, which support 
the cells passage across the BBB into the CNS (McFarland & Martin 2007). These 
autoreactive T cells once in the CNS become re-activated when in contact with specific 
CNS APCs, causing cellular proliferation and secretion of an array of cytokines and 
chemokines  (Bar-Or 2008). In turn this stimulates the recruitment and activation of 
microglia and astrocytes along with other immune cells, releasing a further array of 
cytokines and chemokines, causing OLG damage and demyelination resulting in the 
typical neurological symptoms associated with MS (Bar-Or 2008). The process by 
which T cells become autoreactive is hugely debated and has been proposed as being 
the result of molecular mimicry. In molecular mimicry an external environmental 
antigen resembling a self-antigen, thought to be a myelin protein, is presented to the T 
cells together with MHC on the surface of APCs in the periphery (Sospedra & Martin 
2005). Once in the CNS, autoreactive T cells become reactivated by myelinated axons 
presented to infiltrated immune cells by CNS APCs. Myelin basic protein (MBP) 
positive CD4+ T cells (predominantly Th1 cells) are initiators of MS, however it is 
predominantly the CD8+ T cells that reside in the inflammatory MS lesions (Neumann et 
al 2002, Shivane & Chakrabarty 2007). Activated T cells express molecules including 
very late antigen-4 (VLA-4) and leukocyte-associated antigen-1 (LFA-1), that bind to 
adhesion molecules present on EC such as vascular cell adhesion molecule-1 (VCAM-
1) and intercellular adhesion molecule-1 (ICAM-1), to facilitate their traffic across the 
BBB (Bar-Or 2008). 
In MS, the sites of inflammation within the brain are dominated by CD8+ T cells 
resulting in lesion formation throughout the CNS (Compston & Coles 2008). In 
contrast, research on the EAE model of MS identified the primary stage of disease 
inflammation occurs through the Th17 lymphocyte subtypes, that secrete IL-17 under 
IL-23 control. The release of IL-17 can disrupt the BBB allowing Th17 cells and other 
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immune cells to infiltrate into the CNS. The precise activity of the inflammatory 
response in MS in unknown and most probably involves a complex interplay between 
genetic and environmental factors (Gilgun-Sherki et al 2005). An individual’s different 
disease stage and subtype may determine whether Th17 or Th1 cell lineage is the main 
driver of pathology. As well, these individual differences may also play a hand in the 
different cell type involved in disease pathogenesis, with the Th lineage initiating 
disease and possibly other immune cells, such as the CD8+ CT cells continuing the 
detrimental effects (Gilgun-Sherki et al 2005). 
In a similar way autoreactive T cells are considered to develop, increasing evidence is 
implementing the role of B cells and the production of CNS directed autoantibodies in 
MS pathogenesis (Bar-Or 2008). Specifically associated with MS, antibodies are 
produced by B cells stimulated by particular cytokines including Il-4, Il-6 and Il-10 
(Barun & Bar-Or 2012). These antibodies participate in demyelination through the 
formation of immune complexes which activate complement, or partake in antibody 
dependent cell cytotoxicity (Barun & Bar-Or 2012). B cells can also act as APC 
involved in the activation of T cells in MS (Barun & Bar-Or 2012). Over 95% of 
patients with established MS have increased levels of soluble clonal IgG, known as 
OCB in their CSF (Walsh et al 1985), yet deciphering the target antigen of B cell 
immunity in MS is contradictory. There is evidence to support myelin peptides and 
EBV antigens as targets for OCB antibodies (Cepok et al 2005, O'Connor et al 2005). 
However, whether autoantibodies produced in MS contribute to disease pathogenesis, or 
are generated as a result of tissue injury associated with the disease is not fully 
understood (Bar-Or 2008). 
1.6.4 Neurodegeneration in MS 
Disease progression in MS is associated with the accumulation of axon degeneration in 
an acute inflammatory setting (Trapp et al 1998), and demyelination of axons is a key 
factor in this (Dutta et al 2006, Trapp & Nave 2008). For example, a partially 
demyelinated axon cannot conduct nerve signals effectively explaining the symptoms of 
fatigue (Compston & Coles 2008). Axonal damage occurs early in the disease alongside 
inflammatory demyelination and continues throughout the disease. Within the 
progressive phase of the disease, the accumulation of neurodegeneration accounts for 
permanent disability in MS, generally in the absence of new inflammatory 
demyelinating lesions (Frischer et al 2009, Kuhlmann et al 2002). Ultimately, the 
driving force behind permanent neurodegeneration must be caused by additional factors 
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to infiltrating immune cells and inflammation (Trapp & Nave 2008). A number of 
theories have been put forward as to alternative/additional causes of neurodegeneration 
in MS, involving mitochondrial injury, oxidative damage and glutamate excitotoxicity 
as key factors.   
1.6.4.1 Mitochondrial damage in MS lesions 
Determining a specific factor that could drive neurodegeneration in all MS patients has 
been a continuing area of research. An autoimmune attack of myelin epitopes present in 
OLG and on myelinated axons is a naïve view and rarely seen in MS lesions. Only in 
aggressive forms of MS are CD8+ CT cells shown to be infiltrating MS lesions and 
exhibiting toxic effects on OLG and axons (Neumann et al 2002). Similarly, the 
observation of autoantibodies towards myelin proteins have only been seen in a subset 
of MS patients, generally children with MS (Brilot et al 2009). Therefore the proposed 
immune response mounted against myelin in MS may only account for a subset of 
patients. Instead, an alternative mechanism for tissue injury in all MS lesions must be 
apparent and has been linked to mitochondrial dysfunction in cells (Lassmann & van 
Horssen 2011). Mitochondria partake in a number of roles crucial to cell survival, 
primarily the organelle produces adenosine triphosphate (ATP) as a source of cellular 
energy, while also being involved in maintaining ion homeostasis and cellular 
apoptosis. Alterations in mitochondria have been associated with MS pathogenesis, 
identified by immunohistochemistry (IHC), gene expression microarray studies, 
biochemical studies and electron microscopy (Mahad et al 2008, Mahad et al 2009, Su 
et al 2013, Su et al 2009, van Horssen et al 2012). In acute lesions these changes 
include a loss of cytochrome C oxidase-I (COX-I) and complex IV immunoreactivity, 
components of the mitochondria respiratory chain (Mahad et al 2008). In contrast, 
mitochondria levels and activity in inactive (IA) lesions is increased to meet the energy 
demands of demyelinated axons (Mahad et al 2009). In relation to MS pathogenesis, 
disturbances in mitochondria can lead to proapoptotic events, which has been linked to 
OLG damage and demyelination associated with the disease (Veto et al 2010).  
Ineffective mitochondria in oligodendrocyte precursor cells (OPCs) can cause impaired 
cell differentiation, therefore affecting remyelination in areas of demyelination 
(Ziabreva et al 2010). Consequently, neuronal mitochondrial dysfunction in MS can 




1.6.4.2 Oxidative damage in MS lesions  
Damage to mitochondria in OLGs and other cells in the CNS can be accounted for by 
oxidative stress. Neuroinflammation is a major instigator of oxidative stress in MS 
through two possible mechanisms; the production of ROS by activated glia cells 
including microglia and astrocytes, and also through the activation of cyclooxygenases 
and lipoxygenase pathways involved in the production of prostaglandins and conversion 
of polyunsaturated fatty acids respectively (Ortiz et al 2013). As well oxidative stress 
can occur when the production of oxidants exceeds the antioxidant capacity of cells, or 
when a cell’s defence system against oxidative species becomes impaired (Ortiz et al 
2013). ROS and nitric oxide (NO) can damage lipids, proteins and nucleic acids leading 
to cell death. In MS it has been suggested that the diffuse inflammatory activity and 
prolonged disease duration is associated with increasing levels of ROS and NO, leading 
to mitochondria damage within CNS cells compared to controls (Campbell et al 2012). 
ROS are mainly derived from activated microglia and macrophages which promotes 
demyelination and axonal damage (Haider et al 2011). It has been shown that oxidative 
damage in MS in is an early event in the disease and is implicated in active MS lesion 
development (Lassmann & van Horssen 2011). Another source of ROS comes from iron 
or related divalent cations that can cause the formation of highly reactive hydroxyl 
(OH•) radicals through the Fenton reaction (Jomova & Valko 2011).  Consequently, the 
accumulation of oxidative damage within MS lesions can contribute to additional 
demyelination and neurodegeneration, which can feedback to produce further oxidative 
species. In MS lesions as a result of mitochondrial dysfunction there is an increase in 
pro apoptotic events, leading to OLG degeneration. These cells are a major source of 
iron, therefore increasing iron levels within the CNS and ultimately increasing oxidative 
species (Lassmann & van Horssen 2011, Williams et al 2012). In the same way, 
activated macrophages remove myelin debris and excess iron in MS lesions, leading to 
additional oxidative burst and ROS production by these cells. At the same time, 
defective mitochondria in cells residing in the MS lesion, leads to proapoptotic action of 
these cells, supplementing a second wave of oxidative species and iron release into the 
lesion. Consequently, the continued cycles of oxidative damage within a lesion centre 
increases tissue damage and neurodegeneration associated with the progression of the 
disease, irrespective of the presence of inflammation.   
1.6.4.3 Glutamate excitotoxicity in MS lesions 
In MS lesions an increase in glutamate is common due to the activation of microglial 
and macrophages, along with a reduction in glutamate transporter expression by cells 
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such as astrocytes in the lesions that leads to excitotoxicity (Su et al 2009). Glutamate 
excitotoxicity leads to a disruption of ion channels and impairment of Ca2+ homeostasis 
resulting in an increased influx of Ca2+ into the cell. Increased levels of Ca2+ leads to 
mitochondrial dysfunction, but also causes the release of several enzymes that disrupt 
cellular DNA, cytoskeleton and cellular membrane promoting apoptosis (Su et al 2009), 
all factors that can lead to neurodegeneration in MS.  
1.7 Animal models of MS 
Studying the pathological basis of MS in patients is challenging due to the difficulty in 
accessing CNS tissue throughout the course of the disease. Therefore, a number of 
animal models of CNS demyelination have been developed, which enable the pathology 
of disease to be interrogated and aid the identification of potential diagnostic and 
therapeutic targets. These models include chemically induced [cuprizone (van der Star 
et al 2012) and ethidium bromide (Guazzo 2005)], and viral-induced [murine hepatitis 
virus (Bergmann et al 2006) and Theiler’s virus (Mecha et al 2013)] models of 
demyelination. In addition, zebrafish can provide a model system for investigating 
remyelination mechanisms in vivo (Buckley et al 2008, Buckley et al 2010) but can also 
be used as a demyelinating model, through the ablation of oligodendrocytes (Chung et 
al 2013).  However, the most widely used animal model for CNS demyelination is EAE, 
a term used to describe multiple models of CNS autoimmunity that can mimic a wide 
range of MS traits (Baker et al 2011, Mecha et al 2013). First discovered when 
monkeys were immunised with rabbit brain extract, the disease presents with paralysis 
and is pathologically associated with perivascular infiltration and demyelination of the 
brain and spinal cord (Rivers et al 1933). Since these initial experiments, EAE has been 
induced in many species including non-human primates (Haanstra et al 2013), and 
guinea pigs (Aritake et al 2010) but the majority of research to date has primarily 
investigated EAE in mice and rats. There is no single EAE model that mimics all 
aspects of MS, however the course of this autoimmune, inflammatory, demyelinating 
disease has proven to reflect several aspects of the human disease. Variation is 
dependent on a number of aspects including the age, sex and genetic background of the 
animal, through to the antigenic substance used and the way it is administrated into the 
animal (deLuca et al 2010) resulting in models that mimic RRMS (McRae et al 1992), 
SPMS (Hampton et al 2008) and PPMS (Tsunoda et al 2000). 
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1.7.1 Induction of experimental autoimmune encephalomyelitis (EAE)  
EAE can be induced in animals via two methods: active or passive induction. Active 
EAE is induced in susceptible animals by immunisation with animal CNS tissue or 
myelin proteins, such as MBP, myelin oligodendrocyte glycoprotein (MOG) or 
proteolipid protein (PLP) (Constantinescu et al 2011). After 9-12 days disease onset 
occurs with various pathological and symptomatic behaviour consistent with relapse-
remitting or chronic progressive CNS inflammation (Constantinescu et al 2011). In 
contrast, passive EAE, or adoptive transfer EAE (AT-EAE), is induced when 
pathogenic, myelin-specific CD4+ T cells from actively induced EAE animals are 
transferred by active immunisation. Specific alterations of T cells can occur prior to AT 
by the use of specific cytokines to prime the cells, or by labelling T cells prior to 
transfer to enable the cells’ activity, localisation, and interactions with other cell types 
to be determined (Constantinescu et al 2011). EAE models include the traditional RR 
disease course model where PLP139-151 antigen is administered into SJL/J mice (Tuohy 
et al 1989). A more chronic relapsing disease course is induced in Biozzi AB/H 
(antibody high) using spinal cord homogenate in adjuvant (Baker et al 1990), while 
mimicking PPMS C57BL6/J mice are immunised with MOG35-55 (Sayed et al 2011). 
1.7.2 Autoimmune hypothesis of EAE 
AT-EAE, mediated by myelin-specific T cells, infers the strong association of MS with 
MHC class II alleles (Simmons et al 2013). Myelin specific activated Th1 cells, Th17 
cells and autoantibodies enter the CNS across a disrupted the BBB. Within the CNS the 
T cells interact with infiltrating APC that present MHC class II antigen to them, 
resulting in inflammation, myelin breakdown and axonal damage (Figure 1.3). 
To date, the identity of the Th cells which are critical for EAE induction is still 
unknown and highly debated. The majority of the literature claims the Th1 subset of 
cells are the main pathogenic cell type in both EAE and MS (Fletcher et al 2010). 
However, the critical involvement of an alternative Th17 cell was proposed when 
researchers identified IL23, rather than the Th1 promoting cytokine IL12 essential to 
initiate EAE (Becher et al 2002, Cua et al 2003). It has been proposed that the overall 
phenotype of disease is associated with the T cell lineage used to induce EAE, with a 
more clinically severe phenotype being associated with Th17 cell-induced EAE 
compared to Th1 cell induced EAE (Jager et al 2009, Langrish et al 2005). The T cell 
lineage administered also has a direct effect on the clinical symptoms, initially both Th1 




Figure 1.3 The pathophysiology of classical EAE induction                                                
In EAE the animals are immunised with a myelin antigen in complete Freund’s adjuvant 
(CFA). Antigen presenting cells (APC), the dendritic cells (DC) become activated by 
CFA presenting the administered myelin antigen to naïve CD4+ T cells supporting their 
differentiation into Th1 and Th17 T cells (1). The activated myelin specific T cells enter 
the bloodstream and cross the BBB (2), which leads to further infiltration of additional 
cells including gamma delta (γδ) T cells, regulatory T cells (Tregs), as well as other 
inflammatory cells (3). On entering the CNS, the primed T cells recognise the innate 
myelin protein present in the myelin sheath surrounding axons, causing the reactivation 
of the T cells by local APC (4). The reactivated T cells undergo clonal expansion and 
release cytokines and chemokines that attract additional inflammatory cells and activate 
resident microglia. Additional cytotoxic mediators including a variety of cytokines, 
chemokines, reactive oxygen species (ROS) (5) are released leading to the breakdown 
of myelin surrounding axons (6), and ultimately neuronal damage. Figure adapted from 
Fletcher et al 2010.
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however Th17 cells also develop additional symptoms including ataxia and rolling 
(Domingues et al 2010). 
A number of factors can affect the pathophysiology of EAE models including the 
animal species or strain used, along with the type of immunisation peptide or subclass 
of Th cells administered (Simmons et al 2013). Variations of these factors determines 
the specific disease course of the model whether this be acute, chronic progressive or 
relapsing remitting (Steinman 1999). Clearly, no overall model displays every aspect of 
MS, however these animal models have helped to define certain immunologically 
processes in MS and supported the development of  key therapeutics including 
Copaxone, Mitoxantrone and Natalizumab (Rosenling et al 2011). 
1.7.3 Translation of EAE to MS; the pros and cons  
There are clear distinctions in the innate and adaptive immune systems between rodents 
and man (Mestas & Hughes 2004), therefore caution must be taken when translating 
potential pathology mechanisms from the EAE model to MS (Baker et al 2011). The 
activation of both Th1 and Th17 cells in EAE requires specific classes of cytokines, 
however it is unclear as to what extent MS is driven by CD4+ and MHC class II+ cells, 
especially as MHC class I CD8+ T cells are more dominant in MS lesions (Lassmann & 
Ransohoff 2004). Several EAE models lack the involvement of the brain, with 
inflammation mainly presenting in the spinal cord of the animal leading to paralysis 
(Simmons et al 2013). This lack of pathological similarity infers differences in the 
pathological mechanisms between EAE and MS, which has been proposed as being the 
reason for the increased number of drug failures in clinical trials, which had 
successfully been used in treatment for EAE models (Sriram & Steiner 2005). Another 
limitation to the EAE model is the artificial administration of myelin specific protein to 
initiate disease, which does not mimic the spontaneity of MS (Mecha et al 2013) and 
therefore does not reflect important disease initiator mechanisms. Furthermore, animal 
models are restricted in environmental exposures, which may affect the way in which 
the animal’s immune system is primed. Many animals used in EAE models are raised in 
specific pathogen free conditions, in laboratories not comparable to a human 
environment (Adams et al 2003).  Despite the limitations of the animal model EAE, it 
remains the main focus of MS research, with successful drug treatments derived from 
its study. However in order to establish more clinical, pathological relevant processes 
associated with MS, results from multiple EAE studies should be combined (Rosenling 
et al 2011). As well, new enhanced EAE models need to be developed using species 
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more closely resembling humans, with a similar genetic make-up and mature immune 
system with more environmental exposures, such as the marmoset (Kap et al 2010).  
1.8 Glial Cells in MS 
Several processes and various cell types contribute to the pathology of MS (Sobel & 
Moore 2008). Glial cells form the supportive and protective network of the CNS, 
surrounding neurons and axons, glial cells do not conduct electrical impulses but are 
capable of extensive signaling in response to specific stimuli, such as inflammation 
(Sobel & Moore 2008). There are three main types of glial cells; oligodendrocytes are 
involved in the production of the myelin surrounding axons. Microglia act as 
macrophages and form the basis of the CNS immune system. Astrocytes support 
neuronal metabolism, maintenance of the extracellular environment and transmission of 
nerve signals (Figure 1.4), (Sobel & Moore 2008). 
1.8.1 Oligodendrocytes in MS  
OLG are primarily involved in the production of myelin that surrounds axons in the 
brain. These cells help provide nutritional support to axons and are critical for axon 
function and survival (Funfschilling et al 2012). Myelin acts as a protective, insulating 
layer and accelerates neural conduction along axons. OLG produce myelin in segments 
along axons, which are separated by myelin free areas known as nodes of Ranvier 
where sodium and potassium channels are located. Nerve impulses pass from one node 
of Ranvier to another, therefore accelerating nerve conduction across the myelinated 
axon (Dupree et al 1999). A single mature OLG in the CNS is capable of generating 
myelin for upto 40 axons (Brodel 2010). Diseases affecting OLG, such as in MS, lead to 
a loss of myelin in addition to axonal loss (Brodel 2010). 
1.8.2 Microglia in MS 
Microglia make upto 20% of the total glia in the brain and are the resident macrophages 
of the CNS (Brodel 2010, de Pablos et al 2013). The cells have a role in development, 
plasticity and immune surveillance (Jack et al 2005), exhibiting several macrophage like 
actions in the brain, reinforcing its major role as the resident immunosurveillance cell of 
the CNS. The cells are relatively evenly distributed throughout the CNS (Brodel 2010), 
but in injury or response to CNS insult the number of microglia with phagocytic 
capabilities increases (Brodel 2010). Microglia can be defined by their activation state, 
the typical ramified morphology of a microglia is characteristic of a resting cell. Many 






Figure 1.4 Brain structures involved in multiple sclerosis                                                       
The blood capillaries in the brain are surrounded by microglia/macrophages that act as 
the immunosurveillance cell in the CNS. Astrocytes ensheath blood vessels and align 
with axons releasing an array of neuromodulatory molecules into the CNS supporting 
neurotransmission. Oligodendrocyte (OLG) myelinate axons and increase axonal 
stability, also releasing soluble factors that induce sodium channel reorganisation to 




ensuring the cell is ready to respond in case of any insult (Nimmerjahn et al 2005). In 
comparison, microglial cells under insult are enlarged and spherical in shape, lacking 
processes and are termed amoeboid cells. These activated microglia have shown to 
express an increase in MHC class II molecules, having the ability to activate 
lymphocytes in an immune response. In a positive manner, activated microglia can 
release neurotrophins that support neurons, also activated cells can eliminate 
neurotoxins and ROS through their expression of superoxide dismutase (SOD) and 
other catalases, along with the removal of dying cells and cellular debris  (Stables et al 
2010, Wang et al 2004). However, persistent microglial activation, as in MS, has shown 
to be detrimental affecting the permeability of the BBB promoting further infiltration of 
immune cells into the CNS (Stables et al 2010). As well, microglia can release an array 
of chemokines, and cytokines upon activation, deciphering whether the cell is being 
protective or damaging in relation to neurodegeneration is highly debatable and possibly 
depends on the manner in which the microglia were activated (Boche et al 2013).  
1.8.3 Astrocytes in MS 
Initially, astrocytes were believed to solely function in a structural role within the CNS 
(Sofroniew & Vinters 2010). Yet with more research, astrocytes are increasingly being 
implicated as having a fundamental role in many neurological diseases, whether that 
role is protective or harmful is a continuing debate. In MS, astrocytes exhibit opposing 
roles and are known to enhance immune responses, prevent myelin repair, and aid in 
inflammation. On the contrary, astrocytes can serve in protecting against the disease and 
support remyelination by limiting CNS inflammation, supporting OLG action and 
axonal preservation by uptake of excess glutamate (Marz et al 1999, Mason et al 2001, 
Moore et al 2011, Yi & Hazell 2006). The impact of astrocytes on the pathogenesis of 
MS is most probably dependent on a number of factors including: the stage of disease, 
the environment surrounding the lesion, along with the interactions made with other cell 
types that may affect their state of activation (Nair et al 2008). 
1.8.3.1 Astrocytes and the BBB in MS 
Astrocytes are a fundamental cell of the BBB forming the glial limitans, and have been 
suggested to play a role in both its function and dysfunction in MS. Factors released by 
astrocytes have shown to have beneficial effects on the BBB. For example, astrocytes 
have been shown to secrete sonic hedgehog (Shh), a glycoprotein that acts on EC 
receptors which has shown to induce and maintain BBB function limiting the passage of 
immune cells into the CNS (Alvarez et al 2011b). Levels of Shh were increased in 
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activated astrocytes in vitro, also supported by corresponding human studies Shh 
immunoreactivity in MS lesional tissue was increased identifying astrocyte involvement 
in facilitating BBB repair in demyelinated WML (Alvarez et al 2011b). Alternatively 
astrocytes may promote a loss of BBB integrity as in response to increased levels of IL-
1 expressed in MS lesions, astrocytes have been shown to increase their expression of 
both transcription factor hypoxia-inducible factor 1 (HIF-1), and it’s target vascular 
endothelial growth factor (VEGF-A) (Argaw et al 2006). VEGF-A binds with its EC 
receptor promoting a downregulation of TJ proteins claudin-5 and occludin, causing an 
overall loss of BBB integrity allowing for immune cell infiltration across the disrupted 
BBB and MS lesion development (Argaw et al 2012, Argaw et al 2009). 
1.8.3.2 Astrocytes and their role in preventing myelin repair in MS 
Astrocytes can inhibit OPC maturation through the release of fibroblast growth factor-2 
(FGF-2), a trophic factor that is required for survival and proliferation of progenitor 
cells. However, FGF-2 prevents the development of mature OLG needed for 
remyelination to occur. FGF-2 is predominantly produced by astrocytes upon myelin 
injury and has been shown to produce elevated levels of OPCs around demyelinated 
regions (Messersmith et al 2000). However, intravenously administered FGF-2 in rats 
has been shown to result in patchy myelinated axons, demonstrating the potential 
negative effect that FGF-2 released by astrocytes may have on remyelination (Goddard 
et al 1999). Recent studies have shown MS patients to have elevated CSF levels of 
FGF-2 compared to control patients, with even higher levels being observed in relapse 
patients compared to those patients in remission (Sarchielli et al 2008). Hyaluronan 
(HA) is another molecule believed to prevent maturation of OPCs, and is found 
throughout the CNS WM (Sherman et al 2002). HA binds to its receptor CD44 on 
astrocytes in control WM and on astrocytes, T cells and OPCs in MS WM tissue 
altering their function (Williams et al 2007). 
1.8.3.3 Reactive astrocytes associated with inflammation and gliotic scar formation 
Hypertrophic astrocytes are abundant in early MS lesions compared with the glial 
scarring evident in later chronic active and IA lesions. Severe astrogliosis results in a 
higher expression of glial fibrillary acidic protein (GFAP), increased astrocyte 
proliferation and secretion of proinflammatory cytokines (Eng & Ghirnikar 1994). 
Severely activated astrocytes are associated with gliotic scar formation, where a 
physical border of hypertrophic astrocytes separates an area of CNS damage from non-
diseased tissue (Fitch & Silver 2008) resulting in changes in the ECM that prevents 
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remyelination. Along with the physical barrier presented by the gliotic scar, 
remyelination is restricted due to the increased release of proinflammatory cytokines, 
and toxic products as a result of tissue damage and the presence of immune cells (Nash 
et al 2011a). In contrast, the gliotic scar can be protective preventing further spread of 
damage across the CNS tissue (Miljkovic et al 2011), indicating the astrocyte’s dual 
role in MS, probably dependent on the location and extent of pathology present within 
the brain.  
1.8.3.4 Astrocytes and the immune system 
Astrocytes are known to attract T cells via the release of chemokines, and support the 
production of autoreactive T cells (Stuve et al 2002) through the release of cytokines 
(Constantinescu et al 2005), MMPs (Crocker et al 2006, Larsen et al 2003) and 
additional chemokines contributing to MS pathogenesis. Astrocytes can act as immune 
cells, with increasing evidence of  the cells contribution to both the adaptive and innate 
immune responses in the CNS (Nair et al 2008). Directly, astrocytes have shown to be 
capable of acting as APC, with astrocytes in vitro having shown to express MHC class I 
and II (Wong et al 1984). Following treatment with IFNγ, astrocytes have shown to 
increase their expression of costimulatory molecules CD80 (B7-1) and CD86 (B7-2) 
which interact with CD28 expressed on T cells contributing to their activation (Wong et 
al 1984). Astrocytes treated with IFNγ are able to activate both classes of CD4+ and 
CD8+ T cells (Nikcevich et al 1997, Tan et al 1998). 
Supporting the role of astrocytes involvement in the immune response, in vitro 
astrocytes expressing MS associated MHC-Class II HLA-DR2 and HLA-DR4 led to the 
combined pro- and anti-inflammatory cytokine release in MOG-specific T cells (Kort et 
al 2006). In contrast, a predominant stimulation and differentiation of Th2 cells over 
Th1 cells has been associated with astrocyte interactions in vitro (Aloisi et al 1999, 
Aloisi et al 1998). Consequently, in a chronic inflammatory environment as seen in 
MS/EAE where Th1 cells predominate the CNS, astrocytes may act as an APC to drive 
the recruitment and differentiation of an increased number of Th2 cells supporting an 
anti-inflammatory effect in areas of chronic inflammation. 
In vivo studies deciphering the involvement of astrocytes in the immune response in the 
CNS are inconclusive; Sprague-Dawley rats treated intrathecally with IFNγ led to the 
increased expression of MHC class II on astrocyte’s cell membrane and proximal 
processes as identified by IHC, suggesting the cells capability of acting as APC in 
inflammatory disease (Vass & Lassmann 1990). However, another study concluded that 
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astrocytes do not express the costimulatory molecules required to act as APC ruling out 
their involvement in EAE development (Cross & Ku 2000). Clearly, the role of 
astrocytes in the immune system is not fully distinguished and is worth further 
investigation in particular in relation to a neuroinflammatory setting. 
1.8.3.5 Astrocyte cytokine actions in MS pathology 
Astrocyte cytokine production is believed to contribute to inflammation in MS, 
astrocytes produce IL-12 and IL-23, which help initiate both Th1 and Th17 T cells 
thought to play a role in the demyelinating disease (Constantinescu et al. 2005). Other 
cytokines released by astrocytes include IL-1, IL-6, TNFα and IL-10, depending on the 
inflammatory environment these cytokines can drive and determine the immune 
response. The most prominent cytokine to be released from astrocytes is TNFα, levels 
of which are  increased in the CSF of MS patients (Tsukada et al 1991). In vitro, TNFα 
has been shown to increase OLG and myelin damage (Selmaj and Rain 1988) and the 
extent of demyelination in MS patients directly correlates with their levels of TNFα 
(Bitsch et al 2000). TNFα has been shown to prevent the differentiation of OPCs in 
local MS lesional sites preventing OLG maturation and therefore inhibiting   
remyelination (Cammer 2000). Not only do astrocytes produce proinflammatory factors 
during tissue damage, studies have shown that astrocytes promote anti-inflammatory 
effects on other cell types such as microglia, a key contributor to CNS inflammation 
(Sofroniew 2009). 
In vitro studies have demonstrated that astrocytes promote both a pro- and anti-
inflammatory cytokine network (Nair et al 2008). For example, not only are the 
production of proinflammatory cytokines induced through the activation of astrocyte 
toll like receptors (TLR), but the expression of TLR3 by a specific subtype of adult 
human astrocytes in vitro, has led to the production of anti-inflammatory cytokines IL-
9, IL-10 and IL-11. As well, TLR3 expression led to the downregulation of IL-12 and 
IL-23 (Bsibsi et al 2006), however this theory has yet to be tested in vivo. 
1.8.3.6 Astrocyte derived chemokines in MS pathology 
Immune mediated demyelination in MS is thought to be associated significantly with 
astrocyte chemokine production, such as chemokine C-X-C ligand (CXCL)9 and 10 and 
chemokine ligands (CCL)3 and 5. CXCL10 is expressed on the processes of astrocytes, 
in particular those in close proximity to blood vessels. This chemokine is chemotactic 
for Th1 T cells which may provide the driving force behind the infiltration of 
lymphocytes across the BBB in MS (Nair et al 2008). Close to the edge of lesions, 
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chemokines CXCL12 and CCL2 are expressed by astrocytes which help to recruit 
macrophages and microglia as well as lymphocytes to the lesion (Calderon et al 2006, 
Tanuma et al 2006, Van Der Voorn et al 1999). Studies conducted in vitro on human 
astrocytes have shown that cytokines IL-1β, TNFα and IFNγ normally expressed in vivo 
during the inflammatory response, help promote chemokine production, which supports 
the theory that astrocytes are involved in the activation of T cell infiltration associated 
with MS (Barna et al 1994, Calderon et al 2006, Salmaggi et al 2002). 
There is conflicting evidence for the role of secreted cytokines and chemokines from 
astrocytes in MS. For instance the chemokine CXCL10, secreted by activated 
astrocytes, shares its chemokine CXC receptor (CXCR)3 with CXCL9 and CXCL11, 
and because OLG express CXCR3 this may be the target for CXCL10 secreted by 
astrocytes, hindering OLG maturation and axonal wrapping (Nash et al 2011a). 
However on the contrary a viral model of MS showed that neutralising antibodies to 
CXCL10 led to a reduction in disease progression and suppressed ongoing 
demyelination (Liu et al 2001), suggesting opposing roles of CXCL10 secreted by 
astrocytes in CNS pathologies (Nash et al 2011a). Other positive actions of chemokines 
secreted from astrocytes in MS is evidence that CXCL1 and it’s receptor CXCR2 have 





1.9 Overall aims of this thesis 
Astrocytes perform many essential functions in the CNS and are known to be both 
protective and detrimental in their action. The role of astrocytes in MS is most probably 
associated with their location within the brain and the extent of pathology present. 
Therefore, the overall hypothesis of this thesis is that specific astroglial changes exist in 
MS NAWM compared to control WM that are contributing to the overall WM 
pathology in MS. In order to elucidate the exact role of astrocytes in the pathogenesis of 
the disease astrocytes in MS NAWM, areas of WM absent in apparent pathology were 
analysed, to determine whether specific genes are expressed and proteomic astroglial 
changes exist, which either support lesion development and disease progression or 
inhibit tissue damage, lesion expansion and disease development. To establish an 
understanding of the behaviour and functions of astrocytes in MS the project aims will 
be addressed by the following objectives; 
1. To perform a detailed characterisation of the astrocyte phenotype in MS by 
immunohistologically investigating a panel of known astrocyte markers.  
2. To develop a method to isolate glial cells from post mortem (PM) CNS tissue 
using immuno-laser capture microdissection (LCM) 
3. To use microarray technology to identify transcriptomic differences in MS 
NAWM astrocytes compared to control WM astrocytes to distinguish the role of 
astrocytes in MS NAWM. 
4. To apply additional quantitative real-time polymerase chain reaction (qPCR), 
IHC, western blotting (WB) and matrix assisted laser desorption ionisation-mass 





2 CHAPTER 2 
HISTOLOGICAL CHARACTERISATION OF 
THE ASTROCYTE PHENOTYPE IN THE 
WHITE MATTER IN MULTIPLE SCLEROSIS
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2.1 Introduction  
Astrogliosis is a poorly understood event within the CNS and occurs when astrocytes 
undergo varying molecular and morphological changes in response to CNS insult. The 
activation state of astrocytes is directly related to the degree of CNS injury and can 
range from mild subtle molecular changes to extreme astrocyte hypertrophy, 
proliferation and scar formation (Figure 2.1).  A recent paper suggests that a change in 
astrocyte phenotype, rather than astrocyte proliferation, accounts for the apparently 
increased number of astrocytes detected in Alzheimer’s disease (AD) (Serrano-Pozo et 
al 2013a). It is known that reactive astrocytes respond differently to particular signaling 
events, leading to a loss or gain of function. Consequently this highlights the dual role 
of astrocytes as a potential supportive and/or toxic influence in the surrounding CNS 
environment.  Histologically, astrogliosis is characterised by a dense increase in the 
protein GFAP, an intermediate filament protein, currently the most commonly used 
marker for astrocytes. Molecularly, astrogliosis can be identified by changes in the 
cells’ gene expression profile, with evidence of an increase in nuclear factor kappa-
light-chain-enhancer of activated B cells (NFkB) resulting in changes in synaptic 
signaling and in immune responses (Brambilla et al 2005) and upregulation of signal 
transducer and activator of transcription (STAT)3 responsible for changes in cell growth 
and apoptosis (Herrmann et al 2008).  
An overall account of the extent of astrocyte activation, proliferation, change in 
morphology and function in MS pathogenesis is still missing from the literature. Many 
histological studies on astrocytes have been carried out, yet the precise role of astrocytes 
is still unknown. Astrocytes are a heterogeneous population of cells, therefore 
characterising them is challenging due to a lack of appropriate markers. There are 
anatomical distinctions between astrocyte ‘types’ such as fibrous and protoplasmic 
astrocytes, which reside in the white and grey matter respectively (Sofroniew & Vinters 
2010, Swanson et al 2004). These cells also have distinct gene expression profiles, 
highlighting the diversity of these astrocyte cell populations. Undoubtedly the 
capabilities of these cells to activate and proliferate, their anatomical location and the 
molecules they express, for example whether pro- or anti-inflammatory, are all factors 
that play a vital role in understanding the function of astrocytes in neurological disease. 
With the increasing number of astrocyte markers being proposed, most recently 




Figure 2.1 Astrogliosis                                                                                                   
Astrocytes in normal healthy control CNS tissue, each individual astrocyte has its own 
domain (a). Mild to moderate astrogliosis is identified by astrocytes becoming 
hypertrophic with changes in their molecular and functional roles. This type of 
astrogliosis occurs due to either low level local trauma or in response to some drastic 
trauma in distant tissue; such as infection or inflammation. The majority of these 
astrocytes are GFAP+, however very little proliferation occurs and the astrocytes are 
still conserved in their own domains (b). A dispersed spread of severe astrogliosis 
occurs in areas of lesions, infections or in response to neurodegenerative initiators. 
These cells are hypertrophic, proliferative and have changes in their molecular and 
functional activity. The cells no longer reside in their own domain causing chaotic 
tissue architecture (c). Severe astrogliosis occurs after prolonged insult/inflammation, 
the densely packed astrocytes form a gliotic scar barrier between the inflamed area and 
healthier tissue, the processes of these astrocytes overlap and act as barriers to 
inflammatory cells and other pathogenic agents as well as preventing the regeneration of 
axons in areas of demyelination (d). Figure adapted from Sofroniew & Vinters 2010.
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study was designed to carry out a detailed characterisation of all current candidate 
astrocyte markers in MS. Astrocytes are the most abundant cell type in the CNS 
contributing more than 90%  of the total number of cells in the human brain (He & Sun 
2007). Due to their role in CNS surveillance and maintaining homeostasis, astrocytes 
respond to any alterations in brain pH as a result of agonal states, inflammation as a 
result of trauma, infection or autoimmunity. Astrocyte hypertrophy is a result of an 
increase in cytoskeletal proteins including GFAP (Ridet et al 1997). GFAP was first 
isolated from old, established demyelinated MS plaques, and was associated with the 
cytoplasm of reactive astrocytes, as detected by IHC  (Eng & Ghirnikar 1994) and was 
identified as an early marker of astrogliosis (O'Callaghan & Sriram 2005). When GFAP 
is knocked down in mice, astrocytes become unstable, leading to their inability to 
regulate the BBB effectively (Liedtke et al 1996). Prolonged GFAP knockdown has 
shown to lead to other neurological deficits including poor CNS vascularisation 
(Liedtke et al 1996) and an increased sensitivity to traumatic injury (Li et al 2008b). 
Immunohistochemical staining of GFAP labels the cell body and immediate processes 
of astrocytes, which is regarded as the typical astrocyte stellate morphology in 
neuropathology (Nedergaard et al 2003). 
Alongside GFAP, S100B previously known as S100-beta calcium binding protein, is 
highly expressed in the brain, mainly by astrocytes (Nair et al 2008).  However, the 
expression of S100B within the CNS is not restricted to astrocytes and is also associated 
with a number of other cell types including oligodendrocytes, hippocampal neurons and 
EC (Steiner et al 2007). Also, within the periphery, S100B is expressed by Müller cells 
in the retina (Kondo et al 1984), T cells (Takahashi et al 1987), chondrocytes and bone 
marrow cells (Donato 2001). S100B has many roles including: maintaining calcium 
homeostasis (Donato et al 2009, Xiong et al 2000), regulating cellular structure and 
proliferation (Donato et al 2009, Goncalves et al 2008), and  inhibiting the 
phosphorylation of presynaptic proteins (Heizmann et al 2002, Rothermundt et al 
2003). Within the CNS, S100B is located in the nucleus and cytoplasm of astrocytes, 
complementing the pattern of immunoreactivity displayed by GFAP.  
Astrocytes play a key role in regulating synaptic transmission through the expression of 
a number of glutamate transporters and receptors. Within the CNS, astrocytes regulate 
levels of the major excitatory neurotransmitter, glutamate, in a sodium and potassium 
coupled process, sodium is required for glutamate binding and potassium for transport 
into the cell (Danbolt 2001). Approximately 80% of the total uptake of glutamate by 
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astrocytes is by two specific transporters, namely excitatory amino acid transporter 1 
(EAAT1) and EAAT2 (Rothstein et al 1996), both of which are routinely used as 
immunohistological markers of astrocytes. Glutamate is vital for neuronal function and 
neurotransmission, however too much extracellular glutamate, as a result of 
pathological changes within the brain can result in glutamate excitotoxicity which is 
detrimental for both neurons (Wang & Michaelis 2010)  and other glial cells including 
oligodendrocytes (Matute et al 1997, McDonald et al 1998) leading to dysfunction and 
degeneration (Lau & Tymianski 2010).  Astrocytes express EAAT1 [rodent analog: 
glutamate aspartate transporter (GLAST)] and EAAT2 [rodent analog: glutamate 
transporter-1 (GLT-1)] in areas that are close to the sites of glutamate release by 
neurons, and have the ability to react to increasing levels of glutamate by redistributing 
their transporters for optimum uptake of excess glutamate within the CNS (Shin et al 
2009).  
Glutamine synthetase (GS), the enzyme involved in transforming excitotoxic glutamate 
into glutamine, was initially proposed to be solely expressed by  astrocytes, however 
further studies identified the expression of the GS protein by Müller cells of the retina 
(Derouiche & Rauen 1995, Prada et al 1998), as well as oligodendrocytes (Werner et al 
2001). 
The expression of GS is highly regulated and mediated by a number of mediators such 
as insulin, thyroid hormone, corticosteroid hormone (Grenier et al 2005, Juurlink et al 
1981, Koyama et al 1997, Patel et al 1989). Within astrocytes the GS enzyme is located 
within the cytoplasm (Coulter & Eid 2012). The activity of GS has been shown to 
decrease in the presence of ADP suggesting this reduction in enzymatic activity is a 
result of energy deprivation in the cells (Yamamoto et al 1987). 
ALDH1L1 association with the CNS, in particular with astrocytes, was first identified 
in adult rat studies by IHC (Neymeyer et al 1997), however the role of ALDH1L1 and 
its link with neurodegenerative diseases is largely unknown. ALDH1L1  plays a role in 
cell division and growth, participating as a folate enzyme aiding in the conversion of 
10-formyltetrahydrofolate to tetrahydrofolate (Krupenko 2009). ALDH1L1 is 
associated with  highly branched astrocyte processes and cell bodies (Cahoy et al 2008).  
CD44 is a cell surface glycoprotein that serves as a receptor for HA and an adhesion 
molecule mediating cell-cell and cell-matrix interactions (Lesley et al 1993, Ponta et al 
2003). In comparison to GFAP, where the immunoreactivity of astrocytes is restricted 
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mainly to the cell body and immediate proximal cell processes, CD44 is expressed on 
the cell surface, and it’s immunostaining pattern is therefore  more extensive, running 
along the fine, delicate processes of astrocytes (Akiyama et al 1993). CD44 is present in 
the human WM from birth and expression in the cortex occurs from around 60 years of 
age (Cruz et al 1985). CD44 expression is not restricted to astrocytes and is highly 
expressed on antigen activated T cells, suggesting a role in controlling lymphocyte 
trafficking to sites of inflammation (Bradley & Watson 1996, Brennan et al 1999, 
Brocke et al 1999, Budd et al 1987). Despite CD44 being found in astrocytes of normal 
and diseased brains (Zeltner et al 2007), there is very little recent research into its role 
in neurological disease. 
The aim of this study was to characterise the astrocyte phenotype in MS by 
immunohistologically investigating the expression of all currently known astrocyte 
markers, namely GFAP, S100B, EAAT1, EAAT2, GS, ALDH1L1 and CD44, in a 
range of MS WM lesion types in comparison to control WM. Both qualitative and 
quantitative assessment of the immunoreactivity of each marker across the different MS 
lesion types classified according to (Lassmann 2011b) was performed. Specific 
differences of the astrocyte phenotype within the lesion centre, immediate lesional edge 
and NAWM compared to control WM were determined, reflecting a possible change in 
astrocyte function in MS. Furthermore, the selection of the most suitable astrocyte 
marker for use in LCM of astrocytes from NAWM and control tissue was determined.
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2.2 Aims and objectives of the study 
The aims of this study were to: 
 Characterise the astrocyte phenotype in MS by immunohistologically 
investigating the expression of a panel of astrocyte markers in MS tissue 
compared to control tissue. 
 Provide a qualitative description of the staining pattern of each astrocyte marker 
within different lesion types in MS compared to control tissue.  
 Provide a quantative analysis of the immunoreactivity of each astrocyte marker 
within the lesion centre of different lesion types in MS, the perilesional edge, 
and the NAWM/ control WM.  
 To identify the most suitable marker for LCM in the isolation of astrocytes from 




2.3 Material and methods 
2.3.1 Suppliers  
Abcam, 330 Cambridge Science Park, Cambridge, CB4 0FL, UK; DAKO UK Ltd., 
Cambridge House, St Thomas Place, Ely, Cambridgeshire CB7 4EX; Fisher Scientific 
Inc., Bishop Meadow Road, Loughborough, Leicestershire, LE11 5RG, UK; Leica 
Microsystems Ltd., Davy Avenue, Knowhill, Milton Keynes, MK5 8LB 
Buckinghamshire, UK; Millipore Ltd., Suite 3&5, Building 6, Croxley Green Business 
Park, Watford, WD18 8YH, UK; Olympus, KeyMed House, Stock Road, Southend-on-
Sea, SS2 5QH, UK: Vector laboratories Ltd., 3 Accent Park, Bakewell Road, Orton 
Southgate, Peterborough, PE2 6XS. 
2.3.2 Case selection 
All human PM CNS tissue was obtained from the UK MS Society Tissue Bank 
(MREC/02/2/39, Appendix I). Tissue was donated from MS patients and control 
patients with no neurological disease, who had provided informed consent. The role of 
the MS Tissue Bank is to supply tissue to MS researchers, with the aim of developing 
and enhancing research and knowledge about the disease. Preparation of tissue blocks 
used throughout this project was completed at the MS Tissue Bank (Appendix II). The 
brain was either fixed in formalin to provide formalin fixed, paraffin embedded (FFPE) 
material or directly cut into blocks and snap frozen (Appendix II). For this study FFPE 
sections (5μm) from 12 MS cases (3 separate brain regions) and 12 control cases (2 
separate brain regions) were provided, as detailed in Appendix III. Prior to carrying out 
the astrocyte phenotype study, all samples were histologically characterised into 
relevant lesion type based on published criteria (Lassmann 2011b).  
2.3.3 Neuropathological assessment of samples 
Tissue sections were histologically stained with haematoxylin and eosin (H&E) and 
Luxol fast blue (LFB) and IHC was carried out for CD68. H&E was used to assess the 
inflammatory state of the case and overall tissue structure. LFB was used to determine 
the extent of demyelination, and CD68, a lysosomal marker, used to identify the 
presence of phagocytic microglia (Zotova et al 2011). 
2.3.4 Haematoxylin and Eosin (H&E) stain 
H&E staining is commonly used to assess the histological architecture of tissue 
(Bancroft & Gamble, 2008). The basic haematoxylin dye stains basophilic tissue 
components by reacting with the acidic components of cell nuclei and ribosomes, 
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displaying a blue/purple colour (Bancroft & Gamble, 2008). In contrast, the acidic eosin 
stains acidophilic cytoplasmic components of the cell pink/red such as the connective 
tissue, collagen and cytoplasm (Bancroft & Gamble, 2008).   
FFPE sections (5μm) were dewaxed in xylene (Fisher Scientific, UK), rehydrated in a 
graded series of ethanol [100%, 100%, 95%, 70% (Fisher Scientific, UK)] for 5 minutes 
in each. All sections were immersed in filtered Harris’s haematoxylin (Leica, UK) for 2 
minutes at room temperature (RT). Sections were quickly rinsed with tap water and 
differentiated in acid/alcohol (Appendix IV) for approximately 30 seconds and placed 
into Scott’s tap water (Appendix IV) for 10-15 seconds before being rinsed in tap water 
and placed in eosin (Leica, UK) for 5 minutes at RT. The sections were quickly washed 
in tap water and dehydrated through graded alcohols [70%, 95%, 100%, 100% (Fisher 
Scientific, UK)] for 30-60 seconds in each. Sections were cleared in xylene (Fisher 
Scientific, UK) for 5 minutes, before being mounted using DPX mountant media (Leica, 
UK) and glass cover slips (Fisher Scientific, UK). 
2.3.5 Luxol Fast Blue (LFB) stain 
LFB enables the visualisation of myelinated axons within brain tissue, any areas of 
demyelination are identified by loss of LFB stain. The staining works via an acid-base 
reaction with the base of the lipoprotein in myelin replacing the base of the dye and 
causing a colour change (Bancroft & Gamble, 2008). 
FFPE sections (5μm) were dewaxed in xylene (Fisher Scientific, UK), rehydrated in 
graded decreasing concentrations of ethanol [100%, 100%, 95%, 70% (Fisher 
Scientific, UK) for 5 minutes in each].  All sections were placed in LFB solution 
(Appendix IV) for 2 hours at 60°C. Any excess stain was removed in 95% ethanol 
(Fisher Scientific, UK) and the sections rinsed in distilled water (dH2O). Sections were 
differentiated in lithium carbonate (Appendix IV) for 30 seconds until the cortex and 
WM were clearly defined. The sections were cleared in xylene (Fisher Scientific, UK) 
for 5 minutes before being mounted using DPX mountant media (Leica, UK) and glass 
cover slips (Fisher Scientific, UK). 
2.3.6 Immunohistochemistry - background to the technique 
Antibodies are routinely used to visualise the cellular localisation of proteins (antigens) 
of interest in cells, tissues or biological fluids. This detection of antigens using specific 
antibodies in tissue is known as IHC, the technique used in this study was the standard 
horseradish peroxidase-conjugated avidin-biotin complex (ABC-HRP) IHC technique 
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(Vectastain Elite kit; Vector Laboratories UK) with 3, 3’-diaminobenzidine (DAB) 
(Vector Laboratories UK) as substrate (Figure 2.2). 
Prior to antibody application the tissue was fixed, permeabilised and if necessary 
blocked.  Fixation preserves the cellular structures within the tissue as well as 
preserving the antigen of interest. An example of a common fixative is formalin to 
preserve the tissue structure, or the use of acetone/ethanol to remove lipids, dehydrate 
cells and precipitate out antigens. However, cross linking fixatives such as formalin can 
prevent the binding of some antibodies to their specific antigen, and therefore often 
require antigen retrieval prior to IHC (refer to sections 2.3.6.2 and 2.3.6.3).  
2.3.6.1 Blocking endogenous peroxidase activity 
All sections were dewaxed in xylene (5 minutes in Xylene 1 and 2 [Fisher Scientific]) 
and rehydrated in a graded series of ethanol (100%, 100%, 95%, 70% [Fisher Scientific, 
UK]) for 5 minutes in each.  Many cells, including red blood cells, contain endogenous 
peroxidase, which must be saturated prior to IHC. Without saturation, the endogenous 
peroxidase would react with the DAB substrate during the IHC and lead to non-specific 
staining of the tissue section. Therefore prior to antigen retrieval and after dewaxing and 
rehydrating, sections were placed in 3% hydrogen peroxide (Fisher Scientific, UK) in 
methanol (Fisher Scientific, UK) for 20 minutes to prevent any endogenous peroxidase 
activity. 
2.3.6.2 Tri-sodium citrate (TSC) antigen retrieval 
Sections in a plastic slide rack, were placed into tri-sodium citrate (TSC) solution pH6.5 
(Appendix IV), and heated in a microwave on full power (800W) for 10 minutes and 
rinsed in tap water until cool.  
2.3.6.3 Ethylenediaminetetraacetic acid (EDTA) antigen retrieval  
Sections were placed into specifically designed plastic pressure cooker slide holders 
with 200 mL 1mM EDTA pH8.0 (Appendix IV). The sections were placed in the 
pressure cooker surrounded by 500 mL d.H2O and run at 125°C, 20 psi, for 30 secs. 
2.3.7 CD68 immunohistochemistry  
FFPE sections (5μm) were dewaxed, rehydrated, blocked for endogenous peroxidase 
activity (section 2.3.6.1) and antigen retrieval carried out by microwaving in TSC pH6.5 
(section 2.3.6.2). Sections were cooled in running water and subjected to IHC following 
the standard ABC-HRP technique using a mouse Vectastain Elite kit (Vector 




Figure 2.2 Overview of immunohistochemistry                                                                        
The primary unlabelled antibody binds with high affinity to the specific antigen of 
interest (a) The species specific biotinylated secondary antibody binds to the primary 
antibody (b). ABC-HRP is applied which irreversibly binds with high affinity to the 
biotinylated secondary antibody through avidin (c) the HRP substrate DAB is added and 
produces a brown insoluble reaction product which can be visualised (d).  
Key: 1°: primary antibody, 2°: secondary antibody, ABC-HRP: avidin/biotin 
horseradish pereoxidase complex, DAB: substrate.
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Sections were blocked in 1.5% normal horse serum (150μl in 10 ml Tris-buffered saline 
[TBS]) for 30 minutes and the serum removed from the sections. Mouse monoclonal 
anti-human CD68 antibody (Dako, UK) was applied to the sections at 1:100 dilution in 
1.5% horse serum and incubated for 60 minutes at RT. For negative controls, the 
primary antibody was omitted from a section in each IHC run, or the section was 
incubated with an isotype control at the same protein concentration as the primary 
antibody. All sections were washed in 2 x 5 minute washes in TBS. 0.5% biotinylated 
secondary antibody (50μl in 1.5% horse serum) was applied to all sections and 
incubated for 30 minutes at RT. Sections were washed in 2 x 5 minute washes in TBS 
prior to the addition of the ABC-HRP reagent (100μl ‘A’ reagent, 100μl ‘B’ reagent’ in 
10 ml TBS, prepared at least 30 minutes prior to use), and left to incubate for 30 
minutes. A final 2 x 5 minute wash step with TBS followed. Antibody staining was 
visualised by incubating sections for 5 minutes with the substrate DAB (Vector 
Laboratories, UK) (100μl buffer, 200μl DAB, 100μl hydrogen peroxide in 5 ml dH2O), 
the enzyme reaction was quenched by washing the slides with dH2O. Sections were 
counterstained using Harris's haematoxylin (Leica, UK) (5-10 seconds) before being 
dehydrated through graded alcohols [70%, 95%, 100%, 100% (Fisher Scientific, UK)] 
for 30-60 seconds each and cleared in xylene (Fisher Scientific, UK) for 5 minutes. 
Sections were mounted using DPX mounting media (Leica, UK) and glass cover slips 
(Fisher Scientific, UK) and viewed using an Olympus microscope (BX61) (Olympus, 
UK). 
2.3.8 Astrocyte marker immunohistochemistry 
IHC was carried out on all cases (Appendix III) following the standard ABC-HRP 
technique (Vectastain Elite kit; Vector Laboratories UK) with DAB (Vector 
Laboratories UK) as substrate. Rabbit or mouse immunoglobulin (Ig) ABC elite kits 
(Vector laboratories, UK) were used depending on the species of primary antibody 
(Table 2.1).The antigen retrieval method required for each antibody is indicated in 
Table 2.1. Control staining was carried out on additional sections with the omission of 






Table 2.1 Antibody source, specificity, antigen retrieval method and role of antigen 
Astrocyte candidate markers were used to qualitatively and quantitatively assess the 
phenotype of astrocytes in PM CNS tissue. (All dilutions were made in the appropriate 
blocking serum). 




2.3.9 Immunohistochemistry (IHC) 
For ALDH1L1, GFAP and S100B IHC sections were incubated with 1.5% goat serum 
for 30min at RT, whilst for EAAT1, EAAT2, GS and CD44 IHC sections were 
incubated with 1.5% horse serum. Blocking sections prevented non-specific binding of 
the primary and secondary antibodies. CD44 antibody was initially optimised by 
selecting a range of dilutions based on the manufacturer’s recommendations, while all 
the other primary antibodies were used at previously published concentrations, 
(Simpson et al 2010). Table 2.1 provides a summary of the primary antibodies used in 
this study, each primary antibody was prepared in blocking solution and sections were 
tapped to remove excess blocking solution prior to the addition of ~100μl primary 
antibody to each section. The sections were left to incubate for 1 hour at RT before 
being washed with TBS (2 x 5 minute washes). Biotinylated species-specific secondary 
antibody was prepared, by adding 150 µl goat/horse serum in 10 ml TBS and then 
adding 50 µl of biotinylated secondary antibody. Secondary antibody (100 µl/section) 
was left to incubate at RT for 30 minutes prior to being washed with TBS (2 x 5 minute 
washes). The ABC reagent was prepared by adding 100 µl reagent A and reagent B to 5 
ml TBS at least 30 minutes prior to use. ABC reagent was added to the sections and left 
to incubate at RT for 30 minutes, prior to washing with TBS (2 x 5 minute washes). 
DAB substrate (Vector Laboratories, UK) was prepared by adding 100 µl hydrogen 
peroxide 200 µl DAB and 100 µl buffer to 5 ml dH2O. DAB was added to the sections 
(100 µl/section) and left for 5 minutes and the reaction was stopped by washing the 
sections in water. Sections were counterstained in Harris's haematoxylin (Leica, UK) for 
30 seconds, rinsed in tap water until the water ran clear, dehydrated in a series of graded 
alcohols (Fisher Scientific, UK) and mounted using DPX (Leica, UK) and glass 
coverslips (Fisher Scientific, UK). For internal controls, the primary antibody was 
omitted to ensure the absence of non-specific binding from the secondary antibody. 
2.3.10 Image analysis  
All IHC and histology was examined using the BX61 Olympus microscope and CellR 
image software system (Olympus, UK). Case identification and classification was 
determined by two independent observers (Rachel Waller and Dr. Julie Simpson) based 
on the published criteria by Lassmann 2011b. A qualitative description of the staining 
pattern of each antibody was noted across the different lesion types and control samples. 
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2.3.11 Quantitative analysis of astrocyte marker immunoreactivity  
To provide a quantitative analysis of the different astrocyte markers, the analySIS^D 
software was used on captured images from all lesion types. Images were captured from 
5 random fields within the three regions of interest (ROI), these being the lesion centre, 
the immediate lesion edge (periplaque white matter [PPWM]), NAWM/control WM at 
x20 magnification. In order to increase the number of cases investigated, data from both 
control WM and MS NAWM cases were pooled together as there was no difference in 
the data from each of the markers investigated between the two groups. Using 
analySIS^D software the total immunoreactive area of the field was determined per total 
area studied. For S100B a particle counting of greater than 300 pixels was used to 
eliminate any positive identification of the smaller positively stained oligodendrocytes, 
thereby only measuring the larger astrocytes. The average percentage area of 
immunopositive staining of each marker within the WM from all ROI was used for 
statistical analysis. 
2.3.12 Statistical analysis 
Statistical analysis of the expression of each astrocyte marker across control/NAWM 
and lesional groups was performed on PASW 18 (formerly SPSS) and overseen by 
Prof.. Stephen Wharton. Using a Kruskal-Wallis test the relationship between the 
different astrocyte markers and the lesion types were carried out. This identified, across 
the cohort, whether statistical relevance was present. This was followed by a pair wise 
Mann-Whitney U test to identify statistical differences in marker expression between 
the lesional groups and control/NAWM samples. 
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2.4 Results  
2.4.1 CNS tissue classification  
Initially 55 MS and control samples, [(12 MS cases, 3 brain regions) (10 CO cases, 2 
brain regions*)] were assessed for evidence of inflammation, demyelination and the 
presence of amoeboid microglia to enable classification into lesion type (Lassmann 
2011) (Table 2.2). The majority (33/36) of MS patient samples displayed some level of 
inflammation and lesional activity with only 3 samples identified as classical MS 
NAWM i.e., no inflammatory cell infiltration, no evidence of demyelination (as shown 
by positive LFB staining) and a regular distribution of resting ramified microglia (as 
shown by CD68 staining). Around one third (36%) of MS patient samples presented 
with multiple lesion types which varied considerably.  
14 tissue blocks were classified as EA lesions, these lesion centres were highly 
attenuated with the region being hypercellular, as identified through H&E staining. 
There was a loss of LFB stain, which was patchy in some samples depending on the 
advancement of the lesion. EA lesion centres contained a dense distribution of CD68+ 
microglia with a phagocytic phenotype presenting as large, swollen, amoeboid cells 
with retracted processes, in comparison to the surrounding NAWM where the CD68+ 
cells were bipolar, ramified with extending processes (Figure 2.3). 
26 MS patient samples contained one or more LA lesion, these lesion centres were 
highly attenuated and hypocellular, with the presence of PVC and inflammation. There 
was a complete loss of LFB in LA lesions with a clear demarcation of the lesion border. 
Within the lesion centre, few CD68+ cells were present, and were ramified and bipolar 
in appearance. CD68 immunoreactivity was increased at the lesion border where a band 
of swollen, amoeboid microglia were identifiable, suggestive of a phagocytic phenotype 
at the area of ongoing demyelination (Figure 2.3). 
5 MS patient samples presented with IA lesions, these lesions were again highly 
attenuated with thickening of blood vessels. There was a loss of myelin pallor and the 
lesion centre was hypocellular. Clear demyelination was evident by the complete loss of 
LFB staining, however there were very little CD68+ microglia and no evidence of 
amoeboid microglia with a phagocytic phenotype, suggesting no ongoing demyelination 
in these IA lesions (Figure 2.3).   




Table 2.2 Overall histological classification of MS samples                                                  
All samples were histologically characterised by two independent observers for full 
patient details see Appendix III. 
Key: EA: Early active lesion (acute), LA: Late active lesion (chronic active), IA: 
Inactive lesion, NAWM: normal appearing white matter, (1): Superior frontal gyrus, 
(8): Thalamus + subthalamic, (9): Hippocampus anterior, (10): Temporal cortex, (11): 
Precentral gyrus - Motor cortex, (12): Primary visual cortex anterior, (13): Parietal 




Figure 2.3 Tissue classification using H&E, LFB and CD68                                                
EA lesions contained swollen, amoeboid phagocytic microglia with strong CD68 
staining, in comparison to LA lesions that showed a hypercellular band of CD68+ 
amoeboid microglia at the perilesional (PL) edge (black arrows) with very few CD68+ 
cells within the lesion centre. Inactive (IA) lesions were highly attenuated, with 
complete loss of myelin and hypocellularity present in the lesion centre with no 
evidence of microglia activity.  Control and NAWM were grouped together showing 
similar characteristics with no evidence of perivascular leukocyte accumulation, intact 
myelin and few CD68+ microglia with a phagocytic phenotype. Key: GM: grey matter. 
Scale bar represents 1000μm.
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All 19 control samples showed no evidence of inflammatory cell infiltration and 
contained a regular distribution of cell nuclei on H&E. There was no evidence of 
demyelination with a uniform distribution of LFB staining throughout the tissue, and a 
regular distribution of CD68+ microglia with a resting ramified profile (Figure 2.3).  
Similar to control WM, MS NAWM surrounding all lesions investigated showed no 
evidence of inflammation or PVC, the cell distribution was regular throughout the tissue 
with intact myelin shown by positive LFB staining. A regular distribution of CD68+ 
microglia with a resting ramified appearance was apparent, with the occasional 
clustering of microglia. 
2.4.2 Microglia phenotype – ramified versus amoeboid 
Microglia are sensitive to environmental changes and respond to stress, trauma, 
infection (Boche et al 2013), therefore the phenotype of microglia provides an insight to 
each tissue sample, helping to classify the lesion type present in each case. CD68+ 
microglia with a swollen, hypertrophic, amoeboid appearance accumulate in abundance 
within EA lesions and surrounding LA lesions, with retracted processes indicative of 
phagocytic microglia which play a key role in demyelination (Figure 2.4a). In contrast, 
control WM and NAWM contained a regular distribution of CD68+ cells, displaying a 
more uniform, bipolar appearance with branched processes suggestive of resting 
microglia, which play a role in regulating and surveying the CNS in case of insult or 
trauma (Figure 2.4b).  In some areas of NAWM, clusters of CD68+ microglia were 
present (Figure 2.4c), which have been suggested to form preactive lesions in MS (van 
der Valk & Amor 2009, van Noort et al 2011). 
2.4.3 Negative controls 
To determine the level of background staining when carrying out IHC, negative and 
isotype controls were used. The omission of each primary astrocyte antibody and use of 
appropriate isotype control (at the same concentration as the primary antibody) was 
carried out on an additional NAWM section during each IHC run. No background 




Figure 2.4 Patterns of CD68 immunoreactivity detected in the WM in MS CNS               
The morphology of microglia, as determined by CD68 IHC, is indicative of the 
physiological state of the CNS of the patient. Microglia that take on a swollen, 
hypertrophic, amoeboid appearance with retracted processes are suggestive of 
phagocytic microglia (a, red arrows). In comparison, resting microglia appear bipolar 
and ramified with extending processes (b, red arrows). Within particular areas of 
NAWM the microglia appeared in clusters rather than a regular distribution (c, green 




Figure 2.5 Negative controls                                                                                                  
The omission of primary antibodies for GFAP (a), S100B (b) EAAT1 (c), EAAT2 (d), 




2.4.4 Glial fibrillary acidic protein (GFAP) immunoreactivity increases within 
chronic active lesion centres                               
Dense GFAP immunoreactivity was a common feature of all lesion types (EA, LA, and 
IA lesions) with levels of GFAP significantly different across all groups (GFAP 
p=0.001, Kruskal-Wallis test). In a qualitative assessment, NAWM immediately 
surrounding MS lesions displayed an increase in GFAP immunoreactivity compared to 
control WM. There were clear differences in the size of astrocytes between MS samples 
regardless of lesion type, with some positively stained small stellate cells present in 
some samples, while others contained swollen and hypertrophic immunopositive cells. 
Overall there was a regular distribution of GFAP+ astrocytes with a typical stellate 
morphology and extending processes in control/NAWM samples (Figure 2.6a, red 
arrows). An increase in immunoreactivity was present at the EC of blood vessels within 
all lesion types, yet individual cell types were hard to distinguish as a result of the dense 
gliosis present within lesion centres (Figure 2.6c). In some LA lesions immunopositive 
swollen, hypertrophic astrocytes were present at the lesion edge (Figure 2.6b, green 
arrows). Quantitatively all lesion types displayed a significant increase in GFAP 
immunoreactivity compared to control/NAWM cases (EA; p= 0.002, LA; p= 0.000, IA 
p= 0.023, Mann-Whitney U tests, Figure 2.7), confirming initial qualitative analysis. 
Mann-Whitney U tests between lesion types did not identify significant differences in 
GFAP expression (EA versus LA; p= 0.894, EA versus IA; p= 1.000, and LA versus IA; 
p= 0.945). 
2.4.5 S100B immunoreactivity increases within chronic active lesion centres 
S100B astrocyte immunoreactivity in the WM was primarily associated with the 
astrocyte cell body, with more typical stellate astrocyte profiles seen in the cortex. 
Overall a regular distribution of S100B+ astrocytes was seen throughout the 
control/NAWM comprising of immunopositive cell body and immediate dense 
processes (Figure 2.8a, red arrows). The staining of delicate extended astrocyte 
processes was not as extensive with S100B as with GFAP. Also within the 
control/NAWM samples an intense staining of small spherical cells morphologically 
resembling oligodendrocytes was observed (Figure 2.8a, blue arrows). Some samples 
showed a punctate diffuse pattern of staining, however a qualitative increase in S100B 
immunoreactivity was visualised within the different lesion types, however individual 
cell profiles within the lesions were hard to determine due to gliosis (Figure 2.8c). The 
presence of S100B+ hypertrophic, swollen astrocytes were seen at the lesion edge of 




Figure 2.6 GFAP expression by IHC                                                                                     
The expression of GFAP (brown) within the control/NAWM identified individual 
stellate cells easily distinguishable (a, red arrows). At the lesion border a band of 
swollen hypertrophic GFAP+ astrocytes were prominent (b&c, green arrows), leading 
into the lesion centre with a significant increase in staining (d), individual cells were no 
longer distinguishable in all 3 lesion types.  Sections were counterstained with 
haematoxylin. Scale bar represents 100μm (a,b,d) 50um (c). 
Key: PPWM: Periplaque White Matter, L: lesion, Blue lines represent lesion border. 
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Figure 2.7 Comparison of GFAP immunoreactivity in neurological 
controls/NAWM samples and different MS lesion types                                                        
y-axis represents the overall percentage (%) area immunoreactivity of GFAP. GFAP 
expression was significantly increased in all lesion types in comparison to 
controls/NAWM samples of this study. Individual statistical differences between 






Figure 2.8 S100B expression by IHC                                                                                  
The expression of S100B (brown) within the control/NAWM identified dense cell body 
staining with immediate processes (a, red arrows) the presence of oligodendrocyte like 
staining was evident (a, blue arrows). The immunoreactivity was significantly increased 
within the lesion centre with individual cells hard to distinguish (c).  Sections were 
counterstained with haematoxylin. Scale bar represents 100μm. 
Key: PPWM: Periplaque White Matter, L: lesion, Blue lines represent lesion border. 
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where there appeared to be fewer S100B+ cells. Levels of S100B were significantly 
different across all groups (S100B p=0.000, Kruskal-Wallis test). Quantitatively all 
lesion types displayed a significant increase in S100B immunoreactivity compared to 
control/NAWM cases (EA; p= 0.035, LA; p= 0.000, IA p= 0.033, Mann-Whitney U 
tests, Figure 2.9) confirming qualitative analysis. Mann-Whitney U tests between lesion 
types did not identify significant differences in S100B expression, (EA versus LA; p= 
0.048*, EA versus IA; P=0.704, and LA versus IA; P=0.230).                                                          
* Not significant when the p-value is adjusted using the Bonferroni correction. 
2.4.6 Excitatory amino acid transporter 1 (EAAT1) expression within chronic active 
lesion centres 
EAAT1 protein expression displayed the most varied staining pattern amongst the seven 
different markers investigated. Overall the staining pattern varied greatly amongst the 
different MS/control samples and across the different lesion types. However, in general 
the immunoreactivity was restricted to the fine delicate processes of astrocytes in the 
NAWM and control samples. The extent of the astrocyte process extensions were 
clearly visible in the tissue (Figure 2.10a, red arrows). Qualitatively within the lesion 
centre a decrease in EAAT1 expression was observed across all three different lesion 
types (Figure 2.10c), however the quantitative findings suggesting an increase in 
EAAT1 immunoreactivity within all lesion centres investigated. However, these 
findings failed to reach statistical significance (EAAT1 p= 0.278, Figure 2.11a). 
2.4.7 Excitatory amino acid transporter 2 (EAAT2) expression within chronic active 
lesion centres 
EAAT2 immunoreactivity was restricted to the delicate astrocyte processes (Figure 
2.12a, red arrows). Overall the staining was punctate and irregular throughout the 
different control WM and NAWM samples, with some control samples staining 
extensively (Figure 2.12a) while other samples were completely devoid of staining. 
However, in general a qualitative assessment of the pattern of staining showed a 
decrease in EAAT2 immunoreactivity within the different lesion types in comparison to 
control and NAWM (Figure 2.12c), however the quantitative findings suggesting an 
increase in EAAT2 immunoreactivity within the lesion centres investigated. However, 





Figure 2.9 Comparison of S100B immunoreactivity in neurological 
controls/NAWM samples and different MS lesion types                                                                                
y-axis represents the overall percentage (%) area immunoreactivity of S100B.  S100B 
expression was significantly increased in all lesion types in comparison to 
controls/NAWM samples of this study. Statistical differences between control/NAWM 






















Figure 2.10 EAAT1 expression by IHC                                                                                   
A diffuse irregular pattern of EAAT1 staining was identified in control/NAWM 
labelling the astrocyte processes (a, red arrows) and at the lesion border (b). 
Qualitatively an overall decrease in EAAT1 expression was seen within the lesion 
centres (c).  Sections were counterstained with haematoxylin. Scale bar represents 
100μm. 
Key: PPWM: Periplaque White Matter, L: lesion, Blue lines represent lesion border. 
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Figure 2.11 Comparison of EAAT1 (a), EAAT2 (b) and GS (c) immunoreactivity in 
neurological controls/NAWM samples and different MS lesion types                                           
y-axis represents the overall percentage (%) area immunoreactivity of each antibody.  
Quantitatively a trend of increased reactivity of all three antibodies was observed in all 
lesion types in comparison to control/NAWM, yet no significance for any of the 
markers across the lesion types was observed. 





















Figure 2.12 EAAT2 expression by IHC                                                                                     
A pitted, diffuse astrocyte process stain (brown) was presented in the control/NAWM 
with EAAT2 (a, red arrows). Qualitatively the expression of EAAT2 was reduced at the 
lesion edge (b) and within the lesion centre (c).  Sections were counterstained with 
haematoxylin. Scale bar represents 100μm. 







2.4.8 Glutamine synthetase (GS) expression within chronic active lesion centre 
GS immunoreactivity in astrocytes identified cells with a stellate morphology, and was 
predominantly restricted to the cell body and immediate processes, proving not as 
extensive as with GFAP labelling (Figure 2.13a, red arrows). GS immunoreactivity was 
not restricted to astrocytes as positive staining of the cytoplasm of small, spherical cells 
which morphologically resembled oligodendrocytes (Figure 2.13b, blue arrows) were 
also labelled. Within all lesion types investigated a qualitative assessment identified that 
GS immunoreactivity was reduced in lesion centres (Figure 2.13c), however the 
quantitative findings suggesting an increase in GS immunoreactivity within all lesion 
centres investigated compared to control/NAWM cases. However, these findings failed 
to reach statistical significance (GS p=0.068, refer to Figure 2.11c). At the border of 
some LA lesions was the presence of swollen, hypertrophic GS+ astrocytes (Figure 
2.13b, red arrows). The reactivity of GS appeared greater in the cortex than the WM. 
2.4.9 Aldehyde dehydrogenase L 1 (ALDH1L1) is primarily associated with cortical 
tissue 
The staining pattern displayed by ALDH1L1 immunoreactivity was of the astrocyte cell 
body and did not extend to the fine delicate extended astrocyte processes. ALDH1L1 
also was expressed by small, spherical cells indicative of oligodendrocytes (Figure 
2.14a, blue arrow). A more extensive staining pattern with this marker was seen in the 
cortex compared with the WM, where the immunoreactivity appeared to be dramatically 
reduced and in some samples absent (Figure 2.14b). 
2.4.10 CD44 expression is not detectable in formalin fixed paraffin embedded 
(FFPE) tissue 
Initial optimisation studies with the astrocyte marker CD44 within snap frozen tissue 
sections showed a clear distinct staining of WM astrocytes with the processes 
ensheathing blood vessels (Figure 2.15a). In comparison throughout the cortex CD44 
immunoreactivity was reduced identifying this marker as a potential WM astrocyte 
marker. Despite a comprehensive range of antigen retrieval methods, this CD44 
antibody failed to provide clear immunoreactivity in the FFPE material (Figure 2.15b). 
Overall the immunodetection of CD44 in the FFPE material failed to replicate the 
pattern of staining observed in the frozen material, therefore this antibody was not 




















Figure 2.13 GS expression by IHC                                                                                         
The expression of GS (brown) within the control/NAWM identified small stellate cells 
(a, red arrows).  In some samples at the lesion border a band of swollen GS positive 
astrocytes were prominent (b, red arrows). Also GS positive oligodendrocyte like cells 
were present (b, blue arrows). Qualitatatively GS protein expression was reduced within 
the lesion centre (c) in comparison to the lesion edge and control/NAWM.  Sections 
were counterstained with haematoxylin. Scale bar represents 100μm. 



















Figure 2.14 Higher expression of ALDH1L1 in cortex compared with white matter 
Levels of ALDH1L1 were more abundant within the cortex (a) in comparison to white 
matter (b). Red arrows: astrocytes, blue arrow: possible oligodendrocytes. Sections were 




Figure 2.15 Comparison of CD44 expression in snap frozen and FFPE CNS tissue              
The expression of CD44 (brown) on frozen issue was localised to the astrocyte end 
processes at blood vessels in the WM (a). CD44 staining of FFPE tissue failed to repeat 
the pattern of staining observed in the frozen material (b), despite a range of antigen 




2.5 Discussion   
In this study the astrocyte phenotype was characterised in the WM from both MS and 
controls. Using a panel of seven currently recognised astrocyte markers, the pattern and 
extent of immunoreactivity within the lesion centre, perilesional edge and the 
surrounding NAWM was determined. Significantly more hypertrophic astrocytes, as 
indicated by a significant increase in GFAP and S100B immunoreactivity, were present 
in all lesion types in comparison to surrounding NAWM and control WM. In contrast, a 
dysregulation of glutamate in all MS lesion types compared to control WM and 
surrounding NAWM was identified by a non-significant increased expression of the 
glutamate transporters EAAT1 and EAAT2 along with an increase in the glutamate 
regulatory enzyme GS.  
2.5.1 Increased expression of GFAP and S100β in MS lesions  
With lesion progression and response to pathological injury, astrocytes become reactive 
and undergo astrogliosis with changes in their expression profile, overall morphology 
and function. In remyelinating and demyelinating lesions, astrocytes may act as either 
immune cells or supporting cells, expressing an array of cytokines/chemokines 
dependant on the stage of disease, their interactions with other cell types and changes in 
their surrounding environment (John et al 2002, Nair et al 2008). In the current study 
individual GFAP+ cells were difficult to distinguish within MS lesions due to the 
prominent gliosis present. Within the LA lesion centres GFAP+ astrocytic scar tissue 
were observed, supporting previous observations (Eng et al 1971, Fawcett & Asher 
1999, Fitch & Silver 2008, Hibbits et al 2012, Holley et al 2003). A significant increase 
in GFAP immunoreactivity in MS lesions represents on-going fibrillary gliosis 
(Brosnan & Raine 2013). Large hypertrophic GFAP+ astrocytes were prominent at the 
perilesional edge of a subset of LA lesions, which has previously been reported in MS 
/EAE lesions (Lavrnja et al 2012).  
In response to injury/insult astrocytes undergo cellular hypertrophy and increase their 
expression of GFAP. However previous histological studies investigating GFAP 
expression in MS human brain tissue are surprisingly infrequent in comparison to 
animal/cell models or human CSF/serum studies. A 3-fold increase in GFAP expression 
in the cortex of MS patients compared to control samples has been observed, however 
this study failed to analyse GFAP levels in WM of MS patients, where most MS lesions 
are located (Petzold et al 2002). A small number of human MS PM studies have 
identified an increase in GFAP+ astrocytes in areas of demyelination (Clarner et al 
65 
 
2012, Kipp et al 2011, Nishie et al 2004) supporting the findings from the current study, 
increasing the awareness that astrogliosis is a pathological hallmark MS.  
 
A significant increase in CSF levels of GFAP has been reported from patients with 
SPMS, while levels of GFAP in RRMS patients were similar to control patients, 
suggesting that astrocytes have a role at the later stages of chronic demyelination 
(Linker et al 2009). GFAP levels are likely to correlate with the neurodegenerative 
processes of MS, and have been associated with the Expanded Disability Status Scale 
(EDSS) and the MS Severity Status (MSSS) (Axelsson et al 2011). An increase in CSF 
GFAP levels  in SPMS supports the view that levels of GFAP positively correlate with 
neurodegeneration, which is more apparent in SPMS (Malmestrom et al 2003, Norgren 
et al 2004). However, other studies indicate neither CSF GFAP levels in MS patients 
significantly differ to control patients (Petzold et al 2002) nor correlate with the 
patient’s EDSS (Madeddu et al 2013). 
 The current histological study investigated WM from SPMS, but future studies aimed 
at determining levels of GFAP in RRMS/PPMS patients could determine whether 
GFAP expression is significantly higher in those cases than control cases. However, 
obtaining such material for human studies is challenging as the majority of patients that 
present at PM have transferred into the SP phase of the disease, with a well-established 
disease phenotype.  
 
There are a number of limitations to CSF studies when monitoring potential biomarkers 
of brain disease including GFAP. Foremost, CSF is not brain tissue and the protein 
profile from CSF may in part be influenced by other factors not relevant to the disease 
itself (Giovannoni 2006, Shiihara et al 2013) and with a general lack of CSF samples 
from healthy controls, comparison studies are problematic (Teunissen et al 2013). Also, 
standardised methods of CSF sample collection and processing between laboratories 
need to be applied to prevent variability in these types of study (Giovannoni 2006, 
Mattsson et al 2013). Analysis of CSF and serum samples for biomarkers is restricted 
by technology (Mattsson et al 2013), as many ELISA tests would be impractical in an 
emergency setting (Shiihara et al 2013), however developing mass spectrometry 
techniques may overcome this. Despite the limitations, CSF is the closest biological 
fluid to the pathology of the brain (Smolinska et al 2012) and by using this material 
disease development can be monitored throughout life, whereas histological evaluation 
of brain tissue is limited mainly to PM tissue. 
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Recent work on MS animal models have shown similar findings to the current study, 
with a regular distribution of GFAP+ astrocytes observed in control mice, while over the 
course of MOG induced EAE, astrocytes become strongly GFAP+ with a diffuse 
staining pattern indicative of a gliotic response (Linker et al 2009). An increase in 
GFAP expression has also been observed in other models of demyelination including 
EAE in rats and chronic relapsing EAE in mice (Lavrnja et al 2012, Norgren et al 2004, 
Petzold et al 2003a).  
 
An increase in S100B, an established marker for astrocyte metabolism involved in 
intracellular and extracellular regulatory activities, has been linked to many 
neurodegenerative disorders including Parkinson’s disease (PD) (Sathe et al 2012, 
Schaf et al 2005), amyotrophic lateral sclerosis (ALS) (Migheli et al 1999, Sussmuth et 
al 2010) and AD (Peskind et al 2001, Petzold et al 2003b). As astrocytes are 
increasingly recognised as more than just a supportive cell in the CNS, the increased 
astrocyte expression of S100B within MS lesions may indicate a fundamental important 
role of these cells in the pathogenesis of neurological disease. Elevated S100B levels are 
associated with activation of neurotoxic pathways triggering neuroinflammatory 
responses, including increased expression of receptor for advanced end glycation 
products (RAGE) ligand (Bianchi et al 2007). Also S100B induces the rise in ROS, 
cytochrome C release and activation of the caspase cascade (Bianchi et al 2007, Sen & 
Belli 2007). Elevated S100B encourages the release of proinflammatory cytokines from 
astrocytes, as well as being involved in apoptosis through the decreased expression of 
the anti-apoptotic protein B-cell lymphoma 2 (BCL2) (Rothermundt et al 2003), 
contributing to neurodegeneration (Hearst et al 2011).  
Many studies on MS have identified an increase in S100B protein in the CSF/serum 
samples taken from patients (Bartosik-Psujek et al 2011, Rejdak et al 2007), which has 
been inferred as a marker of activated astrocytes (Rothermundt et al 2003, Sen & Belli 
2007). These findings support our results of an increased trend in S100B expression in 
all MS lesions types (Bartosik-Psujek et al 2011, Michetti et al 1979, Missler et al 
1997, Petzold et al 2004, Petzold et al 2002, Rejdak et al 2007). Despite the many 
studies supporting this theory it is worth noting that there is conflicting research that has 
failed to identify an increase in serum/plasma S100B in patients with either PPMS, 
RRMS or SPMS and consequently no correlation with disease activity (Koch et al 2007, 
Lim et al 2004). The trophic and toxic effects of S100B are mainly controlled by 
RAGE, a cell surface receptor found on neurons and microglia (Bianchi et al 2011, 
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Villarreal et al 2011) known to activate NF-kB and other proinflammatory responses 
such as the induction of TNFα and IL-6 expression (Basta et al 2002). The binding of 
S100B to RAGE initiates the activation of the inflammatory cascade, which may 
contribute to the inflammatory component of MS by chemoattracting RAGE+ CD4+ T 
cells (Yan et al 2003). Crucially the effect of extracellular S100B, whether trophic or 
neurotoxic, depends on its relative concentration, and also on the activation and 
expression of the ligand RAGE on corresponding cells (Sorci et al 2010). Under 
physiological conditions at low (nanomolar) levels S100B has been shown to be 
neuroprotective, protecting neurons from apoptosis, stimulating neurite growth enabling 
astrocyte proliferation and negatively controlling astrocytic/microglia response to 
harmful agents (Bianchi et al 2007, Sorci et al 2013). While at higher concentrations, 
(micromolar levels), S100B has shown to be cytotoxic displaying it’s DAMP (damage-
associated molecular pattern protein) effects (Donato 2001) and increasing intracellular 
NO production and calcium load causing RAGE dependant apoptosis and neuronal cell 
death (Bianchi et al 2011, Hu et al 1997, Iuvone et al 2007, Sorci et al 2013, Villarreal 
et al 2011).  
Studies have shown that glial pathology precedes neuronal degeneration in MS inferring 
a potential role of S100B in disease mechanisms (Petzold et al 2003b). In contrast to 
our findings, where no significant differences between S100B expression in the 
different lesion types was found, a study identified a higher expression of S100B in the 
early lesions compared to the later lesions (Petzold et al 2002). As well, this study 
reported a higher expression of S100B in NAWM compared to control WM, which was 
not seen in the current study. This may be due to a number of factors including 
differences in IHC protocols used and the use of different antibodies, the effects of 
which are discussed later in this chapter. Furthermore, this study based their histological 
criteria using an older, alternative lesion classification method (Li et al 1993), claiming 
that astrocyte activation in early lesion development may return to normal despite 
continuing microglial activation in MS development. In contrast we report a significant 
increase in S100B expression in all lesion types investigated. The overall effect of an 
increase in S100B concentration could contribute to  neurodegeneration, myelin 
degradation and inflammation associated with MS, as in vitro micromolar levels of 
S100B have been shown to induce NO secretion by microglia, and induce the down 
regulation of genes such as BCL2 known to cause apoptosis of neuronal precursor cells 
(Wang et al 1999).  
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To date, there are limited neuropathological studies investigating the distribution of 
S100B at the cellular level in human CNS tissue from diseased cases, as much of the work 
has been conducted on cell lines or animal models of disease, as reviewed by (Steiner et 
al 2011). However a recent paper showed higher levels of S100B protein in PM substantia 
nigra of patients with PD compared with control tissue, concluding that S100B-associated 
neurodegeneration was mainly mediated by the RAGE/TNFα pathway (Sathe et al 2012). 
Future neuropathological studies of human CNS tissue should be carried out to elucidate 
the relationship between S100B and neurological disease and ultimately unravel the role 
of astrocytes in disease.  
2.5.2 Increased expression of EAAT1, EAAT2 and GS in MS lesions  
Glutamate is the primary excitatory neurotransmitter in the CNS and astrocytes play a 
role in moderating its synaptic transmission, through a number of glutamate transporters 
and receptors. Very little glutamate transverses the BBB, this is mainly due to the role 
of astrocytes, and their influence in the selectivity of substances that pass into and out of 
the CNS. Astrocytes regulate levels of glutamate by taking up the neurotransmitter from 
the synaptic cleft via the expression of multiple glutamate transporters. Glutamate is 
converted to glutamine via metabolising enzymes such as GS and released to neurons 
(Deitmer et al 2003). Within neurons, glutamine is converted back to glutamate via 
mitochondrial enzymes and transported to synaptic vesicles for release. The release of 
glutamate into the synaptic space enables excitatory neurotransmitter signals to be 
generated, the signal is terminated when astrocyte transporters such as the EAATs 
remove glutamate from the synaptic space. This cycle of events is referred to as the 
glutamate-glutamine cycle (Hertz 2004).    
Previous studies have identified that around 80% of the total uptake of glutamate is 
through two specific transporters, EAAT1 and EAAT2 located primarily on astrocytes 
(Maragakis et al 2004a, Maragakis et al 2004b, Rothstein et al 1996), but also 
expressed by oligodendrocytes (Danbolt 2001, Werner et al 2001). Many reports have 
suggested a decrease in glutamate transporter expression and increased activation of 
glutamate receptors as being associated with glutamate excitotoxicity in MS (Danbolt 
2001, Frigo et al 2012, Kostic et al 2012). Glutamate binds with glutamate receptors 
expressed on postsynaptic neurons including the a-amino-3-hydroxy-5-methyl-4-
isoxazolepropionic acid (AMPA), N-methyl-D-aspartate (NMDA) and kainite receptors 
causing the initiation of signalling cascades (Stojanovic et al 2014). Yet in MS an 
increase in glutamate within the CNS occurs due to inflammatory mediator actions and 
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the release of glutamate from infiltrating cells (Stojanovic et al 2014). It has been 
proposed that glutamate excitotoxicity in MS is the result of decreased glutamate 
transporter action and therefore an impairment of excess glutamate uptake. This 
contributes to a surplus amount of glutamate available in the CNS that leads to the 
overstimulation of NMDA receptors (Stojanovic et al 2014). The beneficial effects of 
glutamate receptor antagonists used in EAE studies provides additional evidence to 
support the involvement of glutamate in MS pathology (Stojanovic et al 2014). 
Prolonged activation of glutamate receptors directly damages not only neurons but also 
oligodendrocytes (Matute 2006). As a result of an altered glutamatergic system, an 
impairment of calcium homeostasis, activation of nitric oxide synthase (NOS), 
generation of free radicals, programmed cell death and consequently progressive 
neurodegeneration could occur (Mehta et al 2013).  
In this current study there was an increased level of EAAT1, EAAT2 and GS expression 
by astrocytes in MS lesion centres in comparison to the surrounding NAWM and 
control samples. However, these differences failed to reach statistical significance, most 
probably explaining the contradictory qualitative findings that suggested a reduced 
expression of EAAT1, EAAT2 and GS by astrocytes in MS lesion centres compared to 
the surrounding control/NAWM. A reduced expression in these key proteins supports 
existing literature, suggesting that in MS an impaired astrocyte glutamate regulation 
leads to glutamate excitotoxicity, a contributing factor in the development of MS (Frigo 
et al 2012, Kostic et al 2012). 
Astrocytes express EAAT1 and EAAT2 in domains that are close to the sites of 
neuronal release of glutamate. Consequently astrocytes have the ability to react to 
increases in glutamate levels by redistributing their transporters for optimum uptake of 
excess glutamate within the CNS (Shin et al 2009). The expression of these particular 
transporters by astrocytes has been studied in different neurological diseases such as 
motor neuron disease (MND) (Honig et al 2000) AD (Scott et al 2011) and 
schizophrenia (Nanitsos et al 2005). In both MS and EAE, a reduction in EAAT1 and 
EAAT2 expression has been shown by IHC and WB (Olechowski et al 2010, Pampliega 
et al 2008, Vercellino et al 2007) contradicting the current IHC study. Research into 
memory impairment in MS patients also identified the decreased astrocyte expression of 
EAAT1 and EAAT2 by WB despite the presence of strong astrogliosis within the 
hippocampus (Dutta et al 2011).  This study is also supported by the loss of EAAT2 
staining in cortical MS lesions in areas of demyelination and inflammation, due to the 
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loss of astroglial expression rather than loss of astroglial cells which are relatively intact 
in lesions (Vercellino et al 2007). The decrease in both transporters EAAT1 and 2 could 
ultimately lead to an increase in extracellular levels of glutamate associated with 
glutamate excitotoxicity, a possible mechanism underlying MS pathogenesis.  
However in contrast, oligodendrocytes have been shown to express the highest level of 
the glutamate transporters within the CNS, this expression was reduced within MS WM 
lesions centres, where oligodendrocytes had been depleted (Werner et al 2001). 
Carrying out dual labelling with EAAT1/2 and specific cell markers for astrocytes and 
oligodendrocytes, such as Olig-2, would clarify whether the expression is restricted to 
oligodendrocytes over astrocytes as previously described (Domercq et al 1999, Werner 
et al 2001). An obvious limitation to carrying out these proposed dual IHC studies is the 
lack of a specific antibody that only labels astrocytes and that labels all astrocyte 
populations.  The EAAT1/2+ stellate cells, quantitatively assessed in the current study, 
morphologically resembled astrocytes and not smaller oligodendrocytes. The limitation 
with Werner’s 2001 study is the patient cohort size. Only six patients were investigated, 
3 patients had PPMS consisting of a variety of lesion types and 3 patients had SPMS all 
with silent lesions. Evidently this indicates the potential bias of the study, but also 
highlights possible differences in cellular expression of the transporters as a result of 
different disease courses of the patients.  
EAAT2+ cells with the same morphology and distribution as GFAP+ cells have been 
reported in active and chronic active lesions (CAL) directly supporting the non-
significant quantitative findings of the current study (Newcombe et al 2008). Likewise, 
the occasional EAAT1+ branched process bearing astrocyte was detected in control WM 
(Newcombe et al 2008) supporting current results. Similarly in agreement to the current 
study, an increase in EAAT1 messenger RNA (mRNA) and protein levels in the optic 
nerve from MS subjects correlated with an increased uptake of glutamate in these 
particular subjects (Vallejo-Illarramendi et al 2006). Overall these findings reinforce the 
potential differences in cellular and anatomical expression of the transporters between 
individuals. 
In support of the regional differences in glutamate transporter expression, animal 
models of MS have shown GLAST to be distributed differently between regions of the 
rat brain, with a marked reduction seen in the cerebellum at peak EAE disease 
(Mitosek-Szewczyk et al 2008). As well, GLAST mRNA and protein levels were 
related inversely throughout the course of the disease (Mitosek-Szewczyk et al 2008). 
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In comparison, in transgenic mice GLAST was seen to be more highly expressed in the 
dentate gyrus, cerebellum and hippocampus, while GLT-1 expression was localised to 
the cortex, spinal cord and hippocampal grey matter (Regan et al 2007). Similar 
regional differences in glutamate transporter expression between the WM and cortical 
regions of cuprizone treat mice has been detected (Azami Tameh et al 2013). TNFα 
released by infiltrating T cells has shown to increase microglial release of TNFα 
resulting in a reduction of EAAT1 expression by astrocytes, leading to glutamate 
excitotoxicity in a rat EAE model (Korn et al 2005). Similarly within MS WM lesions 
TNFα, released by infiltrating T cells and by resident glial cells, could reduce EAAT1 
expression leading to an impaired regulation of glutamate. 
Opposing qualitative and quantitative findings of EAAT1/2 and GS immunoreactivity 
within the current study suggests that more cases are needed to be investigated in order 
to provide more corroborative and significant results. As highlighted throughout this 
thesis, investigating PM material represents a single snap shot of that individual’s 
disease process. Investigating PM material provides no knowledge of how a particular 
lesion developed or would have developed if the patient had lived longer, which could 
provide the explanation for such varied and non-significant findings in the current 
study. 
As well, variation between the different fields of vision or ROI applied for both the 
qualitative and quantitative assessment of each case could contribute to the large 
variation in findings. Differences in the sampling of IHC ROI for quantitative analysis 
has been identified in other studies (Dunstan et al 2011, Makkink-Nombrado et al 1995, 
Mikkelsen et al 2011), appearing to be the major cause of lack of reproducibility, which 
could also apply in the current study. Clearly a more strict sampling protocol of ROI is 
mandatory to obtain reproducible, quantitative IHC results. However, this poses a 
challenge when studying MS human subjects with varying lesion size, disease stage and 
individual differences. Consequently, a random selection of 5 ROI for quantitative 
measurement in this study may not have been a true representation of EAAT1/2 and GS 
expression in human subjects.    
Clearly there are many studies investigating the role of glutamate transporters in MS 
pathology, however the overall findings are inconclusive. With MS being a 
heterogeneous disease with ever changing lesional activity, understanding the complex 
interplay between neurons and glia cells is crucial. A more systematic characterisation 
of astrocyte glutamate transporters and associated enzymes in relation to 
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neuropathology within the brain is needed. A greater understanding of their cellular 
expression, role in excitotoxicity, and effect on MS pathogenesis could potentially be 
used as a therapeutic target in prevention of disease progression.  
2.5.3 GS expression in MS lesions plays a role in glutamate excitotoxicity  
GS is the enzyme responsible for the conversion of glutamate and ammonia to 
glutamine in the glutamatergic system. The expression of GS is highly regulated and 
mediated by a number of substances such as insulin, thyroid hormone and corticosteroid 
hormone (Suarez et al 2002). GS is also expressed at various levels in different regions 
within the brain as identified in human MS and EAE animal studies (Castegna et al 
2011, Hardin-Pouzet et al 1997, Werner et al 2001). The expression of GS in the brain  
is localised to areas where glutamate binding and clearance is essential to prevent 
excitotoxicity, such as glutamatergic nerve terminals (Eid et al 2013).  GS is 
predominantly expressed by astrocytes at their proximal endfeet, and to a lesser degree 
by oligodendrocytes (Tansey et al 1991).  
In this current study a non-significant increase in GS expression was identified in all 
lesion types in comparison to the surrounding NAWM and control WM, however a 
contrasting qualitative analysis representing a reduction in immunoreactivity within all 
lesion types. A band of hypertrophic GS+ astrocytes were located at the perilesional 
edge of a number of LA lesion, as reported in previous studies (Newcombe et al 2008). 
This finding suggests that as perilesional astrocytes become reactive in response to 
increased levels of glutamate within the lesion centre, they increase GS expression in an 
attempt to prevent the spread of glutamate excitotoxicity and ultimately lesion spread. 
This accumulation of intracellular glutamate coupled to potassium uptake and 
accumulation of water could ultimately lead to cell death. Therefore the presence of 
amoeboid macrophages within EA lesions and surrounding LA lesions may not only be 
a result of on-going demyelination present in those areas but also due to cell death, 
including astrocyte death, as a result of increased levels of glutamate. In order to 
identify the distribution of glutamate within the MS CNS tissue further IHC with 
glutamate antibodies would help to clarify this. As well, additional work looking at 
possible apoptotic/cell damage markers associated with astrocytes would need to be 
carried out to confirm this hypothesis. Prolonged damage and death of astrocytes may 
lead to additional impairment of glutamate regulation exacerbating neuronal and glial 
cell damage (Newcombe et al 2008). Another implication of astrocyte swelling and 
oedema is the disruption of the BBB, which could lead to the infiltration of immune 
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cells and consequently immune responses associated with MS (Hardin-Pouzet et al 
1997). 
From previous human studies, the cellular localisation of GS in MS is of huge debate. In 
comparison to the current work, the presence of GS+ hypertrophic microglia at the 
perilesional edge of active lesions has been identified (Werner et al 2001). As this 
current study was primarily focussed on characterising the astrocyte phenotype in MS, 
the presence of GS+ microglia was not investigated. In previous studies, on normal WM, 
high level expression of GS was localised to CNPase+ oligodendrocytes, yet in MS 
active lesions GS immunoreactivity was lost from oligodendrocytes and primarily 
associated with astrocytes and microglia (Werner et al 2001). This study concluded that 
an absence of glutamate metabolising enzymes from oligodendrocytes demonstrated the 
importance of this cell type in regulating glutamate homeostasis, however this study 
failed to appreciate the loss of oligodendrocytes in MS lesions (Werner et al 2001). In 
comparison GS has shown to be localised to microglia in control WM, and macrophage 
/astrocytes in active plaques (Newcombe et al 2008) which support our findings. These 
differences in cellular expression of GS may be explained by the variances in patient 
cohorts, as it is known that the course of MS is diverse between subjects. Also the 
different antibodies and IHC methodologies used between studies could account for the 
differences, as discussed later in this chapter. 
In EAE models the severity of disease has been associated with a reduction in GS 
expression and elevation of glutamate. The loss of astrocyte GS function within the 
cortex of mice has been shown to result in glutamate excitotoxicity, identifying the 
possible pathophysiological process of glutamate excitoxicity occurring in the absence 
of inflammation or lesions (Castegna et al 2011).  A potential therapeutic treatment, the 
anti-oxidant, fullerene ABS-75, was shown to rescue GS expression in the WM of mice 
with chronic progressive EAE (Basso et al 2008). This anti-oxidant reduced astrocyte 
expression of CCl2, a chemokine attractant for monocytes and leukocytes, but also the 
driver of inflammation, known to increase oxidative damage and add to the impairment 
of glutamate homeostasis by downregulating GS expression in glial cells (Basso et al 
2008). Possibly this could account for the impaired glutamate regulation associated with 
MS. 
 
In contrast to the current study findings, previous human PM studies have identified a 
reduction in GS expression in a range of neurological diseases, including AD (Boyd-
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Kimball et al 2005, Butterfield et al 2006) and epilepsy (Eid et al 2004, Eid et al 2013). 
A uniform reduction in GS expression in the cortical regions of AD patients has been 
described, however this study failed to report WM expression (Robinson 2001). 
Similarly, reduced GS expression in the hippocampus of temporal lobe epilepsy patients 
has been shown (Eid et al 2004), but in this study the glutamate transporter levels 
remained constant (Eid et al 2004). The link between a reduced GS expression and 
increased IL-1 and TNFα associated inflammation and BBB disruptions in epilepsy, 
supports the MS studies that show inflammatory conditions reduces levels of  glutamate 
transporters and GS (Hardin-Pouzet et al 1997, Korn et al 2005, Muscoli et al 2005).  
As well, decreased GS expression in the brain has been seen in neurodegenerative 
disorders involving iron mediated oxidative stress (Fernandes et al 2011). The reduction 
of GS expression in cultured astrocytes was not reliant on hydrogen peroxide (H2O2) 
alone but needed the presence of redox-active iron (Fernandes et al 2011). Iron induced 
oxidative stress and reduced GS expression has been documented in a number of 
neurological diseases including stroke (Carbonell & Rama 2007) AD (Barnham & Bush 
2008, Bishop et al 2002), and PD (Barnham & Bush 2008).  
Evidently from the existing literature and current qualitative analysis a reduction in not 
only GS but EAAT1/2 immunoreactivity within MS lesions contributes to an increased 
level of glutamate excitotoxicity. Therefore more confirmative experiments on 
increased patient numbers may elucidate more corroborative quantitative data. 
2.5.4 ALDH1L1 expression in the cortex versus the white matter (WM) 
Since its identification as an astrocyte marker (Neymeyer et al 1997), there are an 
increasing number of studies into ALDH1Ll and its possible function in the brain. 
Characterisation of the astrocyte, neuronal and oligodendrocyte transcriptome has 
shown an increased  level of ALDH1L1 mRNA associated with astrocytes throughout 
the mouse/rat brain, in comparison to GFAP, which was predominantly expressed in the 
WM (Cahoy et al 2008). Complementary immunohistochemical staining further 
demonstrated an increased number of ALDH1L1+ astrocytes compared to GFAP+ 
astrocytes in rat tissue, with ALDH1L1 immunoreactivity associated with astrocyte cell 
bodies and extensive processes (Cahoy et al 2008). In contrast, while there was a 
considerable amount of ALDH1L1 immunoreactivity associated with astrocytes within 
the cortex, no immunoreactivity was detected within the WM in the current study. 
Furthermore, the immunoreactive staining profile in the cortex, detected astrocyte cell 
bodies and immediate processes rather than the extensive processes detected in the 
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Cahoy et al 2008 paper.  A novel finding in this current study was the presence of 
ALDH1L1+ cells that morphologically resembled oligodendrocytes, conflicting with 
reports that ALDH1L1 is an astrocyte-specific cell marker (Anthony & Heintz 2007, 
Cahoy et al 2008, Neymeyer et al 1997). However this finding should be confirmed by 
dual labelling with ALDH1L1 and a specific cell marker for oligodendrocytes, such as 
OLIG-2.  
 
To date, very few studies have examined ALDH1L1 expression in the human brain 
(Barley et al 2009, Rodriguez et al 2008b, Serrano-Pozo et al 2013a). ALDH1L1 
protein is downregulated in certain forms of pilocytic astrocytomas (PAs) which are 
associated with aggressive histological features and with increased cellularity and 
necrosis. Looking at ALDH1L1 expression in the neural tube during CNS development 
showed increased ALDH1L1 expression correlated with a decrease in cellular 
proliferation (Anthony & Heintz 2007). These papers suggest that ALDH1L1 negatively 
regulates cellular proliferation, further supported by non-CNS studies which have also 
demonstrated that a decrease in ALDH1L1 expression is associated with increased 
cellular proliferation in prostate and lung cancer (Krupenko & Oleinik 2002). 
 
Currently there is only one immunohistochemical study into ALDH1L1 expression in 
human neurodegenerative disease which concluded that ALDH1L1 was a constitutive 
astrocyte marker in the cortex of AD patients (Serrano-Pozo et al 2013a). However 
identification of ALDH1L1 as an astrocyte marker was based on findings of previously 
published animal work on ALDH1L1 (Cahoy et al 2008, Zamanian et al 2012). 
Reactive astrocytes were identified as GFAP+/ALDH1L1+ cells while GFAP-
/ALDH1L1+ were identified as resting astrocytes, this research shows the heterogeneity 
of astrocytes and the need for a marker that labels all astrocytes regardless of their 
activation state (Serrano-Pozo et al 2013a). Across three neurological diseases including 
schizophrenia, major depression and bipolar disorder, ALDH1L1 was identified as an 
astrocyte-associated gene, correlating with GFAP expression which was also linked to 
patient age, while no age correlation was seen with ALDH1L1 gene expression (Barley 
et al 2009).  
 
The majority of  research on ALDH1L1 is from animal models (Anthony & Heintz 
2007, Cahoy et al 2008, Dougherty et al 2012, Doyle et al 2008, Foo & Dougherty 
2013, Neymeyer et al 1997, Pfrieger & Slezak 2012).  The overall role and function of 
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ALDH1L1 is unknown in the brain and research into the expression of the enzyme 
throughout the brain has shown variable results. Within the CNS, ALDH1L1 has shown 
to completely label all astrocytes (Foo & Dougherty 2013), as shown in other studies 
(Barreto et al 2011, Cahoy et al 2008, Yang et al 2011)  yet in contrast this current 
study and others detected localisation of the ALDH1L1 to astrocytes in the cortex in 
humans (Serrano-Pozo et al 2013a). A decrease in ALDH1L1 mRNA, protein and 
promoter activity in astrocytes isolated from the spinal cord of post natal ageing mice 
has been reported, yet a considerable increased ALDH1L1 expression was seen in 
reactive astrocytes in the diseased equivalent animals (Yang et al 2011). In contrast, a 
stroke mouse model found the expression of ALDH1L1+ astrocytes remaining constant 
both pre- and post- stroke (Barreto et al 2011). 
Evidently the expression of ALDH1L1 by astrocytes is associated with a number of 
factors including regional variation in the brain, disease and species specificity, and 
possibly by the age of subjects. All these factors must be studied further to gain a 
greater understanding of the role of ALDH1L1 in the brain and its usefulness as a 
potential marker of astrocytes in human studies.  
2.5.5 CD44 detection in frozen tissue  
When investigating the astrocytic expression of CD44, no staining was seen in the 
FFPE sections when using a range of antigen retrieval techniques combined with either 
manual or automated IHC methods.  This was in contrast to the CD44 positive staining 
detected in frozen tissue, which  labelled astrocytes in the WM, with processes which 
formed thick end feet on blood vessels, in line with a previous study (Akiyama et al 
1993). Also in the study on frozen material, CD44 labelled astrocytes with the typical 
stellate morphology, in addition to astrocyte processes infiltrating into the cortex from 
the WM. The heterogeneity of the astrocyte phenotype and different pattern of astrocyte 
cell identification is especially apparent when using CD44 staining in frozen tissue 
samples. 
CD44 is a receptor for osteopontin (OP) and HA amongst many other proteins and is 
implicated in inflammation associated with neuronal injury. CD44 has been suggested 
to play a role in CNS inflammation by recruiting inflammatory cells into the CNS 
(Brennan et al 1999, Brocke et al 1999) especially in diseases with BBB dysfunction 
(Matsumoto et al 2012). Expression of CD44 is also highly upregulated by glial cells in 
demyelinating conditions including EAE and MS (Back et al 2005, Girgrah et al 1991, 
Kim et al 2004) but also in other neurological conditions including AD (Akiyama et al 
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1993, Vogel et al 1992) tuberous sclerosis (Arai et al 2000), ALS  (Matsumoto et al 
2012) and gliomas (Hagel & Stavrou 1999, Zeltner et al 2007).   
To date, there are very few studies investigating CD44 expression in human CNS 
material in relation to neurological disease.  In vanishing white matter (VWM) disease 
the colocalisation of CD44+/GFAP+ astrocytes was identified in the WM and no other 
CD44+ cell type was identified (Bugiani et al 2013). Snap frozen CNS tissue from MS 
patients was used as disease controls and the presence of CD44+/GFAP+ cells within 
and around chronically demyelinated MS lesions were supported by WB and qPCR 
analysis (Bugiani et al 2013). It has previously been shown that HA accumulates in 
regions of CD44+ astrocytes in chronically demyelinated lesions in MS, increased HA 
prevents the maturation of OPC and therefore inhibits remyelination (Back et al 2005, 
Struve et al 2005). It is thought that HA is broken down into lower molecular weight 
units which block the maturation of OPC through the expression of toll-like receptor 
(TLR)2, a receptor for HA. In support of this concept, the over expression of TLR2 in 
MS tissue was seen in the (Bugiani et al 2013) study.  
In contrast to the current study, in stroke patients the upregulation of CD44 was seen in 
snap frozen infarct tissue in both the cortex and WM, particularly associated with 
inflammatory cells (Al'Qteishat et al 2006). Also, negative CD44 expression was 
observed in control WM and weak expression in the cortex. The colocalisation of  
CD44+/GFAP+ astrocytes has been identified in brain tumours (Hagel & Stavrou 1999, 
Zeltner et al 2007) and CD44 expression correlated with tumour grading (Hagel & 
Stavrou 1999). It has been proposed that CD44+ astrocytes located at the tumour border 
induce the production of increased levels of HA leading to increased extracellular space 
in which tumour cells can grow, divide and expand into. In relation to MS, an increased 
expression of CD44+ astrocytes could lead to the accumulation of increased HA that 
disrupts the BBB facilitating the infiltration of immune cells leading to disease 
progression (Flynn et al 2013, Matsumoto et al 2012).  
In vivo studies using EAE models of MS have shown that increasing levels of TNFα 
and IFNγ result in cell activation, inflammation and immune reactions within the CNS  
inducing the expression of CD44 in astrocytes (Haegel et al 1993).  An increase in glial 
CD44 expression has been demonstrated  at the border of WM lesions in a mouse EAE 
model (Haegel et al 1993), while increasing expression of CD44 by astrocytes in the 
WM is associated with disease progression in a rat EAE model (Kim et al 2004). The 
role of increased astrocytic expression of CD44 in the pathogenesis of EAE is unclear, it 
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has been suggested that CD44 expression by astrocytes regulates OP thereby 
contributing to repair (Kim et al 2004). The removal of CD44 has been shown to 
prevent the recruitment of leukocytes and inhibit the development of EAE (Brennan et 
al 1999, Brocke et al 1999, Guan et al 2011). In contrast, a deficiency in CD44 has 
shown to enhance EAE, possibly due to the accumulation of the CD44 ligand HA, 
leading to a more adhesive endothelial cell surface resulting in increased leukocyte 
extravasation (Flynn et al 2013). These studies demonstrate  the confounding issues 
researching the role of CD44, including the use of different mouse/rat strains, 
inflammatory models and experimental approaches which make comparing these 
studies and relating them to human disease challenging (Flynn et al 2013).  
2.5.6 Limitations of IHC on human PM CNS material.   
There are a number of technical factors that contribute to the conflicting research 
findings from IHC studies, including the IHC methods followed, the tissue type used 
and the different antibodies applied. For example, there are differences between the IHC 
protocols used in the two studies investigating glutamate transporters (Werner et al 
2001) and (Vercellino et al 2007). Firstly, frozen CNS tissue was used in the former 
study in comparison to FFPE CNS tissue in the latter study. The different types of tissue 
used involve the use of different fixative methods, acetone versus formalin which may 
affect the IHC outcome (Shi et al 2011). Secondly, FFPE tissue requires antigen 
retrieval that could alter the way in which antibodies recognise the antigen and therefore 
comparing results between studies is challenging (Engel & Moore 2011). Thirdly, 
different primary antibodies were used in two studies for example in the (Vercellino et 
al 2007) study, monoclonal anti-EAAT antibodies sourced from Novacastra were used 
as were in the current study, while the (Werner et al 2001) sourced polyclonal 
antibodies from Alpha Diagnostics, which are no longer in production. Similarly when 
using a polyclonal CD44 antiserum on frozen tissue the upregulation of CD44 was 
identified in WM lesions of MS patients (Girgrah et al 1991), despite many attempts to 
achieve staining with monoclonal CD44 antibodies on FFPE tissue (Girgrah et al 1991). 
These particular factors must be considered when reviewing the results from this current 
histological study. When using a monoclonal CD44 antibody (Dako, UK) 
immunoreactivity was only present in the frozen CNS samples over the FFPE CNS 
samples. Monoclonal antibodies only recognise one single epitope on the antigen in 
question, making them very specific. Consequently a limitation to this specificity is the 
vulnerability of FFPE tissue losing the single epitope as a result of chemical treatment 
during fixation or during antigen retrieval resulting in IHC failure (Lipman et al 2005). 
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Being able to source a polyclonal antibody recognising multiple epitopes of the antigen 
may be advantageous, yet care must be taken when interpreting positive staining as 
polyclonal antibodies have a tendency to cross react between proteins causing non-
specific background staining (Lipman et al 2005). Also by using a combination of 
monoclonal antibodies in IHC may help improve results (Lipman et al 2005). 
The  ‘gold standard’ of IHC has been debated extensively in the literature  (Arber 2002, 
Boenisch 2005, D'Amico et al 2009, Engel & Moore 2011, Shi et al 2008, Shi et al 
2007, Shi et al 2011, Yamashita & Okada 2005). Aldehyde fixation has been a major 
explanation as to the failure of IHC in previous years. Yet the morphology, storage and 
surplus amount of archival FFPE tissue in hospital and research laboratories indicates 
that this source is more favourable over frozen tissue, which suffers from poor 
morphology affecting IHC outcome, and also requires specific storage conditions. 
Ultimately the fixation of the tissue used in this study and the particular antibodies 
employed (i.e. monoclonal anti-CD44, Dako, UK) may explain the poor IHC outcome. 
Alternative antigen retrieval methods such as the use of enzymatic antigen retrieval may 
need to be explored, or alternative polyclonal antibodies sourced. 
Another limitation when comparing histological studies is not only the type of material 
used (frozen/FFPE) but the species investigated. As the majority of ALDH1L1 studies 
are on animal models care must be taken when comparing IHC findings between 
species, what is seen in the animal may not be apparent in the human.  
 
Other factors to consider when interpreting current IHC findings is the possibility of 
astrocyte subtypes and differences in marker expression between anatomical locations 
investigated. Without further investigation into alternative brain regions and increased 
patient cohort size the current study is limited, which may otherwise provide more 
statistical relevant results rather than qualitative differences in the staining pattern for 
the glutamate transporters and enzymes.  A limited patient cohort size has been a 
weakness in many human histological studies (Newcombe et al 2008, Vallejo-
Illarramendi et al 2006, Vercellino et al 2007, Werner et al 2001). By broadening out 
the study to include different lesion types from different disease courses, in addition to 
increasing the number of control samples for comparison, a greater understanding of the 




In conclusion, without a good pan astrocyte marker, detection of all astrocytes in the 
CNS remains challenging. The differences in astrocyte morphology and phenotype is 
demonstrated by each of the antibodies used in this study and suggests there are distinct 
astrocyte subpopulations. Deciphering the differences between these subclasses of 
astrocytes and their role in CNS physiology/pathology is fundamentally important. 
Furthermore, this study demonstrates that astrocytes are very sensitive to changes 
within the CNS and in MS are continuously changing and adapting to the demands of 
the disease. Future histological studies on a larger cohort of well-defined, classified MS 
CNS tissue from different disease courses would provide a further insight into the 
phenotype of astrocytes in the disease. Having access to biopsy samples at different 
stages of disease course, and not just at PM would allow a better understanding of the 
involvement of astrocytes in the development of the disease. Evidence provided from 
this study, as supported by previous work by others, suggests that astrocytes become 
hypertrophic with lesion progression and show a dysregulation of glutamate 
homeostasis within lesions. This study also highlights that currently GFAP is the best 
astrocyte marker at clearly identifying astrocytes within MS NAWM which will be used 
in proceeding work. Overall, the alteration of the astrocyte phenotype in MS suggests a 




3 CHAPTER 3 
ISOLATION OF ENRICHED GLIAL CELL 
POPULATIONS FROM POST-MORTEM 





Identifying transcriptomic changes within cells of the CNS from both control and 
disease cases may enhance our understanding of the underlying mechanisms of disease. 
Currently the majority of gene expression work in human subjects is carried out on 
whole tissue (Bossers et al 2009, Grunblatt et al 2007, Murray 2007, Wang et al 2006), 
or on individual cell lines or animal models of disease which, despite having many 
advantages, fail to fully replicate human disease processes (Jucker 2010). LCM allows 
the isolation of specific ROI, or an enriched cell population from human tissue 
(Emmert-Buck et al 1996). This technique has since been developed further by 
incorporating histochemistry (Chu et al 2009, Cunnea et al 2010, Greene et al 2010) 
and IHC to provide effective isolation of particular cells of interest from human PM 
tissue (Bi et al 2002, Fend et al 2000, Simpson et al 2011, Waller et al 2012).  
Prior to LCM, the methods used to isolate cells or ROIs from heterogeneous tissue 
samples involved  crude manual techniques including tissue dissection using scalpels or 
razor blades (Ren et al 1996), to more developed techniques including dissection 
needles (Beaty et al 1997, Going & Lamb 1996). However, there are a number of 
limitations with these manual methods of dissection including: contamination from 
other cell types or from the instrumentation employed (Burgemeister 2011). Other 
problems include the limited accuracy and precision, and the capability to effectively 
isolate specific cell-types from tissue, even under dissection microscopy. 
Laser-assisted dissection methods were developed in the 1990s and enabled the 
isolation of cells or specific ROI in tissue proving to be faster, more reliable and an 
easier method to perform than manual dissection techniques. In general two 
methodologies were developed, the major difference between them being the laser 
employed (Emmert-Buck et al 1996, Schutze & Lahr 1998). One methodology uses an 
infra-red (IR) laser, which involves the placing of a cap with a thermoplastic film 
applied to the lower surface on top of a histological tissue section. Under microscopy 
the IR laser is guided over the ROI/cells and fired briefly causing the film to heat, melt 
and adhere to the ROI/cells (Figure 3.1). Upon removal of the cap from the tissue 
section, the ROI is removed leaving behind the remaining tissue (Emmert-Buck et al 






Figure 3.1 Overview of the laser capture microdissection procedure                                     
A histological tissue section is collected onto an uncharged glass microscope slide (a). 
A film cap is lowered onto the tissue section and the infrared (IR) laser beam fired over 
the cells/ROI briefly heating and melting the thermoplastic film, causing the adherence 
to the cell/ROI (b). On lifting the cap from the tissue section, the isolated cells/ROI are 
also removed leaving behind the surrounding tissue (c).
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In comparison, the alternative methodology developed used an ultra-violet (UV) laser to 
cut out cells or ROI and an increase of the laser power causes the transfer of isolated 
cells/tissue into a collection vessel (Schutze & Lahr 1998). The extraction of RNA, 
DNA and/or protein from the isolated cells enables specific gene/protein expression 
changes in diseased versus control samples to be determined.  
Not all PM CNS tissue is suitable for LCM isolation of cells for gene expression 
analysis, as there are a number of factors that impact the RNA quality of the material 
and which must be considered when identifying suitable cases for LCM and subsequent 
transcriptomic studies. When carrying out LCM it has been reported that a general 
decline in sample RNA integrity number (RIN) occurs (Mazurek et al 2013, Waller et al 
2012). The RIN is a numerical value ranging from 1-10, given to a biological sample as 
a measure of RNA quality based on the 28S/18S ribosomal peak ratio, with increasing 
degradation leading to a fall in ratio and decrease in the RIN (Figure 3.2). To ensure the 
gene expression data is comparable across different tissue samples, it is desirable  that 
all cases have similar RINs prior to LCM (Strand et al 2007). However this statement 
has been contradicted, with one microarray study investigating PM CNS tissue showing 
reliable results over a range of RINs (RIN 1.0-8.5) (Trabzuni et al 2011). In general, the 
RIN is recognised as the numerical standard to assess RNA quality for genetic studies, 
yet its true relevance to downstream applications is continuously being questioned 
(Koppelkamm et al 2011, Stan et al 2006). 
Microarray analysis enables the identification of genome wide transcriptional changes 
in diseased versus control samples of either human or animal disease models. The 
expression of thousands of mRNA transcripts from various disease/control samples can 
be quantified and comparisons made between their gene expression profiles. The basis 
underpinning the technique involves the hybridisation of sample mRNA molecules to 
single stranded complementary DNA (cDNA) probes, designed as oligonucleotide 
sequences which are adhered to a glass slide. The mRNA is labelled with a fluorescent 
tag and it’s signal intensity is a measure of quantity of mRNA molecules that have 
hybridised to the probe, which is proportional to the amount of transcript in that 
particular sample (Courtney et al 2010). 
To date, only 14 microarray gene expression studies have been completed on MS CNS 
brain tissue, 12 of which were reviewed by (Dutta & Trapp 2010) with two more recent 
studies using  LCM to identify gene expression of particular areas within the MS brain 




Figure 3.2 RNA integrity of PM CNS samples                                                                       
The quality of each PM CNS sample was assessed on a 2100 bioanalyzer, an example of 
a suitable case for LCM with a RIN value of 6.6 (a). An example of a highly degraded 
PM CNS sample which would not be taken forward to LCM with a RIN value of 2.7 
(b). 
y-axis represents fluorescence units, (FU) and x-axis represents runtime in seconds, (s).
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lesions (Mycko et al 2012). Using LCM to isolate particular cells of interest enables 
gene expression microarray, qPCR, and mass spectrometry experiments to be performed 
on an enriched cell population, in order to gain a better understanding of the 
transcriptomic and proteomic events in disease pathogenesis.   
Ultimately the advantages of working with an enriched cell population is that it allows 
for a greater understanding of the role/function of that particular cell in a range of 
neurological conditions. When investigating a heterogeneous cell population (i.e. whole 
tissue samples) valuable data maybe masked and the association of potential pathogenic 
function to cell type lost. Therefore LCM aids the discovery of genes that could 
potentially indicate novel mechanisms that contribute to disease progression. Glial cells 
within the CNS are defined by their specific morphology and function and are 
comprised of 3 cell types; these include the most abundant cell type in the CNS, 
astrocytes, as well as oligodendrocytes and microglia. Glial cells provide essential 
neuronal support and their dysfunction can contribute to disease (Kettenmann & 
Verkhratsky 2008, Sobel & Moore 2008).  Astrocytes provide neurotrophic support,  
maintain CNS homeostasis by regulating the extracellular environment, are components 
of the tripartite synapses involved in synapse function and plasticity, and participate in 
CNS immune responses (Fellin 2009, Jensen et al 2013, Perea et al 2009, Volterra & 
Meldolesi 2005). Oligodendrocytes primarily form the insulating myelin sheath that 
surrounds axons enabling efficient signal transduction in the CNS (Peferoen et al 2013, 
Sobel & Moore 2008). Microglia, which form around 10-20% of the total glial cell 
population within the CNS (Peferoen et al 2013), are the macrophages of the brain and 
spinal cord, forming the basis of the immune system of the CNS (Sobel & Moore 2008). 
Glia have been shown to contribute to a range of neurological disorders, including MS 
(Sriram 2011), AD (Naert & Rivest 2011, Serrano-Pozo et al 2013b, Verkhratsky et al 
2010), PD (Fellner & Stefanova 2013, Halliday & Stevens 2011), MND (Lasiene & 
Yamanaka 2011), Huntington's disease (Hsiao & Chern 2010) and stroke (Thiel & Heiss 
2011, Zhao & Rempe 2010). Also more recently glial cells have been proposed as 
having an involvement in neuropsychiatric diseases such as schizophrenia (Goudriaan et 
al 2013). As identified in many of these studies, glial cells contribute to and/or prevent 
disease pathogenesis, yet the understanding of each glial cells’ specific role is 
continuously debated, therefore a better understanding of each cell specific roles in 
disease is fundamental.  
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This chapter describes the detailed methodology used to isolate an enriched population 
of each of these 3 glial cell types from PM CNS tissue, acknowledging the advantages 
and limitations of using PM CNS material in transcriptomic studies, along with 
combining rapid immunostaining of tissue sections with LCM. The study also verifies 
the enrichment of each glial cell population using reverse transcription-PCR (RT-PCR) 
and details the number of cells required to gain sufficient mRNA for downstream 
applications including microarray analysis. 
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3.2 Aims and objectives of the study 
The aims of this study were to: 
 To identify suitable PM CNS samples for LCM. 
 To optimise an immuno-LCM method to isolate glial cells from frozen PM CNS 
tissue. 
 To confirm cell enrichment using RT-PCR, and identify the number of cells 
needed to provide sufficient mRNA for downstream applications. 
 To use the developed immuno-LCM to isolate enriched astrocyte populations 




3.3 Materials and Method  
3.3.1 Suppliers  
Abcam, 330 Cambridge Science Park, Cambridge, CB4 0FL, UK; Agilent 
Technologies, 610 Wharfedale Road, IQ Winnersh, Wokingham, Berkshire, RG41 5TP, 
UK; DAKO UK Ltd., Cambridge House, St Thomas Place, Ely, Cambridgeshire CB7 
4EX;Cambridge, UK; Bioline Reagents Ltd., Unit 16 The Edge Business Centre, 
Humber Road, London, NW2 6EW, UK: Cambridge Bioscience Ltd., Munro House, 
Trafalgar Way, Bar Hill, Cambridge, CB23 8SQ UK; Eurofins MWG Operon, 
Anzinger Str. 7a 85560 Ebersberg, Germany; Fisher Scientific Inc., Bishop Meadow 
Road, Loughborough, Leicestershire, LE11 5RG, UK; Leica Microsystems Ltd., Davy 
Avenue, Knowhill, Milton Keynes, MK5 8LB Buckinghamshire, UK; Life 
Technologies Ltd., (Invitrogen, Arcturus) 3 Fountain Drive, Inchinnan Business Park, 
Paisley, PA4 9RF, UK; Newmarket Scientific, (Solis Biodyne) 9-10 Rosemary House 
Lanwades Business Park Kennett, Newmarket CB8 7PN, UK; R&D Systems Europe 
Ltd., 19 Barton Lane, Abington Science Park, Abington, OX14 3NB, UK; Sigma-
Aldrich, The Old Brickyard, New Road, Gillingham, Dorset, SP8 4XT, UK; Syngene 
Europe office, Sales, Service, Support, Manufacture, Beacon House, Nuffield Road, 
Cambridge, CB4 1TF; Thermoscientific, Stafford House, Boundary Way Hemel 
Hempstead, Hertfordshire HP2 7GE, UK; Vector laboratories Ltd., 3 Accent Park, 
Bakewell Road, Orton Southgate, Peterborough, PE2 6XS, UK; VWR International 
Ltd. (Quanta Biosciences), Hunter Boulevard, Magna Park, Lutterworth, Leicestershire, 
LE17 4XN, UK. 
3.3.2 Tissue source 
All frozen tissue used in this study was obtained from the UK Multiple Sclerosis 
Society Tissue Bank and The Sheffield Brain Tissue Bank (SBTB), full ethical 
permission was obtained (Appendix I). Full clinical information and neuropathological 
assessment of each case is described in Appendix III. The RIN of each case was 
determined prior to and post LCM. All cases were from similar anatomical coronal 
brain slices and had a mean post mortem interval (PMI) time of 10 hours (range 5-18 
hours). 
3.3.3 Histological classification 
Cases were histologically examined by H&E, LFB and CD68 IHC, refer to Appendix 
III for full details. If there was evidence of inflammation and/or demyelination, the 
90 
 
cases were eliminated from the study. 7μm sections were stained and classified 
following the protocols described in Chapter 2. As only frozen material was used, the 
sections did not require dewaxing or antigen retrieval, but were fixed in ice-cold acetone 
(Fisher Scientific, UK) for 10 minutes or 95% ethanol (Fisher Scientific, UK) for LFB, 
prior to staining.  
3.3.4 Pre-LCM RNA integrity analysis 
Snap-frozen tissue blocks of CNS material were selected for LCM based not just on 
their histological characteristics but also on their initial RNA quality.  One section of 
each brain block (7 µm) was collected into a sterile 0.5 ml Eppendorf tube, and the 
RNA extracted using the standard Trizol method (Invitrogen, UK). Under sterile 
conditions 0.5 ml Trizol reagent (Invitrogen, UK) was added to each section of tissue 
and mixed until dissolved by pipetting. 0.1 ml chloroform (Fisher Scientific, UK) was 
added, vortexed to mix and left to stand at RT for 10 minutes. Each sample was 
centrifuged (Sigma centrifuges, UK) at 4°C, maximum speed (16,000g) for 15 minutes. 
The aqueous layer was transferred into a new sterile 1.5 ml Eppendorf tube where 250 
µl isopropanol was added and left at RT for 5-10 minutes. The sample was centrifuged 
at 4°C, maximum speed (16,000g) for 10 minutes. The supernatant was discarded, the 
pellet washed with 1.0 ml ice-cold 75% ethanol (Fisher Scientific, UK) and mixed via 
vortexing. A final centrifugation step was carried out at 4°C, 8,000g for 5 minutes. 
Samples were left to air-dry before 25 µl of sterile d.H2O was added to resuspend the 
pellet. To assess the quantity of RNA, the samples were analysed on a NanoDrop 
spectrophotometer (Thermoscientific, UK) and the quality of RNA checked on a 
bioanalyzer (Agilent, UK). Cases with RIN values of less than 4.0 were eliminated from 
further investigations. All RNA samples were stored at -80°C. 
3.3.5 Sample preparation for LCM – rapid IHC 
It was vital that all LCM was completed on freshly cut sections to prevent RNA 
degradation as a result of repeated freeze-thawing of samples (Boone et al 2013). 
Freshly cut, 7μm sections of each case were collected onto uncharged, sterile glass 
slides (Leica, UK) (6 sections per case) and warmed to RT for 30 seconds. The sections 
were fixed in ice-cold acetone (Fisher Scientific, UK) for 3 minutes and immunostained 
using the following modified rapid ABC staining method (Waller et al 2012). The 
protocol was carried out at RT, using sterile solutions made with diethylpyrocarbonate 
(DEPC)-treated water and under RNase-free conditions. Sections were blocked in the 





Table 3.1 Glial specific primary antibodies                                                                 




in 2.5 ml TBS) for 3 minutes, incubated with a glial specific phenotype marker antibody 
(Table 3.1) diluted in blocking serum for 3 minutes, and rinsed briefly with TBS. 
Following a 3 minute incubation with 5% biotinylated secondary antibody (Vectastain 
Elite kit; Vector Laboratories UK) (50 µl secondary antibody in 1.0 ml blocking buffer), 
the sections were rinsed with TBS, incubated with 4% horseradish peroxidase 
conjugated ABC, (Vectastain Elite kit; Vector Laboratories UK) (50 µl drop A, 50 µl 
drop B in 2.5 ml TBS) prepared at least 30 minutes prior to use, for 3 minutes, and 
washed briefly with TBS. Antibody staining was visualised with DAB (Vector 
Laboratories, UK) for 3 minutes.  The sections were dehydrated in a graded series of 
alcohol (Fisher Scientific, UK) (70%, 95%, 100%, 100% for 15 seconds each), cleared 
in xylene (Fisher Scientific) (15 seconds) and left to air dry at RT in an air flow hood 
for a minimum of 60 minutes prior to LCM. 
3.3.6 Laser capture microdissection (LCM)  
LCM was performed using the PixCell II laser-capture microdissection system 
(Arcturus Engineering, Mountain View, CA, USA) and CapSure Macro caps (Arcturus 
Engineering, Mountain View, CA). The air dried, immunostained section was overlaid 
with the CapSure cap, which consists of a thermoplastic film mounted on a transparent 
cap. A focussed infrared laser was fired through the cap causing the film to melt and 
adhere to the immunopositive cells (as demonstrated previously in Figure 3.1), and the 
number of cells captured was recorded. The LCM system was set to the following 
parameters: 7.5 μm spot size and ~40 mW power. Immunopositive cells were selected 
for capture using a 20× objective. After microdissection, the film was removed from the 
cap using sterile tweezers and transferred to a sterile 0.5 ml Eppendorf tube for RNA 
extraction. 
3.3.7 RNA extraction 
Total RNA was extracted from the isolated cells using the PicoPure RNA isolation kit 
(Arcturus BioScience, UK) (Figure 3.3), 50 µl extraction buffer was added to the film 
and the tube left to incubate at 42°C for 30 minutes. Meanwhile an RNA extraction 
column was conditioned for use by incubating with 250 µl conditioning buffer for 5 
minutes, prior to a centrifugation step at 16,000g for 2 minutes, and the flowthrough 
discarded. Following the incubation step, 50 µl 70% ethanol was added to the sample 
and gently pipetted up and down to mix. The sample was transferred to the pre-
conditioned column and centrifuged at 100g for 2 minutes to allow the RNA to become 
93 
 
Figure 3.3 Overview of the PicoPure RNA extraction process from cells acquired 
using LCM                                                                                                                               
The process isolates total cellular RNA in a small volume of low ionic strength buffer 
by using RNA extraction/purification reagents and a purification column in a 




bound to the column followed by a faster spin at 16,000g for 1 minute, and the flow 
through discarded. 100 µl of wash buffer 1 was applied to the column which was then 
centrifuged at 8,000g for 1 minute. 100 µl of wash buffer 2 was applied and centrifuged 
as for buffer 1. A further 100 µl wash buffer 2 was added to the column and centrifuged 
at 16,000g for 2 minutes. The final step of the extraction involved placing the column 
into a fresh sterile 1.5 ml Eppendorf tube, 11 µl elution solution was added and the 
column left to incubate at RT for 1 minute to allow the release of the RNA from the 
column matrix prior to centrifugation at 1,000g for 1 minute, followed by a faster 
centrifugation at 16,000g for 2 minutes. The quantity and quality of the RNA were 
determined using a NanoDrop 1000 spectrophotometer (Thermoscientific, UK) and a 
2100 Bioanalyzer, respectively (Agilent, UK). All RNA samples were stored under 
sterile conditions at −80°C for future analysis. 
3.3.8 cDNA synthesis for RT-PCR 
From each sample extract, RNA was synthesised to cDNA using qScript cDNA 
mix/supermix (Quanta, UK) which contains optimised concentrations of magnesium 
chloride (MgCl2), deoxyribonucleotide triphosphates (dNTPs), recombinant RNase 
inhibitor protein, qScript reverse transcriptase, random primers, oligonucleotide (dT) 
primer and stabilisers. Following the manufacturer’s protocol, in a sterile 0.2 ml 
Eppendorf tube, 2 µg RNA was added to 2 µl qScript and the volume adjusted to 10 µl 
with sterile d.H2O. Samples were mixed thoroughly by gently vortexing and spun down 
to collect all liquid at the bottom of the tube. Samples were incubated at 25ºC for 5 
minutes, 42ºC for 30 minutes, and the reaction stopped by heating to 85ºC for 5 minutes  
and the sample was then held at 4ºC. To check whether cDNA synthesis had been 
successful, RT-PCR was carried out using beta-actin (βA) forward and reverse primers 
(Table 3.2). PCR was performed using 50 ng cDNA, 5x Firepol green PCR mastermix 
(MM) (Solis Biodyne, UK) and optimised concentrations of forward and reverse 
primers in a total volume of 20 µl. To check for specificity, a no template control (NTC) 
was also run alongside the cDNA samples with d.H2O replacing the cDNA. The PCR 
protocol consisted of denaturation at 95ºC for 10 minutes then 40 cycles of (95ºC for 15 
seconds, 60ºC for 60 seconds) and finally 72ºC for 15 minutes. 
3.3.9 RT-PCR optimisation and analysis: purity of glial cell capture 
Confirmation of the isolation of enriched astrocyte, oligodendrocyte and microglia 




Table 3.2 Glial and control primer sequences                                                                  
Details of glial and control primers tested in standard RT-PCR, including details of the 
primer sequences for the forward and reverse primers used, along with the expected 
product size and source of primers. 
Key:  F: forward, R: reverse, bp: base pairs.
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OLIG-2 (oligodendrocyte) and NFL (neuron) (Waller et al, 2012). βA was used as a 
loading control and ran alongside the samples. Gene specific primers were sourced 
commercially or designed in house based on published sequences Primer-BLAST (basic 
local alignment search tool) software (www.ncbi.nlm.nih.gov/tools/primer-blast).  
Optimisation of forward and reverse primer sets involved testing different 
concentrations of cDNA and primers, as well as different PCR programmes i.e. different 
annealing temperatures and cycle numbers. GFAP, CD68 and NFL PCR was performed 
following the programme described in section 3.3.8.  For OLIG-2 an alternative PCR 
programme was used, following denaturation at 95ºC for 10 minutes the products were 
amplified  (35 cycles at 95ºC for 60 seconds, 60ºC for 45 seconds and 72ºC for 60 
seconds), followed by 72ºC for 15 minutes. 
3.3.10 Agarose gel electrophoresis of PCR products 
All PCR products were run on a 3% agarose gel to check that they were of the correct 
size. A 3% ethidium bromide stained agarose gel was prepared by adding 1.5 g agarose 
powder to 50 ml tris-acetate-EDTA (1x TAE) buffer (recipe, Appendix IV), the solution 
was heated in a microwave for ~2 minutes to dissolve the agarose. The solution was 
cooled slightly under a running tap, followed by the addition of 1 µl ethidium bromide 
(Sigma-Aldrich, UK) (from 10mg/ml stock concentration), and poured into a cassette, a 
gel comb was placed into the agarose solution and left to set for 45 minutes. Agarose 
gels were placed into an electrophoresis tank containing 1x TAE buffer. A DNA base 
pair marker, 2 µl DNA Hyperladder (V) (Bioline, UK) was loaded into the first well, 
with 10 µl RNA from astrocyte, oligodendrocyte, microglia and NTC samples loaded in 
consecutive wells. The gel was left to run at constant voltage (100V), for ~60 minutes 




3.4.1 Case selection 
A total of 15 tissue blocks were initially obtained for the study and based on the RIN 
assessment, 66% (10/15) of the tissue blocks had a RIN greater than 4.0. Histological 
evaluation identified 6 cases as having no evidence of inflammation or demyelination, 
these 6 blocks were taken forward for LCM of each of the 3 glial cell types (Table 3.3).  
3.4.2 Immuno-LCM allows the isolation of specific glial cell populations 
The use of the rapid IHC protocol allows for the detection of each glial cell type in 
human PM CNS tissue as shown in Figure 3.4. GFAP+ astrocytes are recognised by 
their stellate appearance with immunoreactivity strongest in the cell’s body and 
extending into the processes (Figure 3.4a, red arrows). OSP+ oligodendrocytes are easily 
distinguished as small spherical cells with potent cell body immunoreactivity (Figure 
3.4b, red arrows). CD68+ resting microglia had a ramified, bipolar appearance with 
branched processes (Figure 3.4c, red arrows). Each cell type was isolated using LCM as 
shown in Figure 3.5 and the number of cells recorded to assess the quantity required to 
provide approximately 50ng of starting mRNA. Approximately 1000 astrocytes, 1500 
oligodendrocytes and 1000 microglia were needed to achieve this. The RIN of each case 
post-LCM was assessed and an average 1.5 decrease in RIN was observed across the 
cases (range 1.1-1.8) as shown in Table 3.3.  Each sample contained sufficient quality 
RNA for downstream studies, including RT-PCR. 
3.4.3 Confirmation of cDNA synthesis from LCM-ed material 
All experimental samples were checked on an agarose gel to confirm cDNA synthesis 
using βA primers. All samples showed a strong band at ~100 base pairs (bp) indicating 
the presence of βA RNA and confirming successful cDNA synthesis (Figure 3.6). 
3.4.4 Isolation of enriched glial cell populations – confirmation by RT-PCR 
RNA isolated from GFAP+ cells had higher transcript levels of GFAP and lower levels 
of Olig-2 and CD68 transcript, confirming an enrichment of astrocytes using the rapid 
immuno-LCM method. Similarly with RNA extracted from OSP+ cells, higher transcript 
levels of Olig-2 were observed with lower levels of GFAP and CD68 transcript 
confirming oligodendrocyte enrichment. RNA extracted from CD68+ microglia 
provided a higher transcript level for CD68 and lower expression of the other two glial 




Table 3.3 Details of cases used in the initial LCM study                                                   
All cases based on their histological characterisation did not contain any evidence of 
inflammation or demyelination and were comparable based on their RIN.  
Key: n/a: data not available, a: case obtained from the Sheffield Brain Tissue Bank 





Figure 3.4 Rapid IHC detection of glial cells                                                                      
GFAP (brown) labelled individual stellate astrocytes (a, red arrows). OSP (brown) 
labelled individual small, spherical oligodendrocytes (b, red arrows). CD68 (brown) 




Figure 3.5 Laser capture microdissection of glial cells                                                    
GFAP+ astrocytes (a), OSP+ oligodendrocytes (e), and CD68+ microglia (i) were 
identified by rapid immunostaining. The laser is fired causing the filmed cap to fuse 
with the underlying cell as indicated by the arrows in (b, f, and j). The cap is lifted off 
the tissue section leaving unwanted cells behind (c, g, and k), while laser captured cells 






Figure 3.6 Agarose gel electrophoresis of RT-PCR cDNA products for beta-actin                   
The presence of βA mRNA in each of the 6 samples and absence in NTC sample 
confirms all extracted RNA was successfully converted to cDNA. 




Figure 3.7 RT-PCR analysis of glial cells isolated from PM CNS tissue using 
immuno-LCM                                                                                                                                
Specific glial cell populations are shown to be enriched by RT-PCR. GFAP+ astrocytes 
are associated with higher transcript levels of GFAP and lower expression of OLIG2 
and CD68 transcript (Astro column, red box). Oligodendrocyte enrichment is confirmed 
by higher levels of OLIG2 transcript in comparison to GFAP and CD68 transcripts 
(Oligo column, red box). CD68+ microglia correlate with a higher CD68 transcript level 
compared to GFAP and OLIG2 transcripts (Mg column, red box). Figure adapted from 
Waller et al 2012.  
Key: Astro: astrocytes, Oligo: oligodendrocytes, Mg: microglia, NTC: no template 
control, βA: beta-actin, GFAP: glial fibrillary acidic protein.
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To further validate the presence of enriched glial cell populations, RT-PCR was carried 
out to show levels of NFL, an axonal marker. Very low NFL expression was identified 
in the oligodendrocyte and microglia samples (Figure 3.8) while the astrocyte 
population showed a slightly higher level of NFL transcripts, recognising the close 
proximity astrocytes have with axons. However RT-PCR confirms the enriched glial 




Figure 3.8  Neurofilament light RT-PCR analysis of glial cells isolated from PM 
CNS tissue using immuno-LCM                                                                                                    
Low levels of neurofilament light (NFL) transcripts were detected in the astrocyte 
samples reflecting their close proximity to axons, no NFL transcripts can be detected in 
the oligodendrocyte or microglia samples. 
Key: Astro: astrocytes, Oligo: oligodendrocytes, Mg: microglia, NTC: no template, 




In this study the isolation of enriched populations of glial cells from frozen human PM 
CNS was demonstrated using a novel rapid immuno-LCM method. Using 3 specific, 
recognised glial-specific antibodies: GFAP (astrocytes), OSP (oligodendrocytes) and 
CD68 (microglia), a rapid IHC method combined with LCM was developed, which 
limited RNA degradation thereby enabling downstream applications such as RT-PCR to 
be carried out. Confirmation of glial cell enrichment was demonstrated by RT-PCR for 
glial-specific transcripts. In addition, the number of cells required to gain sufficient 
starting material for downstream applications such as microarray analysis, was 
confirmed as in a previous study (Simpson et al 2011). Isolation of approximately 1000 
astrocytes, 1500 oligodendrocytes and 1000 microglia was required to obtain 50ng of 
total RNA. This technique enables the isolation of specific cell types from both disease 
and control PM CNS samples for transcriptomic and proteomic studies, an advantage 
over the studies to date which have investigated heterogeneous cell populations, and it 
enables specific disease processes and pathological mechanisms to be linked to cell 
type.  This approach may also identify potential biological disease biomarkers and be 
beneficial in identifying therapeutic targets for a range of neurological diseases, 
including MS.  
3.5.1 LCM as a tool to investigate neurological disease 
With the continuing advancements in ‘omics’ technology the potential to identify 
differentially expressed genes/proteins in single cell populations is made more 
achievable using LCM techniques. An increasing number of studies, both in animal 
models and human subjects, of a range of neurological diseases have investigated gene 
expression of LCM-ed material by means of RT-PCR and microarray platforms (Boone 
et al 2013, Chu et al 2009, Kumar et al 2013, Pietersen et al 2009, Simpson et al 2011, 
Torres-Munoz et al 2004). In relation to MS, the technique has only been used to isolate 
specific regions of interest thus far. For example, LCM was used to isolate CAL and 
gene expression microarray analysis identified significant transcriptional changes in 
heat shock proteins in areas of chronicity compared to surrounding NAWM (Mycko et 
al 2012). Similarly, carrying out RT-PCR on specific anatomical areas of the MS brain 
including normal appearing, perilesional and lesional identified a significant expression 
of endoplasmic reticulum genes in lesional tissue (Cunnea et al 2011). An earlier study 
by the same group used LCM to isolate blood vessels from MS patients, through 
microarray analysis the significant upregulation of a disintegrin and metalloprotease 
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domain (ADAM)17 and other MMPs associated with the breakdown of the BBB were 
identified in the MS cases compared to control cases (Cunnea et al 2010).   Relatively 
few studies have investigated the use of LCM in the brain to look at protein expression 
in relation to specific cell populations or ROI, due to a number of issues to be discussed 
later in this chapter. However, proteomic analysis has been possible on LCM-ed dentate 
granule cells from patients with frontotemporal lobar degeneration (FTLD) (Gozal et al 
2011) and IHC assisted LCM was used to identify Lewy bodies from patients with 
dementia with Lewy bodies (Leverenz et al 2007), with similar IHC-LCM performed to 
isolate neurofibriallary tangles in patients with AD (Wang et al 2005). The only 
proteomic LCM study in MS demonstrated the isolation of three separate lesion types 
from patients, the extracted protein resolved using sodium dodecyl sulphate 
polyacrylamide gel electrophersis (SDS-PAGE), and protein bands digested with trypsin 
and analysed on a nanoliquid chromatography tandem mass spectrometer. 158, 416 and 
236 unique proteins were identified across the acute, CAL and chronic lesions, with 
more than half the identified proteins having unknown function, while the analysis 
showed CAL displayed high expression of coagulation proteins (Han et al 2008).  
3.5.2 Limitations of LCM for genomic work 
The use of LCM to isolate specific regions/cells and identify potential gene/protein 
changes can be used to identify changes that may contribute to disease pathogenesis. To 
date, however there are relatively few studies which have employed LCM on human 
PM CNS material, which can be explained by a number of factors, many of which need 
to be considered prior to commencing any work applying LCM to PM tissue (Ordway et 
al 2009). 
When carrying out transcriptomic studies, using the RIN as a measure of RNA quality, 
enables the identification of potential suitable, usable cases for LCM. As identified in 
this study, not all PM CNS material appears to be suitable owing to a number of factors 
known to affect the RIN including the agonal state of the patient at death, as prolonged 
hypoxia can affect RNA and protein stability (Harrison et al 1991, Kingsbury et al 
1995, Trabzuni et al 2011). Also, RNA quality of tissue has been shown to deteriorate 
with increasing numbers of antemortem events (Durrenberger et al 2010). Another 
factor to consider in determining suitable cases for LCM is the pH of the patient’s CSF, 
shown to be a good indicator of RNA quality of tissue (Durrenberger et al 2010), as pH 
levels below 6.0 have been shown to be detrimental and affect the RNA quality of PM 
CNS tissue (Kingsbury et al 1995). Additionally, the brief freeze-thaw of the snap 
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frozen samples during LCM preparation can contribute to a loss in RNA quality 
(Mazurek et al 2013). In the current study, the tissue preparation time from section 
cutting, rapid IHC through to section dehydration in xylene was kept to a minimum (no 
longer than 25 minutes), despite the actual total LCM process taking around 2.5 hours.  
It is vital that the rapid immuno-protocol was implemented and sections were 
thoroughly dehydrated into xylene as quickly as possible to prevent RNA degradation, 
as aqueous condition have been shown to increase RNA degradation (Bernard et al 
2011). Tissue preparation beyond this short time period can affect the RNA integrity of 
the sample (Burgess & McParland 2002, Fend et al 1999, Keays et al 2005, Mojsilovic-
Petrovic et al 2004, Strand et al 2007). Also the LCM procedure itself can affect the 
RNA integrity of samples, including the duration of capture, which must be kept to a 
minimum (Michel et al 2003, Nawshad et al 2004). During this study each LCM sitting 
lasted no longer than 1 hour, accounting for around 10 minute capturing per 
section/slide, thereby preserving the RNA integrity of the sample from the effects of the 
laser power. Overall the actual processing and isolation of cells from tissue sections of 
different cases, using LCM, can be time consuming and, when implementing rapid IHC 
techniques with concentrated antibody titres, expensive experimental costs can occur 
(Kuhn et al 2012).  However more automated LCM systems that incorporate an image 
analysis software designed to identify stained areas of tissue can improve the speed and 
automation of the LCM procedure (Tangrea et al 2011).  
Another consideration is the type of laser employed to isolate the cells, which can affect 
the RNA quality of the isolated tissue. An LCM system can be utilised with either a UV 
or IR laser, the former being of higher power and hence potentially more damaging to 
the quality of mRNA obtained from the LCM-ed tissue (Vandewoestyne et al 2013). 
Furthermore, it should be noted that most PM cases are at end stage of disease and this 
additional factor must be considered when interpreting LCM derived transcriptomic 
data in relation to potential disease mechanisms. Interpreting ‘omics’ data from LCM 
samples must be viewed with caution, as the technique can only ensure an 'enriched cell' 
sample which may not be entirely pure, as was observed in the current study where an 
NFL transcript was present in the astrocyte enriched population, presumably due to the 
close proximity of astrocytes with axons. Therefore to confirm any data derived from 
LCM-ed material, validation must be carried out at both the transcriptomic and 
proteomic level. This type of validation may include implementing additional 
techniques such as qPCR to look at gene expression, and WB, IHC and mass 
spectrometry to assess protein expression. 
108 
 
3.5.3  Investigating tissue proteomics using LCM 
Understanding a cell’s genomic and proteomic profile in health and disease is vital in 
associating potential pathogenic roles to particular cell types. Investigating the 
transcriptome of cells isolated from tissue using LCM has been carried out in an array 
of settings as discussed, however the majority of a disease phenotype is the product of 
protein expression rather than gene expression. Therefore relating the role of a 
particular cell’s protein expression in disease compared to health is crucial to improving 
disease understanding and can also assist in the development of protein biomarkers (Xu 
et al 2009).   
LCM has been used to isolate regions of interest or enriched cell populations, and 
protein expression analysed, particularly in a number of studies in cancer (Baker et al 
2005, Cha et al 2010, Liu et al 2012, Mu et al 2013, Patel et al 2008). However, a major 
limitation to using LCM as a method of generating proteomic information is the small 
amount of sample availability, especially from biopsy specimens in clinics and an 
absence of any in vitro amplification steps as in gene expression studies (Baker et al 
2005). Consequently in order to overcome this there is a need for increased sensitivity 
in protein detection systems and improved cell isolation from tissue, while preserving 
tissue morphology.  
There is a range of different systems currently available to study the proteome 
including: two-dimensional differential gel electrophoresis (2D-DIGE), liquid 
chromatography-tandem mass spectrometry (LC-MS/MS), MALDI-MS as well as WB. 
Over the years, the sensitivity of protein detection systems have developed to enable 
identification of protein expression in LCM material.   
Conflicting findings have identified that methods of tissue processing as being a 
fundamental factor as to the amount of protein recovered from the LCM-ed tissue.  One 
early study using 2D-DIGE proteomic analysis, identified that histologically staining 
brain tissue prior to LCM acted as a hindrance to recovering protein using gel 
electrophoresis (Mouledous et al 2002). However immunostaining of brain tissue 
showed improvement of protein recovery but only with the use of fluorescently labelled 
antibodies rather than the traditional enzymatic avidin biotin system, which gave a 
poorer protein recovery (Mouledous et al 2003b). In conclusion, using the traditional 
ABC IHC kits, high antibody titres and short incubation times are required when 
preparing tissue for LCM. This method of preparing tissue for LCM using enzymatic 
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detection based-IHC has been shown not to affect RNA integrity but the ability to 
identify low abundant antigens by 2D electrophoresis was hindered. In contrast, 
fluorescent detection based-IHC for LCM showed very little difference in the amount of 
proteins extracted and detected compared to the unstained samples. However, their 
appeared to be reproducibility variations as to the intensity of some protein spots, 
mostly affecting low molecular weight proteins (Mouledous et al 2003b). This group 
used navigated LCM as a means of avoiding problems with protein recovery of 
immuno-processed sections, whereby a serial section is histologically stained to help 
guide the LCM process of an unstained section. This technique was shown to be useful 
in identifying regions of interest but not absolute for the isolation of particular cells of 
interest (Mouledous et al 2003a).  
More recently improved proteomic detection systems have enabled the use of 
histological staining or IHC of tissue sections prior to LCM and generated adequate 
protein for use in WB and mass spectrometry studies. For example S100B labelled 
astrocytes were isolated using LCM and WB used to confirm cell enrichment from 
human brain tissue (Koob et al 2012). Also haematoxylin stained germinal cells in 
human tonsils were analysed by WB for β-actin  and procaspase-3 (Martinet et al 2004). 
To overcome the issue of limited sample availability from LCM, pooled microdissected 
protein extracts have been used in WB studies to identify differentially expressed 
proteins in LCM-ed isolated H&E stained stromal cells from colon adenocarcinoma 
tissue (Mu et al 2013). 
Traditionally the use of 2D-DIGE combined with mass spectrometry techniques has 
enabled protein expression and comparison between diseased and control tissue to be 
made. The limitation with 2D-DIGE is that some proteins cannot be separated in this 
way due to size, hydrophobicity and specific isoelectric point (pI) as well as the 
laborious, non-automated method of identifying and dissecting out the many protein 
spots on a gel. Apart from 2D-DIGE, protein extracts from LCM-ed samples have been 
separated by traditional gel electrophoresis based on molecular weight. In breast cancer, 
around 60,000 tumour epithelial cells were isolated by LCM prior to protein extraction 
and gel electrophoresis to enable the identification of proteins based on their molecular 
weight. LC-MS/MS was used on the tryptic digested proteins to identify 298 




Continuingly improved methods of tissue processing, LCM and protein extraction have 
enabled the use of mass spectrometry to identify proteins direct from LCM isolated 
tissue samples, with no need for prior protein separation by some kind of gel 
electrophoresis. Proteomic analysis of squamous cell carcinoma of the head and neck 
(HNSCC) used LCM to isolate 20,000 tumour epithelial cells, which were tryptically 
digested and peptides run on an LC-MS/MS system to determine around 700 expressed 
proteins (Patel et al 2008). Three skin regions were isolated using LCM and the 
proteomic components of each region determined by mass spectrometry (Mikesh et al 
2013). Ultimately these studies avoid the limitations of gel electrophoresis including 
protein instability, limited fractionation ranges and protein recovery (Baker et al 2005).  
In conclusion, the advancement of proteomic techniques and the application of LCM to 
isolate particular regions or enriched cell populations is opening up a library of 
proteomic data, some of which is currently beyond the knowledge of present 
understanding of expressed proteins and their relevance in the human body (Han et al 
2008). Yet this data along with increasing data sets of future studies has the potential to 
support many new discoveries and help develop new therapeutic interventions and 
improve disease understanding. 
3.5.4 Potential use of FFPE in LCM studies 
To avoid the number of factors that can affect the RIN of frozen CNS sample and their 
unsuitability for LCM derived transcriptional studies, an alternative strategy would be to 
use FFPE tissue when carrying out LCM. One advantage of using FFPE tissue in 
molecular investigations such as in IHC, is the preserved morphology of FFPE tissue 
compared to snap frozen tissue (Shi et al 2008). Also storing such material is easier than 
the requirements of frozen material, with the majority of archival tissue samples stored 
as FFPE samples. However extracting usable mRNA from FFPE tissue is challenging 
and to date methods of RNA extraction from such tissue are still developing and have 
proven to be unreliable. Owing to its ability to intercalate into nucleic acids, formalin 
has a degrading effect on both RNA and DNA, however studies have carried out 
transcription expressions studies (qPCR) on extracted RNA from LCM-ed material from 
FFPE tissue (Joseph & Gnanapragasam 2011). Very few studies have used RNA 
extracted from LCM-ed FFPE tissue for gene expression microarray studies and snap 
frozen material is still the preferred choice of RNA (Coudry et al 2007). In the same 
manner the use of FFPE tissue for LCM-ed proteomic studies is hampered by the 
formalin fixing causing methylene bridges between proteins leading to a huge degree of 
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protein cross linking, therefore the amount of protein recovery from FFPE tissue 
sections is limited. Consequently when analysing the proteomics of LCM-ed material 
frozen tissue is the preferred choice while FFPE tissue is not recommended for such use 
(Hernandez & Lloreta 2006, Rodriguez et al 2008a). 
3.5.5 Conclusion 
In conclusion, this study has identified a robust method to isolate an enriched population 
of specific glial cells from human PM CNS tissue using immuno-LCM. In addition the 
study identifies the required number of each cell type to achieve a suitable amount of 
mRNA (50ng) needed for downstream investigations, such as microarray analysis. 
There are a number of limitations when employing LCM on human PM CNS tissue, 
however the potential information which may be realised using this technique and from 
this valuable resource in relation to disease pathogenesis is vital, and superior to cell 
lines and animal models that fail to fully replicate human disease (Jucker 2010).  
Glial cells play a key role in the pathogenesis of many neurodegenerative disorders. 
Gaining a greater knowledge of each specific cell type’s role is vital to understanding 
the underlying pathology of neurological disease and this method described here has the 
potential to allow their use in the study of disease. 
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4 CHAPTER 4 
MICROARRAY ANALYSIS OF THE 
ASTROCYTE TRANSCRIPTOME IN 
MULTIPLE SCLEROSIS NORMAL 
APPEARING WHITE MATTER 
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4.1 Introduction: Gene expression profiling in multiple sclerosis   
A large amount of MS research has focussed on the pathological and immunological 
differences between demyelinated lesions, the pathological hallmark of the disease, 
compared to control WM. However, these studies do not identify the influence of early 
pathological events in relation to disease pathogenesis. Recent advancement in the 
transcriptomic field has allowed microarray technology to investigate the gene 
expression profile of individual samples, allowing for comparisons between 
differentially expressed genes in disease and control samples subjects to be achieved. 
 
Microarrays are comprised of complementary DNAs (cDNAs), PCR product or 
oligonucleotides covalently bound to a solid support (Lock & Heller 2003). Depending 
on the species to be analysed, the array can cover the whole genome, to gain a full 
understanding of the major genes contributing to disease susceptibility (Kinter et al 
2008) or can be designed specifically to investigate the expression of a selected panel of 
genes (Affymetrix, 2009). The method by which an array can be prepared varies from 
using modified ink-jet printing, photolithography or microspotting onto a glass surface 
or membrane (Lock & Heller 2003). Over 20,000 genes and more than 47,000 
transcripts are represented on each Affymetrix human genome U133 Plus 2.0 
microarray as used in the current study, with each gene being represented by a probe set 
consisting of 11 25-mer oligonucleotides (Affymetrix 2009). There are numerous 
microarray platforms available to investigate gene expression profiling, which differ by 
a number of factors including the number of gene sequences covered by the array and 
the length of probes (Comabella & Martin 2007, Kinter et al 2008). Also, the pre-
processing of sample RNA must be considered such as the various RNA amplification 
protocols available, antisense RNA (aRNA) labelling and hybridisation (Comabella & 
Martin 2007, Kinter et al 2008). In general, labelled amplified aRNA samples are 
fragmented and hybridised to the microarray chips and scanned. The signal intensity of 
each spot on an array is directly proportional to the amount of the labelled aRNA bound 
to the chip (Figure 4.1), and can be used for statistical comparisons between samples. 
 
The first microarray study on human MS brain tissue was published in 1999 (Whitney 
et al 1999). Since then, advancements in microarray technology, including an increased 
number of represented genes and reproducibility between arrays, has led to numerous 
gene expression studies in MS tissue using microarray technology, as summarised in 




Figure 4.1 Sample preparation and microarray technique                                                           
A RNA sample (poly-A + mRNA) is reverse transcribed (a) to double stranded cDNA, 
in vitro transcription (IVT) synthesises multiple single strands of biotin labelled 
complementary aRNA (b) which is then fragmented (c) and hybridised to the array chip 
(d). After washing and staining, the array map is scanned and quantified using a scanner 
(e-f). The intensity of each specific array spot is directly proportional to the amount of 












 White matter (WM) microarray studies in MS 
Main study findings Reference 
1xMS (PP) (2x AL, 1x NAWM) 
 
 Differentially expressed genes in AL compared to NAWM 
associated with immune response, cell cycle and growth, 
intracellular signaling, adhesion, transport and myelin. 
  
(Whitney et al 1999) 
2xMS (PP: 1x EA  and 1x LA lesion) (RR: 16x LA lesions) 3xCO 
(pooled samples) 
 
 Proinflammatory leukotriene genes upregulated in all MS cases. 
 
(Whitney et al 2001) 
4xMS (SP) (1x AL, 2x CAL, 2x IA lesions) 2xCO 
 
 An increase in inflammatory related genes and decrease in 
neuronal molecules and myelin associated genes. 
 
(Lock et al 2002) 
10xMS NAWM 7xCO 
 
 Upregulation of genes associated with signaling pathways related 
to oxidative stress and ischaemic preconditioning.  
 Upregulation of genes involved in inflammation in the NAWM. 
 
(Graumann et al 2003, 
Zeis et al 2008) 
5xMS (SP) (3x CAL, 2x AL) CO (No. unknown) 
 
 Associations with cytoskeletal reorganization, cell motility and 
immune response were common between the two lesion types. 
 
(Tajouri et al 2003) 
4xMS (SP) (2x CAL, 2x IAL) 
 
 At the CAL margins immune mediator genes were expressed.  
 IALs genes were associated with cell death. 
 
(Mycko et al 2003, 
Mycko et al 2004) 
6xMS (SP) (4x matched CAL & NAWM, 1x CAL only 
1x NAWM only) 8xCO 
 
 Differentially regulated immune response and neural homeostasis 
genes in lesions. 
 Differentially regulated immune response genes in NAWM. 
 
(Lindberg et al 2004) 
LCM microarray studies in MS  
Main study findings Reference 
12xMS (4xPP 8xSP) (4x CAL, 4x IAL, 4x NAWM) 4xCO 
 
 Endothelial cell activation genes differentially expressed in 
lesions compared to control or NAWM. 
 
(Cunnea et al 2010) 
5xMS (SP) All CAL (5x lesion margins 3x lesion centre and 5x 
NAWM regions) 
 
 Heat shock protein (HSP) genes were upregulated in different 
areas of CALs. 
 Transcriptional changes were observed between demyelinated 
regions and NAWM.  
 
(Mycko et al 2012) 
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Grey matter (GM) microarray studies in MS (continued) 
Main study findings Reference 
6xMS (1xPP, 5xSP) (non- lesional GM) 6xCO 
 
 Differentially regulated genes in MS non lesional GM compared 
to control GM related to oxidative phosphorylation, synaptic 
transmission, cellular transport, and immune response. 
 
(Dutta et al 2006, 
Klegeris & McGeer 
2005) 
6xMS (5xSP, 1x n/a) (GM Lesion and NAGM) 8xCO 
 
 Upregulation of Ig-related genes in MS GM compared with CO 
GM. 
 
(Torkildsen et al 2010) 
8xMS (2xPP, 6x SP) (4x myelinated, 4x demyelinated hippocampal 
areas) 4xCO 
 
 Between the lesional and myelinated hippocampus differentially 
altered genes associated with axonal transport, glutamate 
neurotransmission, synaptic maintenance, memory and learning. 
 
(Dutta et al 2011) 
FFPE tissue 3xMS (SP, 1x AL, 2x CAL) 3xAD 3xTM 3xCO 
 
 MS specific genes belonging to inflammation, immune cell 
activation/migration, oxidative injury, DNA damage/repair, cell 
death and tissue repair/regeneration. 
 
(Fischer et al 2013) 
 
Table 4.1 Summary of all microarray studies published on MS tissue                                      
Key: MS: multiple sclerosis, PP: primary-progressive multiple sclerosis, SP: secondary- 
progressive multiple sclerosis, AD: Alzheimer’s disease, TM: tuberculous meningitis, 
CO: control, AL: acute lesion, CAL: chronic active lesion, IAL: inactive lesion, 
NAWM, normal appearing white matter, NAGM: normal appearing grey matter, WM: 
white matter, GM: grey matter, Ig: immunoglobulin, n/a: not available.
117 
 
To date, gene expression microarray studies in MS have primarily concentrated on 
peripheral blood mononuclear cells (PBMC) from patients. The number of studies 
investigating gene expression profiling in MS PBMC has risen rapidly in recent years, 
likely reflecting the ease of sampling and improved genomics technology, and to date 
almost 30 studies have been reported. These studies primarily focus on identifying 
potential biological markers in MS (Achiron et al 2010, Goertsches & Zettl 2007), 
tracking of disease course (Ratzer et al 2013) and examining patients’ response to 
treatment (Kress-Bennett et al 2011, Munro & Perreau 2009). A number of PBMC 
studies have identified the activation of genes associated with the inflammatory 
response including B and T cells, when compared to the gene expression profile of 
control patients’ PBMC (Bomprezzi et al 2003, Ramanathan et al 2001). Further 
experiments have monitored gene expression of PBMC throughout the disease course in 
relapsing patients compared to those in remission, and demonstrated an increased 
expression of genes related to T cells, epitope spreading and evasion of immune 
regulation in the former group (Mashayekhi et al 2010).  
However, investigating PBMC in the periphery of patients may not parallel what is 
happening in the CNS in MS, and may reflect the systemic response to disease. Due to 
the huge case-to-case variability and lack of suitable, adequate human CNS tissue for 
microarray analysis, animal models of MS are favoured for investigating the 
pathophysiological changes associated with disease progression (Munro & Perreau 
2009). Consequently several studies have investigated large scale gene expression 
changes in these MS animal models, with 20 published microarray studies in EAE to 
date (Table 4.2). Nonetheless investigating the transcriptome of EAE models has led to 
the inevitable bias towards changes in immunological gene expression. MS is widely 
regarded as more than an autoimmune disease, which is not reflected in microarray 
analysis of EAE models, that rely on forcefully inducing an autoimmune reaction by the 
administration of autoantigens (Comabella & Martin 2007). Consequently, the resulting 
gene expression data derived from EAE models is skewed towards the immune 
responses (Comabella & Martin 2007). Furthermore, EAE is induced in healthy 
animals, while MS most likely develops in an already compromised CNS which may in 
part account for the differences in the gene expression profiles between EAE and human 
MS (Comabella & Martin 2007). 
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Microarray studies in EAE 
Main findings Reference 
SJL/J mice; MBP87-99  and C57BL/6 mice; MOG35-55 induced EAE 
– CNS tissue 
 
 5-lipoxygenase (5-LO) upregulation related to the biosynthesis of 
proinflammatory leukotrienes. 
 
(Whitney et al 2001) 
Lewis rats; guinea pig spinal cord homogenate induced EAE – 
CNS tissue 
 
 Upregulation of osteopontin in EAE rats. 
 
(Chabas et al 2001) 
C57BL/6 mice MOG35-55 induced EAE – CNS tissue 
 
 61 genes linked to EAE susceptibility.  
 
(Ibrahim et al 2001) 
C57BL/6 mice MOG38-50 induced EAE – CNS tissue 
 
 Two groups of genes:  
1. Genes encoding ion channels, neurotransmitters and growth 
factors.  
2. Genes important for nervous system regeneration.  
 
(Carmody et al 2002) 
T cell receptor double transgenic B10.PL mice; MBP induced EAE  
- Spleen cells 
 
 Gene expression profile of isolated spleen cells identified that 
oestrogen treatment generated protection from EAE. 
 
(Matejuk et al 2002) 
MBP-Ac1-1-specific T cell receptor double transgenic mice; 
spontaneous EAE – CNS tissue 
 
 The gene expression profile delineates the encephalitogenic 
process in absence of immunisation and adjuvants as seen in 
spontaneous EAE. 
 
(Matejuk et al 2003) 
Lewis rats; guinea pig MBP induced EAE – CNS tissue 
 
 Alterations in calcium balance and neurotransmitter exocytosis 
may lead to EAE onset.  
 
(Nicot et al 2003) 
B10.PL mice; MBP induced EAE – CNS tissue 
 
 EAE symptoms reversed on treatment with vitamin D associated 
with increased apoptosis of inflammatory cells. 
 
(Spach et al 2004) 
C57B1/6 (B6) and C57B1/10.S (B10) mice; MOG35-55 induced EAE 
– lymph nodes 
 
 Gene expression profiling on lymph nodes mapped genes to known 
EAE-linked loci. 
 
(Mix et al 2004) 
Lewis rats: MBP induced EAE – CNS tissue 
 
 Treatment with Lovastatin altered 158 immune-related genes, 
identifying protective mechanisms provided by statins.  
 
(Paintlia et al 2004) 
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Microarray studies in EAE (continued) 
Main findings Reference 
SJL/J mice; MBP induced EAE – CNS tissue 
 
 Study surrounding gene profiling in cell junction, adhesion and 
extracellular matrix. 
 
(Brand-Schieber et al 
2005) 
C57/bl mice; MOG35-55 induced EAE – CNS tissue 
 
 EAE mice treated with an antioxidant showed gene expression 
profiles similar to control healthy mice. 
 
(Gilgun-Sherki et al 
2005) 
WT C57/BL/6 and PAF receptor knock-out mice; MOG35-55 
induced EAE – CNS tissue 
 
 In KO-mice an overall lower expression of inflammatory 
mediators in the CNS tissue. 
 
(Kihara et al 2005) 
NOD mice: MOG35-55 induced EAE – CNS tissue 
 
 Well defined expression pattern identified at specific stages of 
EAE. 
 
(Baranzini et al 2005) 
WT and C57BL/6 mice deficient in IFNγ and IL-12p35; MOG35-55 
induced EAE – CNS tissue 
 
 Genes regulated across the three mouse models were likely to be 
regulated in MS patients. 
 
(Jelinsky et al 2005) 
 
Lewis rats; guinea pig MBP68–86 induced EAE – Lymph nodes 
 
 Study identified 2 genes consistently regulated in the rats that 
developed EAE resistance. 
 
(Liu et al 2006) 
SJL mice; PLP139-151 induced EAE – Lymph nodes 
 
 Genes associated with immune cell function and cell-to-cell 
interactions influenced by Atorvastatin treatment.  
 
(Mix et al 2006) 
C57BL/6J mice; MOG35-55 induced EAE – CNS tissue 
 
 Upregulation of angiogenic genes in acute EAE. 
 
(Roscoe et al 2009) 
C57BL/6 and SJL female mice MOG35–55 induced EAE – CNS 
tissue 
 
 Treatment with triterpenoids suppresses proinflammatory genes 
and induces anti-inflammatory genes. 
 
(Pareek et al 2011) 
Lewis rats; MBP induced EAE – CNS tissue 
 
 Increased expression of immune related genes in the EAE models. 
Inflammatory response and antigen processing/presentation were 
the most upregulated genes. 
 
(Inglis et al 2012) 
 
Table 4.2 Summary of microarray studies published in EAE                                              
Key: CNS: central nervous system, EAE: experimental autoimmune encephalomyelitis, 
KO: knock-out, MBP: myelin basic protein, MOG: myelin oligodendrocyte 
glycoprotein, PLP: proteolipid protein, WT: wild-type.
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An alternative method of analysing the potential pathogenic mechanisms in MS is to 
investigate the transcriptome of cell culture models. Many studies have used microarray 
analysis to investigate the gene expression profile of specific cells under treatment in 
culture. A summary of microarray studies, with a focus on astrocytes, is shown in Table 
4.3. Such investigations have included analysing the cells’ response to different 
treatments, such as treatment with cytokines associated with MS (Argaw et al 2006, 
Zhang et al 2006) or the gene expression profile of different astrocyte phenotypes 
known to exist in MS (Daginakatte et al 2008, Nash et al 2011b). However, it should be 
noted that the expression profile of astrocytes in culture will be different to a 
physiological setting where astrocytes interact with several other cell types. Also many 
of these studies derive from primary astrocytes from either mouse/rat or from human 
foetuses, which is not a true reflection of mature astrocytes. 
 
Ultimately, using RNA extracted directly from human CNS tissue is fundamental to 
identifying the transciptomic modifications in relation to human disease pathogenesis. 
However there are a number of confounding variables which  must be considered when 
carrying out large-scale gene expression studies on human tissue, which have been 
discussed in the previous chapter and reviewed in detail in the literature (Bahn et al 
2001, Bradl & Lassmann 2012, Kinter et al 2008, Stan et al 2006, Weis et al 2007).  In 
the case of MS, understanding the gene expression profiles derived from the different 
microarray studies is complicated and comparability between microarray studies is 
challenging due to the different population of cells/tissue researched, and/or the 
different lesion type(s) investigated. Also, considerations must be made about the 
number of cases to be used in a study, as well as the staging of the disease, choice of 
appropriate control tissue and the different microarray platforms utilised (Bradl & 
Lassmann 2012, Kinter et al 2008). 
 
It is well established that MS is an ongoing, hugely variable disease where the 
architecture of the brain is constantly changing depending on the stage of the disease 
and between different patients (Bradl & Lassmann 2012). To identify the initiating 
factors that lead to lesion formation in MS, studies into the NAWM surrounding lesions, 
traditionally defined as WM devoid of pathology, are required. 
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Microarray studies in astrocyte cell culture 
Main findings Reference 
Human 1321N1 astrocytoma cells 
 Treatment with P2Y2 receptor agonist UTP, upregulated 
neurotrophins, neuropeptides and growth factor gene expression. 
 
MS relevance 
The upregulation of P2Y2 receptors in response to stress maybe 
important in neuronal survival and facilitating neuroprotective 
mechanisms in MS. 
 
(Chorna et al 2004) 
Primary human fetal astrocyte 
 IL-1β induced the expression of genes associated with vessel 
plasticity, including HIF-1α and its target, VEGF-A. 
 
MS relevance 
IL-1β contributes to BBB permeability in MS by activating the HIF–
VEGF pathway. 
 
(Argaw et al 2006) 
Human astrocytes prepared from neuronal progenitor (NP) cells 
(human foetus at 18.5 weeks) 
 Etoposide-treated astrocytes led to the upregulation of p53-
responsive genes (including 14-3-3σ) and downregulation of 
mitotic checkpoint-regulatory genes. 
 
MS relevance  
The astrocytic expression of 14-3-3σ might serve as a marker of 
oxidative and DNA-damage in MS. 
 
(Satoh et al 2006) 
Astrocyte cultures prepared from PM human foetal CNS tissue 
(19–22 weeks of gestation) 
 IL-1β treated astrocytes – regulated expression of chemokines, 
cytokines, cell adhesion molecules, and vascular remodelling 
genes – supporting its role in CNS inflammation and BBB 
permeability in MS. 
 IFNγ treated astrocytes – similar gene expression as seen with IL-
1β treatment, but milder effect. 
 TGF-β1 treated astrocytes – induced or controlled ECM deposition 
and remodelling associated genes, supporting its role in the 
regulation of repair in MS. 
 
(Zhang et al 2006) 
Astrocyte cultures prepared from newborn SJL/J and BALB/c 
Cum mice 




The increased expression of chemokines, including CXCL1 in TMEV 




Primary astrocyte cultures prepared from postnatal day 1−3 WT 
C57BL/6 mice 
 A number of growth control genes were regulated in two separate 
models of reactive astrocytosis. 
 
MS relevance  
The upregulation of particular genes in reactive astrocytes in vitro and 
in vivo may limit the damage produced by ischemia or inflammation. 




Microarray studies in astrocyte cell culture (continued) 
Main findings Reference 
Mixed glial culture prepared from neonatal rat brain 
 Th1, M/M and Th2 cytokine treatment. 
 Differentially regulated gene expression related to metabolism and 
signaling, neuroprotection, axon/glial interactions and immune-
system. 
  
Relevance to MS 
A balance between Th1, M/M and Th2 cytokines in the CNS may be 
paramount in MS lesion development. 
 
(Lisak et al 2009, 
Lisak et al 2007, Lisak 
et al 2006) 
Astrocyte cultures differentiated from neurospheres generated 
from striata of Sprague Dawley rats 
 A direct correlation of astrocyte phenotype with their ability to 
support myelination. 
 Comparison of quiescent and activated astrocyte resulted in the 
upregualtion of distinct genes including THBS4, CTGF and 
CXCL10, all of which have been associated with myelination. 
 
MS relevance  
Potential therapeutic intervention to promote CNS remyelination in 
demyelinating diseases such as MS. 
 
(Nash et al 2011b) 
Astrocyte cultures prepared from 1.5-day-old C57Black 6 mice  
 ROCK inhibitor treatment of astrocytes led to changes in 
biological processes regulating cellular shape and motility. 
 
MS relevance  
Pharmacological manipulation of reactive astrogliosis could ensure 
beneficial and pro-survival outcomes. 
 
(Lau et al 2012) 
 
Table 4.3 Summary of microarray studies published in astrocyte cultures                           
Key: BBB: blood brain barrier, CTGF: connective tissue growth factor, CXCL: 
chemokine (C-X-C motif) ligand, ECM: extracellular matrix, HIF-1α: Hypoxia-
inducible factor 1-alpha, IL: interleukin, IFN: interferon, M/M: monocyte/macrophage, 
ROCK: Rho Kinase, σ: sigma, THBS4: Thrombospondin-4, TMEV: Theiler's murine 
encephalomyelitis virus, TGF-β1: Transforming growth factor-beta 1, VEGF: Vascular 
endothelial growth factor, WT: Wild-type.
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To date, only 3 microarray studies have investigated NAWM (Graumann et al 2003, 
Lindberg et al 2004, Zeis et al 2008), all of which have identified the upregulation of 
genes predominantly related to the immune response. It is important to study the 
NAWM rather than established lesions in MS to determine either factors which may 
initiate and/or prevent disease progression. In order to advance the transcriptomic data 
obtained from these microarray studies a technique is required which limits the potential 
bias as a result of whole tissue sampling. LCM allows for the isolation of a particular 
ROI or specific cell type from tissue, and when used in conjunction with microarray 
analysis can identify differentially expressed genes in relation to an enriched cell 
population. In MS, LCM combined with microarray analysis has recently been 
published in two separate studies (refer to Table 4.1). The first of these studies used 
microarray analysis to identify differential expressed genes in LCM-ed blood vessels 
from different regions within MS brain (Cunnea et al 2010). These regions included 
NAWM, chronic active and IA lesions, and identified specific gene changes in 
endothelial cells related to alterations in BBB function. The second study performed 
microarray analysis on isolated WML and NAWM from well characterised MS tissue 
and identified the upregulation of genes associated with the heat shock protein families 
in relation to lesion activity (Mycko et al 2012). 
In other neurological diseases and settings, LCM has been used to isolate specific cell 
types prior to microarray analysis to help provide an insight into cell activity and 
disease pathogenesis. Microarray analysis has been carried out on LCM-ed isolated 
amoeboid and ramified microglia from the corpus callosum of rat brain, identifying 
genes that are specific to each cell type (Parakalan et al 2012), motor neurons isolated 
from human ALS patients (Brockington et al 2013, Kirby et al 2011),  astrocytes in the 
ageing brain (Simpson et al 2011) and astrocytes in the animal model of ALS 
(Ferraiuolo et al 2011). Having a more definitive transcriptomic analysis of enriched 
cell types in relation to disease, compared to control cases, may identify potential 
pathological mechanisms of disease and open up new approaches to therapy.   
With this in mind, and with clear evidence of astrocyte changes in both disease models 
of MS (Inglis et al 2012, Kipp et al 2011) and MS tissue (Black et al 2010, Brosnan & 
Raine 2013, De Keyser et al 2010, Holley et al 2003, Nishie et al 2004, Rejdak et al 
2007, Williams et al 2007, Zeinstra et al 2000), identifying changes in the astrocyte 
transcriptome is needed to gain a greater understanding of the astrocytes’ role in MS 
(Goertsches & Zettl 2007). As previously mentioned, to date there are very few 
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microarray studies in human MS subjects and even fewer which have implemented 
LCM to investigate gene expression changes in an enriched ROI/cells. A detailed 
characterisation of the astrocyte transcriptome in human MS NAWM will identify 
specific changes in the astrocyte gene expression compared to normal control and may 
elucidate whether astrocytes are driving or preventing disease progression in MS. 
Furthermore, such a transcriptomic study may provide novel gene candidates that have 







4.2 Aims and objectives of the study 
The aims of this study were to: 
• Identify disease-specific changes in the transcriptomic profile of astrocytes in 
MS NAWM compared to control WM, using combined immuno-LCM and gene 
expression microarray analysis. 
• To determine if the gene expression profile of astrocytes suggests they are 
contributing to or preventing lesion development and disease progression.
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4.3 Materials and methods 
4.3.1 Suppliers  
Affymetrix UK., Voyager, Mercury Park, Wycombe Lane, Wooburn Green High 
Wycombe HP10 0HH, United Kingdom; Agilent Technologies Inc., 5301 Stevens 
Creek Blvd, Santa Clara CA 95051, United States; Epicentre Biotechnologies., 5602 
Research Park Blvd., Suite 200 Madison, WI 53719, United States; Life Technologies 
Ltd., (Invitrogen, Arcturus) 3 Fountain Drive, Inchinnan Business Park, Paisley, PA4 
9RF, UK. 
4.3.2 Case selection 
All frozen tissue used in this study was obtained from the UK Multiple Sclerosis 
Society Tissue Bank and full ethical permission was obtained (Appendix I). Full clinical 
information for each case/brain block investigated is described in Appendix III. 
Thorough neuropathological assessment of each case was carried out through H&E, 
LFB and CD68 IHC as described in Chapter 2. As only frozen material was used, the 
sections did not require dewaxing or antigen retrieval, but were fixed in ice-cold acetone 
for 10 minutes (95% ethanol for LFB) prior to staining. Altogether in this study 20 
separate brain blocks from 13 MS cases and 16 separate brain blocks from 10 control 
cases were initially characterised (Appendix III). Selected MS NAWM and control 
cases for use in this microarray study were selected based on a number of factors 
including no evidence of inflammatory infiltrates, demyelination or presence of 
amoeboid microglia, suggestive of phagocytic activity. Also the RIN of each case was 
determined pre and post LCM (see section 3.3.3 for method). All chosen cases were 
from similar anatomical brain regions, from either P1 or P2 coronal brain slice (Table 
4.4) refer to Appendix II for illustration of brain block preparation for this study. Cases 
were also matched based on age, MS NAWM mean 77 years old (range 46-86 years 
old), control mean 71 years old (range 35-91 years old) and sex (MS NAWM 4F:1M, 
control WM 3F:2M) and had an overall mean PMI time of 16 hours (range 5-33 hours). 
Based on the above criteria, in total 5 MS NAWM and 5 control cases were used in the 
study (Table 4.4) which is considered an adequate number of cases to identify 




Table 4.4 The microarray case cohort                                                                                 
5 MS and 5 control cases were identified as suitable for this transcriptomic microarray 
study based on their disease type, age, sex, post mortem interval (PMI) anatomical 
location, neuropathological assessment and RIN pre and post LCM. 
Key: N/A: Not applicable, n/a: not available.
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4.3.3 Laser capture microdissection and RNA extraction  
In brief, for each MS NAWM and control case, 7 µm sections were cut on a cryostat 
(Leica, UK) and rapidly immunostained for GFAP (refer to section 3.3.5). Under 
microscopy GFAP+ astrocytes were identified and LCM was employed on each case to 
isolate these cells from the tissue sections. The captured cells were used for RNA 
extraction (refer to sections 3.3.6 and 3.3.7). Following RNA extraction, the quantity 
and quality of extracted RNA was checked prior to amplification using the NanoDrop 
and Bioanalyser, respectively (section 3.3.4).   
4.3.4 Background to RNA amplification 
In order to carry out successful gene expression microarray studies, up to 15 µg of 
labelled RNA is needed (Affymetrix 2009). However, owing to the low concentration, 
on average 50ng, of RNA extracted from isolated astrocytes using LCM, RNA 
amplification is required to produce amplified and biotin labelled RNA. There are a 
number of commercially available amplification kits that claim to successfully amplify 
RNA from small quantities. However, to achieve optimal amplification from these kits 
samples must be pure and of good RNA integrity, which are both limiting factors in 
RNA extracted from LCM-ed PM material.  
Consequently during this study a number of different amplification protocols were 
assessed to achieve the optimum protocol that provided 6.5 µg aRNA for use in 
downstream microarray analysis. In general, all amplification protocols were derived 
from a method using T7 RNA polymerase (Frisen et al 1993).  In this current study 
approximately 50ng total RNA was achieved from each LCM-ed sample, therefore 
amplification involving cycles of cDNA synthesis and in vitro transcription (IVT) were 
required to gain 6.5 µg of labelled aRNA for microarray analysis.  
In this study three separate amplification kits were assessed, each protocol was 
optimised and tested with use of alternative clean-up and purification kits. A final 
optimum protocol was determined and used on all samples in this study. Outlined below 
are the details of the three main amplification kits used to enhance aRNA recovery from 
LCM-ed PM material. 
4.3.4.1 Two round linear amplification  
Initially two separate RNA amplification kits were employed, the Two-cycle Target 
labelling protocol (Affymetrix, UK) and TargetAmp 2-Round biotin-aRNA 
amplification (Epicentre, USA), each protocol followed a similar two-round 
129 
 
amplification procedure but varied in the amount of starting material required. For the 
first round of amplification using the Affymetrix kit, 50ng total RNA or with the 
Epicentre kit 500pg total RNA from each sample was reverse transcribed along with 
Poly-A control RNA using a T7-oligo(dT) promoter primer which anneals to the poly-A 
tail of  mRNA. Poly-A controls are in vitro synthesised polyadenylated transcripts 
corresponding to the B.subtilis genes, lys, phe, thr and dap. The expression levels of the 
Poly-A control probe sets on the microarray are used to check the RNA amplification 
efficiency independent of sample quality or quantity. Second strand complementary 
cDNA synthesis was achieved using a MM containing DNA polymerase I following an 
RNase H action, which incorporates the T7 polymerase promoter into the double 
stranded cDNA (dsDNA), while RNaseH breaks down the RNA template strand. This 
dsDNA product was purified and served as a template for the first round IVT reaction. 
The IVT reaction used a T7 RNA polymerase and unlabelled ribonucleotide mix to 
generate multiple copies of aRNA. In the second round of amplification numerous 
copies of aRNA were reverse transcribed with random primers and second strand cDNA 
synthesis generated using T7-oligo(dT) promoter primers and a MM containing DNA 
polymerase I and dNTP to create a cDNA template for the second  IVT reaction. 
dsDNA was transcribed into aRNA using biotinylated conjugated nucleotides in the 
second round IVT reaction. At this stage the biotin labelled aRNA was purified using a 
column based clean-up kit to remove enzymes, salts and any unincorporated nucleotides 
(Figure 4.2).  
4.3.4.2 One round linear amplification 
The optimum RNA amplification kit used in this study was the GeneChip 3’ IVT 
Express Kit (Affymetrix, UK) which involved one round of amplification employing the 
T7 IVT step a well-established method for preparing samples for gene expression 
analysis. Initially total RNA (50ng) and poly-A control RNA was reverse transcribed 
with an enzyme and buffer MM containing T7 oligo(dT) primers to synthesise first 
strand cDNA containing a T7 promoter sequence. cDNA was converted to dsDNA by 
the use of an enzyme and buffer MM containing DNA polymerase I and RNase H to act 
as a template for the IVT reaction. IVT synthesised multiple copies of amplified aRNA 
incorporating biotin conjugated nucleotides. The biotin labelled aRNA was purified 
using RNA binding magnetic beads to remove enzymes, salts, and any unincorporated 





Figure 4.2 Two round amplification method of extracted RNA from isolated 
astrocytes                                                                                                                                
RNA and poly-A controls primed with T7 oligo (dT) primers were reverse transcribed 
into cDNA (a, b). Single stranded cDNA was converted to dsDNA (c) using DNA 
polymerase and RNase H action. This dsDNA acts as a template in the first round IVT 
reaction where multiple copies of aRNA were generated (d). A second round of 
amplification followed an aRNA clean-up (e) where aRNA product from the first round 
of amplification was reverse transcribed into cDNA (f). dsDNA was generated (g) and a 
second round IVT reaction produced multiple copies of biotin labelled aRNA from the 
dsDNA template (h, i). aRNA was purified to remove any unincorporated NTPs, salts, 
enzymes (j) aRNA ready for fragmentation and hybridisation to the GeneChip (k, l). 




Figure 4.3 One round amplification method of extracted RNA from isolated 
astrocytes                                                                                                                               
RNA and poly-A controls primed with T7 oligo(dT) primers were reverse transcribed 
into cDNA (a, b). Single stranded cDNA was converted to ds(DNA) (c) using DNA 
polymerase and RNase H action. This dsDNA acts as a template in the IVT reaction 
where multiple copies of biotin labelled aRNA were generated (d). aRNA was purified 
in RNA binding magnetic beads to remove any unincorporated NTPs, salts, or enzymes 
(e) aRNA ready for fragmentation and hybridisation to the GeneChip (f, g). Figure 




4.3.4.3 Assessment of amplified RNA quantity and quality  
Following elution from the RNA magnetic beads, the quantity of amplified aRNA was 
analysed on the NanoDrop spectrophotometer (as described in section 3.3.4). And 
quality of aRNA checked by loading 1μl aRNA onto a Nano LabChip 6000 (capable of 
measuring 25–500 ng/μl total RNA) using the Agilent 2100 Bioanalyser. 
4.3.5 Microarray procedure 
4.3.5.1 Affymetrix Human Genome U133 Plus 2.0 microarrays – the structure 
The use of Affymetrix Human Genome U133 Plus 2.0 arrays enables measurement of 
gene expression over the entire human genome in a single hybridisation. More than 
54,000 probe sets are used to analyse the expression level of more than 47,000 
transcripts and variants, including approximately 38,500 characterised human genes. 
Known gene/transcripts are represented on the microarrays by a probe set which 
consists of 11 25-mer oligonucleotides that are designed to be a perfect match to a 
region on the expressed transcript, these probes are synthesised in discrete areas 
(features) on the microarray. To control for non-specific hybridisation during analysis 
and interfering background noise, each perfect match probe sequence is paired to a 
mismatch probe sequence containing a single base substitution at the 13th nucleotide of 
the probe. Any difference in signals between the perfect match and mismatch paired 
probes is a measure of probe set specificity and can be used to determine the overall 
signal by a specific probe set.  
4.3.5.2 RNA fragmentation, hybridisation and microarray scanning 
In order to increase the specificity and intensity of each array, aRNA fragmentation is 
required to limit the RNA molecule size to eliminate steric hindrance and non-specific 
cross-hybridisation on the microarray. Hence 6.5μg of biotin labelled aRNA from each 
sample was fragmented using an array fragmentation buffer which contains Mg2+ ions 
and is part of the 3’ IVT express kit. To aid the reaction, samples were heated to 94°C 
for 25 minutes. Following fragmentation, 1μl of aRNA was loaded on to a Nano 
LabChip 6000 and run on the 2100 Bioanalyser (Agilent, USA) to analyse the size of 
fragmentation reaction products (Figure 4.4). Meanwhile the microarray chips were 
preconditioned with 200μl prehybridisation mix for at least ten minutes at 45°C, 
rotating at 60 rpm in a hybridisation oven (Affymetrix, UK). 6.5μg fragmented and 
labelled aRNA was mixed in a hybridisation cocktail containing serial concentrations of 
hybridisation controls (bioB, bioC, bioD, and cre genes) and positive oligonucleotide 


















Figure 4.4 Pre and post fragmented aRNA analysis using the Agilent 2100 
Bioanalyser                                                                                                                      
An example electropherogram of amplified aRNA (a) and fragmented amplified aRNA 
(b).  
y-axis represents fluorescence units, (FU) and x-axis represents runtime in seconds, (s).
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efficiency of the array can be assessed, with the signal intensity of each control 
reflecting their applied concentration. Whilst the B2 oligo was used to align the 
processing data at the corners and border of each array. After conditioning the 
microarray chips, the aRNA hybridisation cocktail replaced the preconditioning 
hybridisation solution and hybridisation took place overnight (o/n) for 16 hours at 45°C, 
rotating at 60 rpm. After 16 hours the hybridisation cocktail was removed from each 
microarray chip and the washing and staining of each microarray was carried out in the 
GeneChip Fluidics Station 400 (Affymetrix, UK). Firstly a low stringency wash 
solution was applied to the microarrays, followed by a high stringent wash to remove 
any unbound RNA, before staining with the light sensitive streptavidin phycoerythrin 
(SAPE). Another low stringent wash step followed prior to the application of a 
biotinylated anti-streptavidin antibody and an additional stain in SAPE followed by 
final wash steps. Each microarray chip was scanned in the GeneChip 3000 scanner with 
the use of a high-resolution laser to determine the fluorescent intensity of hybridised 
transcripts. 
4.3.6 Microarray data analysis 
The transcriptional profile of astrocytes isolated from MS NAWM and Control WM 
was compared on Affymetrix U133 Plus 2.0 microarrays. Affymetrix Gene Expression 
Console was used for quality and control analysis of the data and the image or CEL files 
were imported to GeneSpring version 7.0 (Agilent, USA) and normalised to the median 
of all genes prior to statistical analysis to identify differentially expressed genes. As a 
restrictive cut-off point, differentially expressed genes were genes from MS NAWM 
cases that were upregulated (≥ 1.5 fold change and ≤ 0.05 p-value) or downregulated (≥ 
-1.5 fold change and ≤ 0.05 p-value) compared to control cases. Significantly altered 
genes were identified through the Database for Annotation Visualisation and Integrated 
Discovery (DAVID) allowing genes to be grouped based on their biological function 
and the use of Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway analysis, 




4.4.1 Classification of suitable cases for LCM 
In total, 8 MS cases (14 blocks) and 11 control cases (16 blocks) were histologically 
characterised and subjected to pre LCM RNA analysis. One MS case investigated had 
evidence of inflammation as indicated by the presence of perivascular inflammatory cell 
infiltrates and the presence of CD68+ amoeboid microglia (Figure 4.5) therefore case 
MS93 was eliminated from further investigation. In addition, MS103 failed to provide a 
pre-LCM RIN and appeared histologically abnormal with CD68+ amoeboid microglia 
and slight perivascular cuffing, and was therefore also eliminated from the study. Case 
MS159 gave a low pre-LCM RIN of 2.5 and histologically the case appeared abnormal 
with perivascular cuffing and the presence of CD68+ amoeboid microglia, therefore this 
case was also eliminated from the study. The majority of control cases showed no 
evidence of pathology, however one case from the SBTB showed evidence of 
inflammation and therefore was eliminated from further investigation. Of the remaining 
control cases, selection was based on anatomical location, PMI, RIN, sex and age 
matching with the selected MS cases. After exhausting samples from both the UK MS 
Society Tissue Bank and the SBTB for snap frozen material, 5 suitable MS NAWM and 
5 controls were selected to be used in the study (refer to Table 4.4). 
4.4.2 RNA amplification from LCM-ed material 
On average approximately 1500 astrocytes were isolated per case using LCM, from 6-8 
GFAP rapid-immunostained sections, (5 hours maximum of LCM per case) and 
provided approximately 50ng of starting total RNA. Each amplification kit used in this 
study to amplify extracted RNA from isolated astrocytes gave varied results, examples 
of which are presented here. Initial experiments using the two round amplification 
method (Affymetrix kit) employed 50ng starting RNA from each sample, only one 
sample (MS71 P2C3) amplified to the required amount of biotin labelled aRNA needed 
for microarray analysis (7.26 µg). LCM was therefore repeated on all samples and the 
amplification protocol was repeated using a higher amount of starting RNA (70ng), 




Figure 4.5 Perivascular cuffs and CD68+ amoeboid microglia                                       
An example of a MS NAWM cases which was eliminated from the study due to 
evidence of perivascular infiltration (a), and positive CD68 amoeboid microglia which 














Table 4.5 Two-round amplification optimisation (Affymetrix)                                 
Amplification was carried out on all samples with different starting amounts of RNA 
ranging from 50ng and 70ng. Only RNA from case MS71 P2C3 with 50ng starting 
RNA amplified to the sufficient amount required for microarray analysis.
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Due to the limitations of the Affymetrix amplification kit and its removal from sale by 
the manufacturer the use of an alternative amplification kit, the TargetAmp 2-Round 
biotin-aRNA amplification (Epicentre, USA) was evaluated. This kit claimed to amplify 
very small amounts of RNA (a minimum of 500pg) and therefore appeared more suited 
for the limited amount of extracted RNA from samples used in this study. Initial studies 
with this kit yielded 1.9-2.5 µg aRNA, very little advancement in this value was attained 
by implementing 1000pg starting RNA (Table 4.6). However with continued use on 
repeated samples the kit proved unreliable and insufficient amounts of aRNA were 
obtained. Samples from each round of amplification (on average approximately 4 
rounds of amplification were needed per case) were pooled together to provide 
approximately 6.5μg aRNA. Sample fragmentation was carried out and two samples 
hybridised onto microarray chips but only 11.3% probe set coverage for the MS sample 
and 1.4% coverage for the control sample was obtained. As both the NanoDrop and 
Bioanalyser gave ambiguous findings related to the small amounts of RNA being 
amplified in the Epicentre kit, a final separate amplification kit was employed, the 
GeneChip 3’ IVT Express Kit (Affymetrix, UK). This method employed a single round 
of RNA amplification and alternative RNA magnetic bead purification step to which a 
higher yield of aRNA was attained per sample (Table 4.7) a minimum of 6.5 µg biotin 
labelled aRNA was obtained from 50ng starting RNA from one round of amplification, 
except for one case (CO25 P2A3) where two independent single rounds of amplification 
were needed and the two samples pooled to obtain 6.5 µg aRNA. 
4.4.3 Gene expression profiling and quality control 
The GeneChip Operating Software (GCOS) generated data files containing information 
from each of the ten microarray chips analysed. Through Expression Console (Mas5.0 
analysis) quality reports of the transcriptional profile of each sample were produced 
including a number of quality control and normalisation factors to consider. The number 
of probe sets present for each array is calculated as a percentage (%) relative to the 
number of total probe sets on the array, comparative arrays should therefore share 
similar % probe sets. Hybridisation controls are also used to assess the quality of 
replicated RNA samples, the overall intensity of the controls of each gene array is 
compared to an expected target intensity value to calculate the appropriate scaling 
factor. Using the scaling factor normalises the data to a set value, so that the 10 arrays 
can be compared.  Consequently a sample that is degraded or poorly amplified and 





Table 4.6 Two-round amplification optimisation (Epicentre)                                      
Amplification was carried out initially on two samples with different starting amounts 
of RNA ranging from 500pg and 1000pg. A significant amount of RNA was amplified 
but not enough for microarray analysis. 
 
 
Table 4.7 One-round GeneChip 3’ IVT Express amplification                                            
A minimum of 6.5 µg biotin labelled aRNA was achieved in one round of amplification, 
suitable for microarray analysis. (Two independent single round amplification of sample 
CO25 P2A3 was completed and the two samples pooled together).
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compared and normalised to the same target intensity the scaling factor for that poor, 
degraded sample will be higher than for more intact samples. Considering these two 
independent factors, 3/10 array samples (two control and one MS NAWM) were 
eliminated from further analysis. CO22 P1C2, CO25 P2A3, and MS100 P2B3 had 
lower % probe sets present (20.01%, 7.47%, and 22.54%) in comparison to the 
remaining seven samples which gave a mean % probe set present of 34.82% (32.06%-
38.15%). As well the scale factors were considerably higher in these three samples 
(CO22 P1C2: 23.17, CO25 P2A3: 58.35, and MS100: P2B3 19.26) in comparison to the 
remaining seven samples with a mean scale factor: 8.22 (5.16-11.00).  Other factors 
measured included: the average background and RAW noise (RawQ). There is no 
official limit for background values but Affymetrix recommends values, ranging 
between 20-100 are adequate and replicate arrays should have comparable background 
values. In this study, the mean background signal for the seven samples was 26.18 
(26.08-27.18). RawQ measures the pixel-pixel variation of probe cells on the array, the 
noise comes from two factors: electrical noise from the scanner and the sample quality, 
comparable RawQ values between replicate arrays should exist, from the seven samples 
analysed, the mean RawQ value was 0.67 (0.66-0.71). Specifically the internal control 
gene, glyceraldehyde 3-phosphate dehyrogenase (GAPDH), is used to provide 
information on the sample quality and efficiency of amplification and is calculated 
based on the 3’ probe sets for GAPDH compared to the signal values of the 
corresponding 5’ probe sets.  These results are summarised in (Table 4.8). 
Quantification of transcript abundance for each probe set was generated based on the 
MAS5.0 algorithm (Affymetrix 2002); the logged average ratio of fluorescence between 
the perfect match and mismatch probe sets. In order to visualise the variation of 
transcript abundance between microarrays, a logarithmic scaled boxplot of each array’s 
distribution of probe set intensities is calculated from the median signal intensity across 
all the arrays (Figure 4.6). This visual representation of microarray findings supports the 
results from the initial quality control analysis (refer to Table 4.8) indicating three 
outlier samples (CO22 P1C2, CO25 P2A3 and MS100), which were eliminated from 
further analysis. 
4.4.4 Confirmation of astrocyte enrichment  
In order to confirm that the extracted RNA from each sample represented a significantly 
enriched astrocyte population, specific transcript expressions were investigated. High 




Table 4.8 Sample quality control analysis post microarray                                        
Considering the different variables, samples MS100 P2B3, CO22 P1C2 and CO25 
P2A3 (orange) were eliminated from the cohort based on their lower % probe sets 
present and high scale-factor scores.  
 
 
Figure 4.6  The relative expression signal for each array generated in Expression 
Console (MAS5.0 algorithm)                                                                                                     
The median gene expression across all 10 arrays is identified (red line) and the overall 
deviation from the corresponding median is identified for each microarray chip. The Y-
axis is the relative log expression signal for all 10 samples (X-axis).   
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5995.0; range, 1263.7-20549.3) but low levels of CD34 (endothelial cell: probe set id 
209543_s_at, mean signal intensity 50.6; range, 14.7-98.4), CD68 (microglia: probe set 
id 203507_at, mean signal intensity 23.7; range, 4.1-64.1), and OLIG-2 
oligodendrocyte: probe set id 213825_at, mean signal intensity 290.3; range, 133.5-
520.7) confirming the extracted RNA from LCM-ed cells was an enriched astrocyte 
population. Moderately high levels of a neuronal transcripts were detected (NFL: probe 
set id 221805_at, mean signal intensity 3328.6; range, 368.9-5264.2), which may reflect 
the close proximity of astrocytes to axons which  will be isolated along with the 
immunopositive astrocytes as a result of the LCM process.  
4.4.5 Identifying differentially expressed genes associated with astrocytes isolated 
from MS NAWM in comparison to astrocytes from control WM 
GeneSpring analysis was used to identify the differentially significant transcriptional 
changes in astrocytes isolated from MS NAWM compared to control WM. In total 
across the seven samples (four MS and three control) 3375 genes were differentially 
expressed (1778 upregulated and 1596 genes downregulated). Following GeneSpring 
analysis, transcripts were identified as significantly differentially expressed (up or 
down-regulated) if the expression level in the NAWM samples was altered with a fold 
change of ≥ 1.5, and a p-value ≤ 0.05 when compared to the control samples (Table 
4.9).  
4.4.6 Investigating differentially expressed genes in MS NAWM astrocytes 
compared to control WM astrocytes using DAVID 
Significant differentially expressed gene lists (up and downregulated) were imported 
into DAVID, a tool used to group genes into pathways based on their biological 
function (Huang da et al 2009a, Huang da et al 2009b). Genes associated with immune 
response (Table 4.10), homeostasis (Table 4.11), cell signaling (Table 4.12), 
cytoskeleton (Table 4.13) and RNA processing/protein metabolism (Table 4.14) were 
grouped (Table 4.15) full tables of genes are listed in Appendix V. However when 
manually assessing gene expression from the top 20 differentially upregulated genes 
(Table 4.16), 6 genes (metallothionein 1X [MT1X], metallothioenin 1G [MT1G], 
metallothionein 2A [MT2A], metallothionein 1 pseudogene 2 [MT1p2], ferritin light 
chain [FTL], and transferrin [TF]) related to the homeostasis of metal iron, were 
confirmed through literature searching to be associated with oxidative stress and MS 




Table 4.9 Total number of genes identified from the microarray study using 
GeneSpring software (MS NAWM vs control) 
 
 
Table 4.10 Differentially expressed immune response genes identified in astrocytes 
isolated from NAWM compared to control WM                                                     




Table 4.11 Functional grouping of the differentially expressed genes identified 
relating to dysregulation of homeostasis in astrocytes isolated from NAWM 
compared to control WM                                                                                      
Upregulated genes (black), downregulated genes (red). 
 
 
Table 4.12 Functional grouping of the differentially expressed genes associated 
with cell signaling and communication                                                                














Table 4.13 Differentially expressed cytoskeleton genes identified in astrocytes 
isolated from NAWM compared to control WM                                                 




Table 4.14 Differentially expressed RNA processing and protein metabolism genes 
identified in astrocytes isolated from NAWM compared to control WM 






Table 4.15  DAVID analysis of significant, differentially expressed genes in 
astrocytes in MS NAWM versus control WM 
 
 
Table 4.16 Top 20 differentially upregulated genes                                                        
From the top 20 differentially upregulated genes in astrocytes isolated from MS 
NAWM compared to control WM six genes (orange) were related to the homeostasis of 




In MS, it has been suggested that identifying the changes in pathology within the 
NAWM may elucidate the mechanisms of disease initiation and ultimate progression 
(Liang et al 2012, Melief et al 2013, Miller et al 2003, Traboulsee et al 2003, Zeis et al 
2008). In this study LCM-ed isolated astrocytes from PM MS NAWM cases and control 
WM were subjected to gene expression microarray analysis to identify differentially 
expressed genes. Astrocytes perform a variety of key roles in the CNS: they maintain 
homeostasis by controlling ion concentrations including potassium and calcium 
(Sofroniew & Vinters 2010), provide nutritional metabolites to neurons and control the 
osmotic balance within the CNS (Sofroniew & Vinters 2010), release an array of pro- 
and anti-inflammatory cytokines and chemokines partaking in immune responses 
(Jensen et al 2013), and maintain the BBB (Abbott et al 2006).  Furthermore, astrocytes 
respond to stimuli through a process known as astrogliosis (Zamanian et al 2012). The 
significant differentially expressed genes identified in this microarray study identified 
changes in functional gene groups associated with the immune response, homeostasis, 
cellular signaling and communication, cytoskeleton and protein metabolism. Most 
interestingly, from the top 20 differentially upregulated genes, six genes were related to 
the homeostasis of iron and the response to oxidative stress, which is an increasingly 
recognised factor in many neurodegenerative diseases (Al-Radaideh et al 2013, Bishop 
et al 2002, Carbonell & Rama 2007, Hametner et al 2013, Williams et al 2012).  
4.5.1 Significant, differentially expressed genes associated with the immune 
response 
Functional grouping of the significant differentially expressed genes identified 
enrichment of genes associated with the immune response (refer to Table 4.10), with the 
majority (16/19) of genes upregulated in MS NAWM compared to control WM. This 
finding supports previous gene expression studies performed on MS NAWM (Lindberg 
et al 2004, Lock et al 2002). However, also highlighted here and in agreement with 
published studies, was no significant differential expression of the commonly related 
inflammatory genes associated with MS such as TNFα, or IFNγ (Lindberg et al 2004, 
Lock et al 2002).  
 
The upregulation of IL-17C, a proinflammatory cytokine previously linked to MS 
pathogenesis (Stromnes et al 2008), and increased expression of complement 
components (C1QC and C3) associated with complement mediated inflammation in MS 
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were identified (Brink et al 2005, Koning et al 2007, Rus et al 2006). Upregulation of 
immune response genes including C1 and C3 complement components have been 
identified in a microarray study of the MS model, Theiler’s murine encephalomyelitis 
(Ulrich et al 2010) and in EAE mouse models (Matejuk et al 2003, Spach et al 2004). 
Corroborative studies in MS patients consistently identify an increased level of plasma 
C3 along with other complement factors (Ingram et al 2012). Through IHC the 
deposition of C3 expression by enlarged microglia in MS NAWM has been reported 
however this study failed to describe any astrocytic expression (Ramaglia et al 2012). 
Studies in EAE have shown mice deficient in C3 have reduced cellular infiltration and 
demyelination (Barnum 2002) with the expression of C3 required for full development 
of the disease (Szalai et al 2007), suggesting the increased expression of components of 
the complement cascade by astrocytes contributes to lesion pathogenesis. 
 
A significant reduction in signal transducer and activator of transcription 6 (STAT6) in 
MS NAWM astrocytes compared to control WM was found in the current study. This 
finding is in contrast to previous reports of an increased STAT6 expression associated 
with the presence of activated macrophage/microglia which were documented to be 
present throughout the NAWM cases used in that study, concluding an increased 
expression of STAT6 was related to a persistent activation of macrophages/microglia in 
MS (Graumann et al 2003). These differences may reflect the stringent case selection 
parameters used in the current study which included the elimination of any NAWM 
cases which contained amoeboid CD68+ microglia. Furthermore, the current study was 
performed on an enriched astrocyte cell population, which likely express a different 
transcriptomic profile to the heterogeneous cell population present in whole tissue 
studies. Immunohistochemical investigation of STAT6 expression in NAWM has 
demonstrated the colocalisation of STAT6 with myelinating oligodendrocytes and 
occasional GFAP+ astrocytes, with no colocalisation of STAT6 expression and CD68+ 
microglia (Zeis et al 2008). The downregulation of STAT6, which forms part of the anti-
inflammatory Janus kinase/STAT (JAK/STAT)-signaling pathway, opposes the 
upregulation of its main receptor IL-4R, which was upregulated in the present 
microarray study and supports published qPCR findings (Zeis et al 2008). IL-4R 
expression may activate other unknown pathways in astrocytes as opposed to the 
STAT/JAK signaling pathway as no other STAT or JAK genes were identified in the 
current study, in contrast to whole tissue studies (Graumann et al 2003, Lindberg et al 




The current study also identified significant downregulation of prostaglandin-
endoperoxide synthase 2 (PTGS2) also known as cyclooxygenase-2 (COX-2) which is 
known to be expressed by inflammatory cells, infiltrating macrophages and ramified 
microglia close to the inflammatory infiltrates in MS (Minghetti 2004). COX-2 
synthesises the production of prostanoids that contribute to chronic inflammation (Hinz 
& Brune 2002) and production of free radicals (Minghetti 2004). Non-steroidal anti-
inflammatory drugs (NSAIDs) are a recognised treatment in MS (Klegeris & McGeer 
2005, Lleo et al 2007) and may downregulate COX-2 gene expression and ultimately 
the functioning protein, thereby having a beneficial anti-inflammatory effect. The 
decreased COX-2 expression identified in this study may reflect patients’ unspecified 
therapeutic treatment in life.  Furthermore the reduction in COX-2 expression may 
reflect neuroprotective action by astrocytes, limiting their production of free radicals, 
decreasing oxidative stress and preventing disease progression (Minghetti 2004). 
4.5.2 Significant, differentially expressed genes associated with homeostasis 
The current microarray study identified significant, differentially expressed genes 
associated with homeostasis (refer to Table 4.11), which can be subdivided into 3 
groups related to neurotrophic support, metal ion binding and transcription, as shown in 
Table 4.15 (full gene list, Appendix V). These findings support published microarray 
studies in MS NAWM, which also identified significant differential expression of genes 
associated with cellular homeostasis and neuroprotection (Graumann et al 2003, 
Lindberg et al 2004, Zeis et al 2008). Similar to these reports, major downregulation of 
neurotrophic-related genes (15/21) was detected in the NAWM. However, in contrast to 
Lindberg’s study, increased expression of transforming growth factor, beta 3 (TGF-B3) 
was detected in NAWM.  TGF-B3 is an astrocyte derived regulator of neuronal survival 
known to enhance the action of neurotrophic factors (Krieglstein et al 2002), therefore 
the increased astrocytic expression of TGF-B3 may potentially be neuroprotective in 
NAWM. Furthermore, TGF-B3 gene expression is increased in EAE mice treated with 
anti-inflammatory oestrogen molecule, which also resulted in the decreased mRNA 
expression of the proinflammatory cytokine TNFα compared to untreated EAE mice 
(Matejuk et al 2002).  
 
Neurotrophic tyrosine kinase receptor, type 2 (NTKR2), also known as tropomyosin 
receptor kinase B (TrkB), is activated by ligands, including brain-derived neurotrophic 
factor (BDNF), and contributes to neuroprotection (Colombo et al 2012). In the current 
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study, a marked reduction of NTKR2 was identified in astrocytes isolated from MS 
NAWM, which is in direct contrast to other microarray studies where an upregulation of 
TrkB transcripts in MS NAWM and WML was reported (Graumann et al 2003, Mycko 
et al 2004). Also, TrkB protein expression was identified in active and IA lesions of MS 
patients (Stadelmann et al 2002) and in an EAE study (De Santi et al 2009). Conflicting 
accounts as to the expression of TrkB by astrocytes has been discussed (Colombo et al 
2012, Song et al 2013). Mice that lack astrocytic TrkB are protected from EAE-induced 
neurodegeneration and compared to normal EAE-induced mice show a reduced cellular 
infiltration resulting in reduced neuroinflammation (Colombo et al 2012). Astrocytes in 
culture when stimulated with BDNF, increase their release of NO and astrocyte 
conditioned media was detrimental to neurons. Ultimately this suggests that NO 
synthesis in the CNS contributes to the development of EAE and is dependent on 
astrocyte expressed TrkB, with increased astrocyte expression of TrkB being 
detrimental due to the increased NO production (Colombo et al 2012). 
 
The reduction in NTKR2 expression in isolated astrocytes from NAWM may suggest a 
response to the increase in NO within lesion centres, and an attempt to maintain 
homeostasis within the tissue. NAWM astrocytes may reduce expression of growth 
factor receptors to limit the potential neurodegenerative effects from interactions with 
neurotrophic factors such as BDNF. Increased disease incidence and severity of EAE 
has been reported in TrkB (+/-) heterozygous mice compared to wild type TrkB (+/+) 
mice (Song et al 2013). This contradicts previous findings that showed the upregulation 
of TrkB receptor expression in astrocytes in MS lesions and that the astrocyte TrkB 
knock-out (KO) model protected against EAE induced demyelination (Colombo et al 
2012). The increased disease severity in the TrkB heterozygous mouse was presumed to 
be as a result of an increased BDNF interaction with its alternative p75 receptor because 
of reduced levels of TrkB. Evidently a better understanding of TrkB and its interactions 
in MS is needed. The discrepancies between these studies could reflect different 
downstream effects of TrkB signaling at different time points, or in different cell types 
during the disease course (Song et al 2013). Previous microarray studies indicating an 
increase in TrkB in MS lesions and NAWM were derived from whole tissue (Graumann 
et al 2003, Mycko et al 2004), however the transcriptomic data in the current 
microarray study originates from an enriched astrocyte population from MS NAWM, 
highlighting one of the advantages of using LCM based methodology in transcriptomic 
studies in assessing gene expression to a specific cell population.  
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The expression of proinflammatory molecules by activated glia plays an important role 
in the pathogenesis of MS and is also critical to the regulation of genes associated with 
oxidative stress and tissue damage (Miller et al 2013). Despite lack of specific 
expression of IFN genes in this study, apart from the interferon induced transmembrane 
protein (IFITM)1 and IFITM2, which have not been reported previously in MS 
pathology, a number of genes were differentially expressed which play a role in limiting 
oxidative stress and maintaining homeostasis (Haider et al 2011).  
The current study identified significant upregulation of various metal ion binding genes 
including five metallothionein (MT) isotypes, TF and FTL.  These genes regulate levels 
of metal ions, in particular iron, which have been shown to accumulate in MS lesions 
and exacerbate oxidative damage through the conversion of hydrogen peroxide to free-
radical ions (Hametner et al 2013). An increase in TF and MT1L expression has also 
been identified by microarray analysis in both acute and CAL when compared to control 
tissue (Tajouri et al 2003). Similarly microarray analysis identified the increased 
expression of MT genes, representing a stress response in MS lesions compared to 
control tissue was detected (Lock et al 2002) and MT1 has been demonstrated in MS 
chronic and active lesions (Jelinsky et al 2005). MT’s have been indicated in the 
development of lesions in both MS and EAE studies (Jelinsky et al 2005, Penkowa et al 
2003b, Penkowa et al 2003c). These findings are in contrast to one study which did not 
report any significant alteration in MT1 or MT3 expression in the spinal cord of EAE 
mice (Carmody et al 2002). However, the expression of these two genes in the spinal 
cord of control C57BL/6 mice formed part of the top 20 most abundant genes in the 
normal CNS (Carmody et al 2002). Discrepancies between studies maybe due to the 
anatomical area investigated, as the spinal cord is not a true reflection of the whole CNS 
and may reflect regional variations in gene expression (Carmody et al 2002). Reports 
indicate that lactotransferrin (Ltf), a member of the TF family, is highly expressed at all 
stages of EAE in comparison to control mice (Baranzini et al 2005).  The current study 
suggest that astrocytes play a key role in reducing the amount of iron within the NAWM 
in MS, thereby preventing the accumulation of oxidative damage and the spread of 
lesion formation. 
4.5.3 Significant, differentially expressed genes associated with cell signaling and 
communication 
Although KEGG pathway analysis of the microarray data did not identify alterations in 
specific signaling pathways, functional grouping analysis identified the differential 
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expression of genes related to mitogen-activated protein kinase (MAPK), insulin, 
calcium and ubiquitin signaling pathways, in addition to genes involved in apoptosis 
and cell junction/synapses. These findings support previous studies which have shown 
differential expression of genes associated with receptor mediated signaling pathways in 
NAWM compared to control WM (Graumann et al 2003, Zeis et al 2008).  
Dysregulation of intracellular signaling pathways is also a feature of acute MS lesions  
(Whitney et al 1999), active MS lesion margins (Mycko et al 2003), and cortical 
pathology in MS (Dutta et al 2007).  In a recent LCM study genes associated with a 
cellular response to stress and/or hypoxia were identified through qPCR on LCM 
isolated MS NAWM in comparison to control cases (Cunnea et al 2011). Clearly 
dysregulation of signaling pathways play a key role in the pathogenesis of MS, but 
understanding the origins and consequences of these signals is difficult to comprehend 
in the heterogeneous cell population present in the CNS, yet has the potential to identify 
specific therapeutic targets.  
The emerging role of MAPK in MS has recently been reviewed (Krementsov et al 
2013). MAPK signaling is associated with directing cellular responses to stimuli such as 
heat, hypoxia, and cytokines and is involved in the control of many cellular processes, 
particularly those related to cell proliferation, cell stress and apoptosis (Berridge 2012). 
In support of the literature, the current study identified significant upregulation of 
mitogen-activated protein kinase-activated protein kinase 2 (MAPKAPK2) (Graumann 
et al 2003) and mitogen-activated protein kinase kinase kinase kinase 4 (MAPK4) in the 
NAWM (refer to Table 4.12), both of which have been linked to ischaemic 
preconditioning and oxidative stress associated with MS (Graumann et al 2003). 
 
Calcium signaling is associated with the regulation of many cellular processes including 
cellular excitability, exocytosis, motility, apoptosis, and transcription (Clapham 2007). 
Ca2+ binds to and affects the localisation, association and function of proteins (Clapham 
2007). Dysfunction of calcium pumps and exchangers are linked to axonal injury and 
neuronal dysfunction in both MS and EAE (Kurnellas et al 2007). Abnormal influx, 
extrusion, buffering and sequestration of calcium results in calcium imbalance, which 
may initiate detrimental mechanism(s) that ultimately result in neuronal degeneration 
and cell death (Kurnellas et al 2007).  
 
Recent comparisons of other microarray datasets identified dysregulation of 
calcium/calmodulin-dependent protein kinase activity in MS (Borjabad & Volsky 
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2012). In the current study, a downregulation of genes associated with intracellular 
calcium signaling have been demonstrated, including a gene involved in the extrusion of 
calcium from cells, the ATPase, Ca2+ transporting, plasma membrane 1 (ATP2B1) also 
known as plasma-membrane Ca2+-ATPase 1 (PMCA1).  Although changes in the 
expression of this gene have not previously been linked to MS (Nicot et al 2005, Nicot 
et al 2003), a decreased expression of its alterative isotype PMCA2 has been reported in 
both MS and EAE (Kurnellas et al 2007, Nicot et al 2005).  
 
Apoptosis plays a key role in the removal of autoreactive T cells in EAE (Okuda et al 
2002). However, apoptosis of immune cells can also lead to the damage and destruction 
of oligodendrocytes and neurons in MS (Banisor & Kalman 2004). In the current study, 
an upregulation of the anti-apoptotic gene BCL2 was identified in astrocytes isolated 
from MS NAWM compared to control WM, supporting previous work that showed 
increased expression of anti-apoptotic BCL2 and pro-apoptotic BCL2 antagonist killer 
(BAK) in MS NAWM and CAL (Banisor & Kalman 2004). It has been suggested that 
efficient control of inflammation in MS is due to activation of the  Fas/FasL pathway 
resulting in cell death (Banisor & Kalman 2004). Increased expression of BCL2 has also 
been reported in microarray studies investigating cortical involvement in MS (Dutta et 
al 2007). The current study identified downregulation in expression of programmed cell 
death 5 (PDCD5) gene which has not been previously been discussed in relation to MS, 
however PDCD5 protein is known to accelerate apoptosis and has been shown to be 
downregulated in many cancer studies (Du et al 2009, Li et al 2008a, Spinola et al 
2006, Xu et al 2012, Yang et al 2006). One study investigating ischaemic damage in the 
brain hypothesised that the inhibition of PDCD5-induced apoptotic pathways is 
protective to neurons in ischemia by reducing apoptotic-related protein such as p53, Bax 
and caspase-3 (Chen et al 2013a). The downregulation of pro-apoptotic and 
upregulation of anti-apoptotic genes in isolated astrocytes from MS NAWM may reflect 
functional changes in the cells to limit their own death as a result of glutamate 
excitoxicity and oxidative stress seen in MS, therefore indirectly protecting surrounding 
neuronal axons. However, the particular role of these anti-apoptotic genes by astrocytes 
in MS NAWM is yet to be fully elucidated and further work is required. 
 
In the CNS FGFs induce axonal growth, neurogenesis, neuroprotection and lesion repair 
through activation of receptors on target cells (Reuss & von Bohlen und Halbach 2003). 
In astrocyte culture systems, FGF-1 is released in response to cell injury such as 
155 
 
oxidative stress, heat shock, hypoxia, and serum starvation (Reuss & von Bohlen und 
Halbach 2003). Increased expression of FGF-1 by activated astrocytes has been 
demonstrated in MS (Kimura et al 1994) and in AD (Mashayekhi et al 2010). The 
current study demonstrates increased expression of FGF-1 by astrocytes in the NAWM, 
which may reflect a response to insult, such as oxidative stress (Ludwin 2006, Zeis et al 
2008) and the astrocytic attempt to prevent lesion spread. 
4.5.4 Significant, differentially expressed genes associated with the cytoskeleton 
The cytoskeleton is a complex network of actin filaments, microtubules and 
intermediate filaments, which support cell structure and function in an array of 
processes such as apoptosis, migration and invasion (Vergara et al 2009). Many 
neurodegenerative diseases such as ALS, PD and AD are hallmarked by changes in 
cytoskeletal proteins, which are categorised into either filamentous aggregates of 
neuronal filament proteins, or inclusions containing microtubule-associated proteins 
(MAP) tau (Cairns et al 2004).  In MS, the main axon cytoskeleton proteins including 
the light, medium and heavy neurofilaments (NF), beta tubulin (TUB) and GAP-43 are 
decreased in lesions (Fressinaud et al 2012). However, the involvement of specific 
cellular cytoskeleton proteins in MS has been overlooked with the disease being 
branded as chronic neuroinflammatory. Consequently, the majority of research has 
revolved around the autoimmune and immunological responses associated with the 
disease, especially apparent from the work conducted on the traditional MS animal 
model EAE (Comabella & Martin 2007).  
 
Astrocytes rapidly adapt to insult in the CNS, this is associated with the differential 
expression of genes associated with the cytoskeleton network, including GFAP. In this 
study the isolation of astrocytes was based on GFAP expression, therefore it is not 
surprising that GFAP was not significantly differentially expressed. However, GFAP 
signal intensities from the study were higher in MS NAWM cases compared to control 
cases with GFAP mean signal intensity in MS NAWM cases being 9066.4 (range; 
2278.3-20549.3), compared to control cases GFAP mean signal intensity of 1899.3 
(range; 1263.7-3046.4), suggesting astrocytes respond to some form of insult in MS 
NAWM by the increased expression of GFAP. Many of the published microarray 
studies in human MS tissue have failed to identify significant differential expression of 
genes associated with changes in cellular cytoskeleton, which may reflect analysis of 
whole tissue, rather than isolated enriched individual cell populations, where specific 
cytoskeletal changes in cells is masked or assigned to other generic functions such as 
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cell signaling or immune response. However, differentially expressed genes associated 
with the cytoskeleton were identified in MS acute and chronic lesions in comparison to 
control WM, in particularly the expression of MAP4 and dynein, cytoplasmic 1, light 
intermediate chain 2 (DYNC1LI2) which were upregulated in the findings of (Tajouri et 
al 2003). 
 
In contrast other components of the cytoskeleton signaling pathway, including dynein, 
cytoplasmic 2, light intermediate chain 1 (DYNC2LI1), were downregulated in the 
current study (refer to Table 4.13). An imbalance in dynein expression in astrocytes in 
MS NAWM may lead to a disruption in function and altered transport of neurotrophic 
factors in MS, as has been seen in ALS (Chevalier-Larsen & Holzbaur 2006). A recent 
study modelling gene-gene interactions in a number of MS GWAS classified calcium-
signaled cytoskeleton regulation as a potential neurodegenerative mechanism in MS 
(Bush et al 2011). However, none of the genes identified in that study were 
differentially expressed in this current one. 
 
As in human microarray studies, the majority of EAE microarray studies identified the 
regulation of immune response-associated genes, with little reference to changes in 
genes related to the cytoskeleton. Although one study categorised a set of cytoskeleton 
associated genes as being differentially expressed in AT-EAE mice, with a general 
equal quantity of up and down-regulated genes, but no reference to specific genes was 
made (Brand-Schieber et al 2005). A similar divide of up- and downregulated genes 
associated with the cytoskeleton was also identified in the current study (Full gene list, 
Appendix V). Specifically an increased expression of kinesin family member 1C 
(KIF1C) was identified, this specific kinesin family member has not been implicated in 
MS before, however the expression of kinesin genetic variants has been linked to the 
disease (Alcina et al 2013, Goris et al 2010). Kinesin is known to play a role in 
supplying energy for glial cells by trafficking mitochondria along the cytoskeleton 
protein, tubulin, in response to the surrounding energy demands (Szolnoki et al 2007). 
Altering expression of kinesin molecules may alter the energy production by glial cells. 
An increased expression of KIF1C by astrocytes may lead to increased energy 
production, an attempt by astrocytes to help maintain myelin integrity within the 
NAWM (Szolnoki et al 2007). Kinesins traffic the myelin synthesis apparatus, therefore 
increased KIF1C may increase myelin synthesis, due to an increased synthesis capacity. 
The current study also reports the increased expression of peripheral myelin protein 2 
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(PIMP2), a protein component of the myelin sheath present in small amounts in CNS 
myelin (Majava et al 2010). Further investigations into the significance of these 
differentially expressed cytoskeletal genes by astrocytes in MS NAWM is required to 
gain a better understanding of their importance in respect to disease pathogenesis. 
8  
In astrocyte cell culture systems, artificial activation of the cells by H2O2 mediates a 
change in the cytoskeletal network associated with changes in actin and myosin (Zhu et 
al 2005). The cytoskeletal network has previously been reported as one of the earliest 
targets in oxidative stress (Dalle-Donne et al 2001, Zhao & Davis 1998), suggesting that 
alterations in cytoskeletal gene expression in astrocytes isolated from MS NAWM may 
reflect an early response to increased oxidative stress in the surrounding demyelinated 
lesions. In culture, rat astrocytes show an altered cytoskeletal organisation when treated 
with IFNβ, a commonly used drug in MS (Vergara et al 2009), suggesting changes in 
the cytoskeleton organisation alter the cells’ morphology and possible function. 
Therefore, astrocytes may alter their cytoskeletal gene expression in NAWM to provide 
protection from disease initiating insults, including oxidative stress.  
 
4.5.5 Significant, differentially expressed genes associated with RNA processing 
and protein metabolism. 
From the published microarray studies on MS/EAE only one study identified a group of 
differentially expressed genes associated with an RNA processing function in spinal 
cord of EAE mice, but failed to report specific genes (Brand-Schieber et al 2005). 
However, a recent study identified the influence of cold inducible RNA binding protein 
(CIRBP) on inflammation, making specific reference to its possible involvement in 
autoimmune disorders (Brochu et al 2013). CIRBP responds to an array of stresses 
including hypoxia and UV irradiation, and  plays a role in RNA processing by binding 
to the 3’untranslated region (UTR) of specific transcripts to stabilise them and support 
their transport to ribosomes for translation (Brochu et al 2013). This study identified the 
association of CIRBP with the expression of an array of transcripts related to 
inflammation including IL-1β, a cytokine also regulated by NFkB (Brochu et al 2013). 
By using small interfering RNA (siRNA) to silence CIRBP expression in fibroblasts, the 
binding capacity of NFkB is disrupted, reducing the expression of IL-1β. Ultimately 
CIRBP affects the sensitivity of cells to a variety of stresses by regulating NFkB 
activity, with CIRBP disruption leading to a reduced IL-1β expression, highlighting 
CIRBP’s role in regulating inflammation. Conversely a forced increased fibroblast 
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expression of CIRBP led to an increased expression of IL-1β (Brochu et al 2013). In 
contrast to the study whereby (Brochu et al 2013) reported in response to UV stress an 
increased expression of CIRBP, in the current study, CIRBP is downregulated 
suggesting that in MS NAWM, astrocytes are decreasing their CIRBP expression to 
prevent an inflammatory response in the NAWM. However more work on astrocyte 
expression of CIRBP and its function related to MS is needed as it is known that CIRBP 
responds to a variety of stresses in different ways (Brochu et al 2013). Astrocytes are 
responsible for maintaining homeostasis within the CNS and are adaptable cells, 
therefore astrocytes in the NAWM may respond by initially decreasing their expression 
of CIRBP in an attempt to halt the spread of inflammation and disease progression. 
 
Differentially expressed genes associated with the regulation of protein activity and 
metabolism are associated with both acute and chronic MS lesions (Tajouri et al 2003). 
Specifically, the upregulation of RAB2 was seen in a microarray study by (Tajouri et al 
2003) which is in contrast to the finding of a decreased expression of this transcript in 
the current study, while the protein inhibitor of the activated signal transducer and 
activator of transcription (STAT) 1 (PIAS1) was decreased in both studies. Differences 
seen in the expression of specific protein metabolism genes may in part be down to the 
samples used. (Tajouri et al 2003) investigated both chronic and acute MS tissue while 
the current study identified differentially expressed genes in astrocytes isolated from 
MS NAWM, clearly varying transcriptomes are apparent across the tissues. Protein 
synthesis and metabolism associated genes have also been identified in EAE mice with 
the decreased expression of ribosomal protein S26 (RPS26) (Ibrahim et al 2001). 
However, the current study identified the upregulation of a number of different 
ribosomal proteins in MS NAWM astrocytes (refer to Table 4.14). Again, these 
differences may be due to gene expression profiles being compared between EAE 
animals and human subjects, the tissue type and disease stage may act as confounders to 
these differences.  
 
Inflammation results in increased expression of genes associated with protein synthesis 
and metabolism in EAE (Mix et al 2004), with many of the genes being linked to an 
increased disease susceptibility. Also, in the TME viral model of MS, genes associated 
with protein metabolic processes including protein tyrosine phosphatase 4A2 (PTP4A2) 
and vascular endothelial zinc finger (VEZF1) are differentially regulated (Navarrete-
Talloni et al 2010), supporting the current study’s findings. Again, direct comparisons 
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between gene expression profiles of a viral animal model of MS and human MS 
subjects, along with differences in cell types investigated will account for many of the 
conflicting results of these microarray studies.   
4.5.6 The ‘pros’ and ‘cons’ of gene expression microarray analysis 
Current MS microarray studies have investigated the gene expression profile of human 
brain tissue, circulating PBMC, and tissue/cells obtained from MS animal models. 
Comparison between studies is hindered by differences in patient groups, the 
heterogeneity of the regions investigated and the experimental design, including the use 
of differing microarray platforms. These differences make the comparison of data sets 
and the associated gene expression between studies highly problematic.  
There are a number of issues to consider when performing RNA profiling of samples 
using microarray analysis. To date, MS microarray studies have primarily aimed to 
identify; 1) biomarkers of disease, 2) molecular mechanisms of disease, and 3) potential 
drug targets (Kinter et al 2008). The primary aim of the study determines which 
sample(s) to use, the number of samples required for statistical significance, the 
appropriate microarray platform and the statistical analysis to perform. This current 
study was a non-hypothesis driven project to investigate the role of astrocytes in MS 
NAWM, thereby enabling the identification of altered expression of novel genes for 
which further hypothesis driven research could be carried out.  
The use of microarray analysis of gene expression clearly has many advantages, 
however there are many limitations to the technique, which should be acknowledged 
and which may explain the lack of consistent findings between studies (Comabella & 
Martin 2007). The variability in MS microarray studies may reflect the genetic variation 
between cases, the patient cohort size employed and the difference in disease type 
investigated, whether PPMS or SPMS for example. Also, the PMI of human samples is 
known to affect the RNA integrity and ultimately gene expression profile, and human 
PM tissue is only a snapshot of disease activity.  In order to avoid these issues, the 
current study investigated NAWM obtained from similar neuroanatomical locations. 
However, it should be noted that the data may also be influenced by the disease course 
of the patient, whether in relapse or remission at time of death, which was unknown in 
the current study, and/or the distance of the NAWM block from a WML. Additionally 
the cellular makeup of tissue investigated in preceding studies and the use of different 
microarray platforms containing different genes and probe sets could add to the 
different findings between studies (Munro & Perreau 2009). Multiple RNA processing 
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steps could, in part, also contribute to the different gene expression profiles between 
studies. For instance RNA extracted from cell culture models is more intact than RNA 
isolated in the current study. Immuno-guided LCM was used to isolate astrocytes from 
PM human tissue prior to RNA extraction and amplification. Therefore, RNA integrity 
of samples may have been affected due to the rapid-IHC protocol used and the laser 
fired from the LCM. RNA extraction and multiple rounds of RNA amplification could 
further modify the RNA integrity of samples and ultimately the hybridisation to 
microarray chips. Also the various methods used for statistically analysing gene 
expression data may account for the diverse findings in studies, with (Lindberg et al 
2004) defining significantly expressed genes as having a 2-fold change compared to the 
current study, which implemented a cut off of 1.5 fold change and 0.5 p-value as being 
significant. Ultimately, this may not be suitable for some genes, where only a slight 
change in expression (below the cut off) could account for a profound effect related to 
disease pathogenesis. However, from previous studies in our research group and the 
large quantity of data generated a balance had to be determined. 
In order to improve the reliability of microarray data, additional validation studies must 
be carried out as discussed in detail in chapter 5. Validation of microarray data should 
be obtained using alternative methods such as analysing the gene expression using 
qPCR, but also by the use of other techniques to assess protein expression such as IHC, 
WB and MALDI-MS to investigate the functional proteomic profiles of these regulated 
genes (Comabella & Martin 2007). Validation should be completed on an additional 
cohort of patients where results from the validation patient cohort should support the 
findings from the original microarray patient cohort (Comabella & Martin 2007). 
Disease heterogeneity in human subjects will always be a limiting factor in any 
investigative study into understanding disease, including microarray studies (Munro & 
Perreau 2009). However, the future direction of microarray research applied to study 
disease needs to consider other supplementary work to gain a fuller, broader yet specific 
understanding of disease pathogenesis. Consideration of the genetic background of 
individuals, environmental triggers, individual differences in immune reactivity towards 
pathological insults, and treatment responses need to be addressed (Comabella & Martin 
2007).  Integration studies combining transcriptomic microarray research with potential 
proteomic work such as MALDI-MS could ultimately help to identify potential 
biological biomarkers of disease (Hori et al 2012). However the need for a better 
understanding of analysis software that enables researchers to compare both 
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transcriptomic microarray data and proteomic mass spectrometry derived data to 
decipher possible links and connections is required. In order to limit the inevitable 
variation in human subjects, integrating microarray data with a thorough 
neuropathological assessment pre and post mortem, along with MRI data, could add to 
the knowledge of that individual’s disease activity, which as has already discussed, 
could ultimately add to the variability. 
The emerging next generation sequencing technology, the transcriptome sequencing 
instrumentation, also known as RNA-Seq is poised to replace microarray based 
technologies for transcriptome analysis (Hitzemann et al 2013). Compared with 
microarray analysis, RNA-Seq has a greater dynamic range and no issues with probe 
saturation (Pozhitkov et al 2010). The technique also detects both coding and non-
coding RNAs, and is capable of identifying the expression of regulatory micro RNA 
(miRNA) (Ziats & Rennert 2013), and can also detect alternative spliced transcripts and 
allele specific expression and nucleotide polymorphisms (Hitzemann et al 2013). The 
subsequent transcriptomic data derived from this technology is not biased to the 3’ UTR 
as observed with many microarray derived datasets. However, RNA-Seq technology has 
its own limitations and disadvantages, including the interpretation and analysis of the 
huge data sets, and the cost of running samples using this technology. However, with 
increasing acknowledgment of the diversity and complexity of disease transcriptomics, 
RNA-Seq is a sophisticated technology that will undoubtedly aid in future 
transcriptomic studies of many diseases.   
4.5.7 Conclusion 
The current microarray study demonstrated that astrocytes isolated from MS NAWM 
are involved in a number of different functions within the NAWM associated with the 
immune response, cell signaling, cytoskeletal changes and the regulation of 
homeostasis. The most significant, differentially upregulated genes were related to the 
regulation of iron and oxidative stress. Therefore, astrocytes in MS NAWM may be 
playing a neuroprotective role by attempting to maintain homeostasis within the brain 
by regulating iron concentration and subsequent oxidative stress established in MS 
lesions in order to prevent lesion spread and ultimately disease progression.  
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5 CHAPTER 5 
THE NEUROPROTECTIVE ROLE OF 
ASTROCYTES IN REGULATING IRON 
HOMEOSTASIS AND OXIDATIVE STRESS IN 
MULTIPLE SCLEROSIS NORMAL 





Iron is vital in many biochemical and enzymatic reactions within the human body and is 
critical in the synthesis of ATP, DNA, myelin and neurotransmitters, within the CNS 
(Crichton et al 2011, Todorich et al 2009). Iron is capable of being oxidised and 
reduced between its ferric (Fe3+) and ferrous (Fe2+) state (Papanikolaou & Pantopoulos 
2005). This ability to accept and donate electrons is pivotal in both its physiological role 
and its proposed pathological role in neurodegeneration. The regulation of iron is 
strictly regulated, since insufficient or excess impacts cell viability. The current study 
identified dysregulation of genes responsible for the regulation of iron homeostasis and 
oxidative stress in isolated astrocytes from MS NAWM. 
To date, the mechanism(s) of iron transport and metabolism within the brain are not 
fully understood due to a number of factors (Ke & Qian 2007). Firstly, the lack of serum 
and blood in the abluminal surface of the BBB, which is shown to be involved in the 
well-established mechanism of iron transport and metabolism in other organs 
(Johnstone & Milward 2010). Additionally, research regarding the expression of iron 
exporter proteins throughout the BBB and CNS is contradictory, for example reports on 
the expression of divalent metal transporter 1 (DMT1) by blood vessel endothelial cells 
(BVEC) is inconsistent (Moos et al 2006, Siddappa et al 2002). Furthermore, as yet 
uncharacterised novel mechanisms/proteins involved in iron regulation in the brain may 
account for the lack of understanding of iron transport and metabolism in the brain 
(Johnstone & Milward 2010).  However, it is established that the brain is unique in its 
method of regulating the transportation and release of iron. An increased understanding 
of how iron is transported, metabolised and regulated within the brain could help in 
understanding the relationship between iron and neurodegenerative diseases.  
Within the human body there is around 4-5g of iron (Zheng & Monnot 2012), the 
majority of which is within haemoglobin, within erythrocytes and is termed ‘heme-
iron’, accounting for at least 75% of the total body’s iron (Gaasch et al 2007). The 
remaining iron within the body is bound to plasma proteins, such as the iron transporter 
protein TF, or the storage molecule ferritin (FT) (Gaasch et al 2007). Iron is believed to 
enter the CNS from the circulation via BVEC, primarily as TF-bound iron (Moos et al 
2007). Within the brain, iron is widely distributed with varying concentrations in 
different regions, associated with different cell types, accumulating progressively with 
age and neurodegenerative disease (Khalil et al 2011b, Moos et al 2007, Ramos et al 
2013). Levels of iron are higher in motor-related areas of the brain compared to non-
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motor regions (Chen et al 2013b, Koeppen 1995, Zhang et al 2010), suggesting an 
imbalance of iron regulation in these regions may contribute to movement disorders. 
 
In order to understand the relationship between iron and neurological diseases, an 
understanding of the mechanisms of iron transport into the brain, the cellular 
distribution/regulation of iron in the brain parenchyma and the process by which iron is 
removed from the CNS is needed. The brain cannot take up iron directly from the 
circulatory system, instead iron crosses the BBB via endocytosis into BVEC (Figure 
5.1) or transcytosis across BVEC (Figure 5.2). The proposed main route of iron entry 
into the brain involves TF/Transferrin receptor-1 (TFR1) interaction, whereby BVEC 
acquire iron from circulatory TF via TFR1 expression on the cells’ membrane. Iron 
passes into and across the BBB via vesicles and is exported as ferrous iron into the brain 
parenchyma. There is huge debate and less understanding as to the processes behind 
free iron exportation into the brain parenchyma (Deane et al 2004, Moos & Morgan 
1998, Takeda et al 2002). As previously mentioned there is conflicting evidence of 
DMT1 expression by BVEC (Moos et al 2006, Siddappa et al 2002). Likewise 
discrepancies in ferroportin (FPT) expression by BVEC have been reported (Moos et al 
2007, Wu et al 2004). It has been suggested that in the absence of DMT1 expression by 
BVEC, astrocytes that form up to 95% of the lining of the abluminal surface of the BBB 
(Cecchelli et al 2007) express DMT1 in vivo at their perivascular endfeet (Burdo & 
Connor 2003). Yet again, the expression of DMT1 by astrocytes is debatable (Moos & 
Morgan 2004). However, astrocytes release citrate and ATP forming complexes with 
iron in the extracellular space and are responsible for an alternative method of iron 
exportation into the brain (Leitner & Connor 2012, Ma et al 2009, Moos et al 2007, 
Qian & Shen 2001). Astrocytes are also capable of delivering transported iron to 
neurons via the action of FPT and ceruloplasmin (Cp) that results in exported ferric iron 
binding to locally circulating TF in the brain (Moos et al 2007). Brain TF can deliver 
iron to TFR1-expressing cells in the CNS including neurons, and OPC where iron is 
released via endocytosis to carry out its functional role.  
 
Alternatively, iron can cross the BBB bound to TF via transcytosis (Fishman et al 1987, 
Moos 2002), where iron bound TF directly interacts with TFR1 expressed on neurons. 
Iron can cross the BBB bound to FT via T cell mucin domain containing receptor 2 





Figure 5.1 The regulation of iron transport into the brain via endocytosis                                 
TF- bound iron in the circulatory system binds TFR1 expressed on endothelial cells of 
the BBB (a). This complex is endocytosed into the cells. Endocytic vesicles possess 
ATPases that pump protons into vesicles resulting in increased acidity (b), the reduction 
in pH causes iron to dissociate from TF (c). Reduced iron is transported into the cytosol 
by the DMT1 (d). Iron can be stored in FT or used in metabolic cellular processes, such 
as in the electron transport chain of mitochondria. Also, free iron inside the cell can 
cross into the brain through an unknown exportation mechanism. Iron can be reoxidised 
by the action of Cp expressed by astrocytes (e) and bind to circulating TF in the brain 
(f). TF-bound iron binds to TFR1 expressed on neurons and is endocytosed into the 
endolysosome where iron is dissociated from TF to carry out its neuronal functions.  
Key: BBB: blood brain barrier, Cp: ceruloplasmin, DMT1: divalent metal transporter 1, 
EC: endothelial cell, FT: ferritin, TF: Transferrin, TFR1: transferrin receptor-1.
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Figure 5.2 The regulation of iron transport into the brain via transcytosis                               
TF-bound iron in the circulatory system binds TFR1 expressed on the endothelial cells 
of the BBB (a). This TF-bound iron complex can be transcytosed across the endothelial 
cells mediated by TFR1 (b) or FT bound iron is transcytosed through receptor mediated 
transport via Tim2 (c). Once TF-bound iron crosses the BBB, it binds to TFR1 on 
neurons and is endocytosed into the endolysosome where iron is dissociated from TF to 
carry out its neuronal functions (d). OPCs express TFR1 and may take up TF-bound 
iron (e) however, mature oligodendrocytes cells no longer express TFR1 but acquire 
iron from FT through their expression of Tim2 (f). Microglia do not express TFR1 and 
obtain iron via phagocytosis of FT, which can also be secreted by microglia to support 
supply of iron to oligodendrocytes (g).  
Key: BBB: blood brain barrier, DMT1: divalent metal transporter 1, EC: endothelial 
cell, FT: ferritin, OPC: oligodendrocyte precursor cell, Tim2: T cell mucin domain 
containing receptor 2, TF: Transferrin, TFR1: transferrin receptor-1.
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Mature oligodendrocytes lose their expression of TFR1 and acquire iron from FT via 
their expression of Tim2 (Todorich et al 2008). Microglia do not express TFR1 and 
acquire iron via phagocytosis of FT. Microglia can also release FT, further 
supplementing the iron source for oligodendrocytes. Excess iron in neurons and glial 
cells diffuses into the interstitial fluid in the brain, where free or TF-bound iron is 
released into the CSF. Choroidal epithelia interact with free iron via DMT1 or TF-
bound iron via TFR1 and transport the excess iron into the blood (Zheng & Monnot 
2012). 
 
Levels of iron in the CNS are regulated in part by the binding of TF with TFR1. The 
expression of TFR1 can be altered by the overall iron concentration present in the CNS 
through iron-regulatory proteins (IRP). When iron levels are low, a conformational 
change in IRP1 increases its binding with the iron-responsive element (IRE) sequence at 
the 3’ UTR of TFR1 mRNA. This binding stabilises TFR1 mRNA and increases its 
protein translation, therefore binding with TF increasing the amount of iron delivered 
into the cells (Leitner & Connor 2012). When iron levels are increased in the CNS, 
IRP1 binding to the IRE sequence on TFR1, and DMT1 is reduced, destabilising TFR1, 
and DMT1 mRNA and reducing their translation, preventing the toxic increase in iron 
that can cause oxidative stress (Leitner & Connor 2012, Zheng & Monnot 2012). CNS 
iron levels are tightly regulated, but when iron homeostasis is compromised, the 
resulting increased iron levels contribute to neurodegenerative pathologies (Gaasch et al 
2007). 
 
In MS, iron accumulation has been proposed to contribute to several pathological and 
physiological processes (Bagnato et al 2011). Excess iron can amplify the activation 
state of microglia causing an increase in proinflammatory cytokine expression 
(Williams et al 2012) that can drive oxidative stress. Increased intracellular iron can 
damage mitochondria directly, while inadequate control of iron can produce damaging 
ROS resulting in oxidative stress (Morelli et al 2012, Williams et al 2012). In the brain, 
oxidative stress is associated with detrimental effects including lipid peroxidation, 
impairment of glutamate and glucose transport, exacerbation of mitochondrial 
dysfunction, increased intracellular calcium concentration and resulting cell dysfunction 




Within the CNS in MS an increase in iron has been identified in areas adjacent to veins 
(Williams et al 2011), and at perilesional margins (Bagnato et al 2011, Hametner et al 
2013). Increased iron deposition in MS is associated with increased oligodendrocyte and 
myelin loss (Bagnato et al 2011). Similarly, the release of iron from proteins whose 
degradation is induced by respiratory burst molecules, produced by microglia and 
macrophages during inflammation, have been linked with increased iron deposition in 
MS (Bagnato et al 2011, Lassmann et al 2012). Cellular toxicity in MS as a result of 
iron accumulation is mainly due to the Fenton reaction and the effects of respiratory 
burst, as demonstrated in (Figure 5.3). Free iron reacts with cellular metabolites 
including H2O2 and superoxide anion (O2
-) to produce highly reactive and damaging 
free radicals, such as the OH• (Khalil et al 2011b). O2
- can also react with ferric iron in 
the Haber-Weiss reaction to produce ferrous iron in a process known as redox cycling, 
which further exacerbate free radical production (Khalil et al 2011b). 
In the CNS, the prominent damaging effects of oxidative stress are associated with 
mitochondrial inner membrane respiratory complexes (Shamoto-Nagai et al 2006). Iron-
induced cell death occurs as a result of the saturation of iron binding, transport and 
storage proteins in cells (Gaasch et al 2007). Consequently, the amount of free 
circulating iron increases, which enters already iron-saturated cells, such as neurons and 
oligodendrocytes, leading to an increased intracellular level of free iron. Oxidative 
damage of DNA can lead to the increased expression of p53 and caspase 3, while 
mitochondrial dysfunction caused by iron results in the release of cytochrome c (Gaasch 
et al 2007).  
Astrocytes are resilient to the neurotoxic effects of excess iron (Gaasch et al 2007), 
which may reflect the high antioxidant and metal binding capabilities of molecules such 
as metallothionein  (Pedersen et al 2009, Penkowa et al 2006, Sawada et al 1994). 
Although astrocytes can accumulate iron and have the capacity to store iron as FT, they 
rarely contain large amounts of either, suggesting astrocytes transport iron to other cells 
(Dringen et al 2007). As with much of the published work on iron metabolism in the 
brain, conflicting literature on the expression of TF and TFR by astrocytes is apparent. 
To date, astrocytes have been shown to express TFR1 in vitro, (Hoepken et al 2004), 
but not in vivo. In order to gain a better understanding of the role of astrocytes in 






Figure 5.3 Respiratory burst and associated tissue damage in MS                                        
During inflammation in MS, activated microglial undergo a respiratory burst with 
increased glucose and oxygen consumption resulting in the release of H2O2 (a, yellow 
shaded area). In combination with NO and ONOO– radicals, these factors lead to 
destruction of axons, myelin and oligodendrocytes. Tissue damage in the absence of 
Fe2+ occurs in local tissue surrounding activated microglia where H2O2 is at its highest 
(a). With Fe2+ accumulation in oligodendrocytes, H2O2 diffuses into these cells, where 
ROS are formed leading to cell death (b). Astrocytes do not contain the same level of 
stored iron as oligodendrocytes and are not as affected by ROS. Free Fe2+ released from 
damaged oligodendrocytes is taken up by microglia which causes these cells to become 
damaged and degenerate resulting in a second surge of Fe2+ release triggering further 
oxidative damage and lesion spread and development (c). Figure adapted from 
Lassmann et al 2012. 
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This chapter describes the detailed investigation of the astrocytic expression of a panel 
of iron regulatory molecules identified as being the most significantly upregulated genes 
in astrocytes isolated from PM MS NAWM, in comparison to controls in the preceding 
microarray study. A dysregulation of iron and oxidative stress have been suggested to 
be involved in a number of neurological diseases and also in MS. Therefore, we 
hypothesise that astrocytes are neuroprotective in MS NAWM involved in regulating 
iron homeostasis and reducing oxidative damage and consequently lesion development 
and disease progression. qPCR, WB, IHC and MALDI-MS were employed to attempt to 
verify the microarray candidates and confirm the potential neuroprotective role of 
astrocytes in MS NAWM.
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5.2 Aims and objectives of the study 
The aims of this study were to: 
Investigate the potential neuroprotective role of astrocytes in MS NAWM. 
 Verify the increased expression of MT, TF and FTL in astrocytes isolated from 
MS NAWM compared to control cases using qPCR. 
 Confirm the increased astrocytic expression of MT, TF and FTL in MS NAWM 
compared to control WM by IHC. 
 Quantify the expression of FTL and MT in MS NAWM compared to control 
WM using SDS-PAGE and WB. 
 Evaluate the presence and distribution of MT, FTL and TF in MS NAWM and 
control WM using MALDI-MS and MALDI-MS imaging. 
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5.3 Materials and methods 
5.3.1 Suppliers  
Abcam, 330 Cambridge Science Park, Cambridge, CB4 0FL, UK; AB Sciex UK, 
Limited Phoenix House, Lakeside Drive, Centre Park Warrington, Cheshire WA1 1RX, 
UK; Agilent Technologies Inc., (Stratagene), 5301 Stevens Creek Blvd, Santa Clara 
CA 95051, USA; Applied Biosystems Inc., 850 Lincoln Centre Drive, Foster City, CA 
94404, USA; BIOplastics, Rӧtscherg 61, 6374 XW Landgraaf, The Netherlands; Bio-
Rad Laboratories Ltd., Bio-Rad House, Maxted Road, Hemel Hempstead, 
Hertfordshire, HP2 7DX, UK; Bruker UK Ltd., Banner Lane, Coventry, CV4 9GH, 
UK; DAKO UK Ltd., Cambridge House, St Thomas Place, Ely, Cambridgeshire, CB7 
4EX, UK; Eurofins MWG Operon, Anzinger Str. 7a 85560 Ebersberg, Germany; 
Fisher Scientific Inc., Bishop Meadow Road, Loughborough, Leicestershire, LE11 
5RG, UK; GE Healthcare Life Sciences, Pollards Wood, Nightingales Lane, Chalfont 
St Giles, Buckinghamshire, HP8 4SP, UK; HTX Technologies, LLC PO Box 1036 
Carrboro, North Carolina (NC), 27510, USA; Labcyte Europe, Unit 12 Enterprise 
Centre Pearse Street Dublin 2, Ireland; Leica Microsystems Ltd., Davy Avenue, 
Knowhill, Milton Keynes, MK5 8LB Buckinghamshire, UK; LI-COR Biosciences UK 
Ltd., St. John's Innovation Centre, Cowley Road, Cambridge, CB4 0WS, UK; Life 
Technologies Ltd. (Invitrogen, Arcturus, Novex®), 3 Fountain Drive, Inchinnan 
Business Park, Paisley, PA4 9RF, UK; MathWorks, 3 Apple Hill Drive 
Natick, MA 01760-2098, USA; Olympus, KeyMed House, Stock Road, Southend-on-
Sea, SS2 5QH, UK; Sigma-Aldrich, The Old Brickyard, New Road, Gillingham, 
Dorset, SP8 4XT, UK; SunChrom, Wissenschaftliche Geräte GmbH, Industriestr. 27, 
61381, Friedrichsdorf, Germany; Vector laboratories Ltd., 3 Accent Park, Bakewell 
Road, Orton Southgate, Peterborough, PE2 6XS, UK; VWR International Ltd., 
(Quanta Biosciences), Hunter Boulevard, Magna Park, Lutterworth, Leicestershire, 
LE17 4XN, UK. 
5.3.2 Case selection 
All frozen tissue used in this study was obtained from the UK Multiple Sclerosis 
Society Tissue Bank (Appendix I). Clinical information for each case is described in 
Appendix III. Due to the limited availability of NAWM snap frozen tissue, the stringent 
criteria set out in the original microarray for case selection was reduced in this selection 
of the validation cohort. The criteria for inclusion into the study was based solely on the 




Table 5.1 The validation patient cohort                                                                            
Due to the limited availability of snap frozen material, the selection of 6 MS NAWM 
and 6 control cases for this validation study was based on neuropathology and not 
stringent RNA integrity. 
Key: N/A: not applicable, n/a not available.
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were chosen based on no evidence of inflammatory infiltrates, demyelination or 
presence of amoeboid microglia, suggestive of phagocytic activity confirmed by 
carrying out a thorough neuropathological assessment of each case as described in detail 
in Chapter 2.  
5.3.3 The principles of quantitative PCR  
qPCR is a tool that allows the detection and quantification of particular genes of interest 
and is commonly used to compare gene expression levels of mRNA targets between 
diseased and control samples. The technique uses a series of heat dependant 
amplification steps employing the typical three stage PCR workflow; dsDNA is firstly 
denatured followed by primer annealing and extension of cDNA through a series of 30-
40 cycles. The dsDNA product is measured after each amplification cycle and can be 
detected via two common methods; firstly through the use of fluorescent tags which 
only omit fluorescence when incorporated into dsDNA, or secondly the use of sequence 
specific DNA probes containing fluorescently labelled oligonucleotides which are only 
detected upon hybridisation of the probe with its complementary sequence. 
Prior to PCR, mRNA is reverse transcribed using reverse transcriptase enzymes to 
cDNA. In this study, qPCR products were quantified in the exponential phase of the 
reaction, through each PCR cycle the product doubles and is measured by SYBR green 
fluorescent dye that bind to dsDNA. qPCR provides more accurate data than traditional 
PCR where only semi-quantitative analysis can be completed at the end of the PCR 
reaction, relying on good band separation and resolution by agarose gel electrophoresis. 
In qPCR two values are measured, the threshold line and the cycle threshold (Ct) value. 
The threshold line is the point in the reaction when the fluorescence from the reaction is 
significantly higher than the background fluorescence, generally 10 standard deviations 
above the mean baseline fluorescence (Agilent Technologies, 2012). The Ct value is the 
point in the reaction when the sample reaches this threshold. Consequently, samples 
with higher expression of the transcript of interest will have lower Ct values compared 
to those samples with less transcript which will have a higher Ct value. 
Natalie Rounding, a University of Sheffield undergraduate student supervised by Rachel 
Waller assisted in the primer optimisation and IHC work completed in this chapter. 
5.3.3.1 cDNA synthesis 
Using an identical method to the microarray experiments, RNA was extracted from 
GFAP+ astrocytes by LCM in 12 additional cases (6 MS NAWM and 6 control WM 
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cases refer to Table 5.1) which had not been used for the microarray study. Total RNA 
was converted to cDNA using qScript cDNA mix/supermix (Quanta, UK) as described 
in section 3.3.8. 
5.3.3.2 Primer design 
qPCR primers were designed using Primer-BLAST (basic local alignment search 
tool) software (NCBI, http://blast.ncbi.nlm.nih.gov/Blast.cgi) or for the different 
metallothionein isotypes and FTL, sequences were taken from published studies (Gebril 
et al 2011, Sequeira et al 2012). When designing qPCR primers a number of 
considerations were made, the primers, where possible, were designed to span an exon-
exon boundary to avoid possible genomic DNA influence. Primers were designed with 
an amplicon length of 70-150 bp, a melting temperature (Tm) between 57-63°C, and 20-
80% GC content. Similar to the IVT microarray probes, primers were designed against 
the 3’ end of the gene to compensate for the poorer RNA integrity of PM, LCM-ed 
RNA samples. Probeset IDs of genes to be validated were searched for using NetAffx 
(http://www.affymetrix.com/), providing details of the sequence used to build the probe 
on the 3’ IVT microarrays. All primers for qPCR (Table 5.2) were purchased from 
Eurofins MWG Operon, Germany.  
5.3.3.3 Primer optimisation and efficiencies 
In order to compare gene expression using qPCR it is vitally important that the primer 
efficiencies of the target genes and housekeeping (HK) genes are approximately equal. 
The efficiency of primers represents the amount of PCR product increase after each 
cycle, ideally a PCR reaction will contain primers with near to 100% efficiency. 
Dissimilar primer efficiencies between the HK and target gene can falsely calculate 
differences in the expression ratio (Pfaffl et al 2002). 
Therefore establishing the primer efficiency along with the optimum combination of 
primer concentrations was required. qPCR was initially carried out using different 
concentration combinations of forward and reverse primers. For primer optimisation, 
1μg of total RNA extracted from the astrocytes of a control case was reversed 
transcribed to cDNA as outlined in section 3.3.8.  qPCR was performed with [25ng] 
astrocyte cDNA, 1X Brilliant II SYBR Green PCR MM (Agilent, UK), along with 





Table 5.2 qPCR primers used for microarray validation                                                   
qPCR primer sequences and optimised concentrations for microarray validation 





Table 5.3 Primer optimisation                                                                                           
For each of the five primer pairs (MT1G, MT2A, MT1X, TF and FTL), appropriate 
volumes of forward and reverse primers were added to the PCR mix to test a range of 




a final volume of 20μl. Each sample was assessed in triplicate and analysed in a PCR 
plate sealed with PCR caps (BIOplastics, The Netherlands) on an MX3000P Real-Time 
PCR system (Stratagene, USA). The PCR programme consisted of denaturation at 95ºC 
for 10 minutes, products were amplified (40 cycles of 95ºC for 30 seconds, and 60ºC for 
1 minute) followed by a final cycle at 95ºC for 1 minutes, 55ºC for 30 seconds, and 
95ºC for 30 seconds. To ensure the primers were efficient over a range of cDNA 
template concentrations, qPCR was also carried out with serial dilutions of cDNA 
(12.5ng/µl - 0.15 ng/µl) using the determined optimal primer concentrations for each 
gene of interest (Table 5.2) and a standard curve prepared and primer efficiencies 
compared. 
5.3.3.4 Selection of a housekeeping gene 
A housekeeping gene is required as a reference gene and is used for normalisation of 
target gene expression in all qPCR experiments. Analysis of the signal intensities of 
corresponding β-actin and GAPDH probe sets from the original microarray data helped 
to define the most suitable HK gene for qPCR.  
5.3.3.5 qPCR validation attempt of candidate iron related genes 
Iron-homoeostasis candidate genes, which showed significant altered expression in the 
original microarray study, were validated by qPCR. For each gene of interest, qPCR 
was performed using the optimised primer concentrations determined in the primer 
optimisation investigations (refer to Table 5.2). Each of the validation samples (6 MS 
NAWM and 6 control WM) was run in triplicate, alongside HK controls (β-actin) for 
each sample. The PCR programme followed is outlined in 5.3.3.3. 
The fluorescent signal generated by each sample at the end of each cycle of the PCR 
was analysed using MxPro software (Stratagene, USA) and the gene expression 
normalised to the HK gene β-actin using the comparative Ct, (delta-delta ΔΔCt) method 
of quantification  (ABI PRISM 7700 Sequence Detection System protocol, Applied 
Biosystems, USA). Initially all triplicate Ct values were averaged for each sample’s 
target gene and HK gene. The difference between both the samples target gene Ct value 
and HK gene Ct value (ΔCt) was taken as an indication of the expression level of the 
studied gene. An average Ct value from all control cases was taken as a reference for 
relative gene expression. ΔΔCt is the difference between the ΔCt for individual samples 
and the average Ct from all control samples. In order to account for the exponential 
nature of PCR the ΔΔCt values were converted into linear form by raising the ΔΔCt to 
2-ΔΔCt, which generates the relative gene expression in MS NAWM compared to control 
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cases. qPCR data was analysed using a non-parametric Mann-Whitney U test performed 
in GraphPad and the relative gene expression differences were assessed between MS 
NAWM and control WM for each of the candidate genes. Significance was set at 
p=<0.05. 
5.3.4 Immunohistochemistry  
5.3.4.1 Single labelling IHC for iron related proteins in MS NAWM and control 
cases 
IHC was carried out on the validation cohort, to identify the expression and localisation 
of MT, FTL and TF and determine the colocalisation of these proteins with astrocytes. 
Primary antibody optimisation was carried out using a range of dilutions (Table 5.4), 
based on the manufacturer’s recommendation, in order to find the concentration that 
provided specific IHC staining with minimal non-specific background stain. 10 µm 
sections were cut on the cryostat and mounted onto poly-lysine coated microscope 
slides (Leica, UK). These sections were fixed in ice-cold acetone for 10 minutes prior to 
IHC using the using the ABC-HRP technique and Vectastain Elite kit (Vector 
Laboratories, UK) with DAB (Vector Laboratories, UK) as substrate (refer to section 
2.3.7 for full details). 
5.3.4.2 Dual labelling IHC for colocalisation of iron related proteins with astrocytes  
Single IHC was carried out with the optimum primary antibody concentration, 
determined from the single labelling optimisation studies using the ABC-HRP 
technique and Vectastain Elite kit (Vector Laboratories, UK) with DAB (Vector 
Laboratories, UK) as substrate. Following the DAB incubation, the sections were re-
blocked in 1.5% normal goat serum (150 μl in 10 ml TBS) for 30 minutes at RT. Excess 
block was removed and avidin applied for 15 minutes at RT (a component of the 
Avidin/Biotin blocking kit, Vector Laboratories, UK). Sections were quickly rinsed 
with TBS, and the second component of the blocking kit, biotin, was added to the 
sections and left to incubate for 15 minutes at RT. Sections were tapped to remove 
excess biotin and a more concentrated GFAP antibody than used in the previous single-
labelled astrocyte phenotype study (1:500) was applied to the sections and left to 
incubate o/n at 4ºC. Following the o/n incubation sections were thoroughly washed in 
TBS for 10 minutes. Biotinylated species-specific secondary antibody was prepared, by 
adding 150 µl goat/horse serum in 10 ml TBS and then adding 50 µl of biotinylated 




Table 5.4 Details of the primary antibodies used in the iron IHC study                               
All dilutions were made in the appropriate blocking serum, the optimum concentration 
used in the study are shown in bold.
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being washed with TBS for 10 minutes. The alkaline phosphatase ABC reagent was 
prepared (Vectastain ABC-AP kit, Vector Laboratories, UK) by adding 100 µl reagent 
A and 100 µl reagent B to 5 ml TBS, this was prepared at least 30 minutes prior to use. 
ABC-AP reagent was added to the sections and left to incubate at RT for 1 hour, prior to 
washing with TBS for 10 minutes, ensuring all excess TBS was removed prior to the 
addition of the alkaline phosphatase substrate. The alkaline phosphatase substrate 
(VECTOR Red Alkaline Phosphatase Substrate Kit, Vector Laboratories, UK) was 
prepared by adding 100 µl reagent 1, 2, and 3 to 5 ml Tris-HCl, 100mM. The substrate 
was added to the sections and left for 10-20 minutes for the reaction to develop, which 
was stopped by washing the sections in d.H2O. Sections were counterstained in 
haematoxylin for 30 seconds, rinsed in tap water until the water ran clear, dehydrated in 
graded alcohols and mounted using DPX and glass coverslips. For internal controls, the 
primary antibody was omitted to ensure the absence of non-specific binding from the 
secondary antibody. 
5.3.4.3 Image analysis  
All IHC and histology was examined using the BX61 Olympus microscope and CellR 
image software system (Olympus, UK). A qualitative description of the staining pattern 
of each antibody and it’s colocalisation with astrocytes was noted across the MS 
NAWM and control samples. 
5.3.5 Western blotting technique 
WB, also known as immunoblotting, is often used to separate and identify proteins 
(Figure 5.4). Ruth Thomas, a Welcome Trust funded undergraduate student supervised 
by Rachel Waller assisted in the WB work completed in this chapter.  In this technique 
a mixture of proteins is separated based on molecular weight, through gel 
electrophoresis (Mahmood & Yang 2012). Separated proteins are identified as distinct 
bands on the gel. The separated protein bands are then transferred from the gel onto a 
membrane and the membrane probed with antibodies specific to the protein of interest. 
As specific antibodies are used, only the protein of interest should be visible after 
probing, the density of the band corresponds to the amount of protein present in the 
sample (Mahmood & Yang 2012).  
5.3.5.1 Tissue protein extraction  
Protein lysates from each validation case (5MS NAWM and 5 control WM) were 
prepared by the addition of 300 µl of CelLytic™ Mammalian Tissue lysis buffer 




Figure 5.4 Western blot technique                                                                                 
Denatured protein samples are loaded onto an SDS-PAGE gel alongside a molecular 
weight protein ladder standard (a) and separated via gel electrophoresis based on their 
molecular weight (b). The separated proteins are transferred onto a nitrocellulose 
membrane (c&d). The transferred membrane is immunoprobed with an antibody 
specific to the protein of interest, followed by the incubation of a fluorescently labelled 




(Sigma-Aldrich, UK) to 10x30 µm WM sections (the cortex from each section was 
removed using a sterile disposable scalpel). The samples were homogenised using a 
hand held homogenizer to break down the tissue, and sonicated on ice for 15-20 
seconds. The lysed samples were centrifuged at 4°C for 30 minutes at 14,000 rpm to 
pellet the tissue debris. The protein containing supernatant was transferred to a chilled 
sterile Eppendorf and stored until uses at -80˚C. 
5.3.5.2 Determination of protein concentration – Bradford protein assay 
Prior to WB, protein concentration of each sample was determined using the Bradford 
protein assay and to allow equal protein loading on to the gel. The Bradford assay relies 
on the binding of a Coomassie Brilliant Blue G-250 dye to proteins (Bradford 1976). 
Prior to binding with the protein samples the cationic Commassie Blue exists in an 
acidic doubly protonated red form. Once protein is added the Commassie Blue is 
changed into to an unprotonated anionic blue form which is detectable at Amax 595nm 
using a spectrophotometer. Therefore the increasing absorbance is proportional to the 
amount of protein bound to the dye and therefore the higher the protein concentration of 
that particular sample.  A standard curve can be created using known concentrations of 
bovine serum albumin (BSA) (Sigma-Aldrich, UK) to which the unknown sample 
concentration can be determined using linear regression analysis;                                                                                                   
y=mx+c     (y=absorbance, m=gradient, x=protein concentration, c=y intercept.) 
5.3.5.3 Western blotting for ferritin light chain and metallothionein  
Protein samples were separated on a pre-cast 18% Novex Tris-glycine gel using the 
traditional SDS-PAGE technique, a range of protein concentrations were used in the 
WB optimisation experiments [5-40 µg]. All buffers and reagents for WB were 
purchased from Life Technologies unless otherwise stated, and recipes found in 
Appendix IV. Samples were prepared by adding 30 µg sample to 6x sample buffer 
(prepared in house, Appendix IV) and adjusting the volume to 20 µl with d.H2O. 
Samples were denatured on a heat block at 70°C for 10 minutes and immediately placed 
on ice until use. Pre cast gels were placed in a Novex® electrophoresis gel tank 
containing Novex® Tris-Glycine SDS Running Buffer. Each 30 µg sample was loaded 
into each well along with 2 µl Precision Plus protein dual extra standard ladder (Bio-
Rad, UK). Electrophoresis was carried out at 125V for 90 minutes, until the dye front 
reached the bottom of the gel. Separated proteins were transferred via WB onto a 
nitrocellulose membrane (NCM) (Hybond-C extra, GE Healthcare Life Sciences, UK). 
Before the transfer, all materials required for the western blot including the NCM, 
184 
 
blotting paper, and sponges were pre-soaked in cold Novex® Tris-glycine transfer 
buffer. The transfer sandwich was assembled (refer to Figure 5.4) submerged in cold 
transfer buffer, to ensure no bubbles were formed between the sandwich layers. The 
assembled sandwich was placed in a transfer tank containing surplus cold transfer buffer 
and protein transfer from the gel to the membrane was carried out for 1 hour at 100V on 
ice. For confirmation of successful protein transfer, the transferred membrane was 
stained with Ponceau S red (Sigma-Aldrich, UK), which is a highly sensitive red stain 
for proteins, such that all transferred protein can be visualised, this stain was removed 
with water prior to immunoprobing (Harper & Speicher 2001).  
5.3.5.4 Immunoprobing  
All transferred membranes were blocked for 1 hour at RT in 5% blocking buffer in 
TBS-Tween20 (TBS-T). All antibody solutions were made up in 5% blocking solution 
to an appropriate concentration, (refer to Table 5.5 for all antibody titrations used 
throughout the WB experiments). The primary antibodies were applied to the membrane 
and incubated o/n at 4°C on a flatbed shaker. An anti-β-actin was ran alongside the 
primary antibody of choice, as a house-keeping and loading control.  To confirm 
specificity of antibody binding, negative controls were also used for each WB by 
omitting the primary antibody and incubating in blocking solution alone. Membranes 
were washed thoroughly in TBS-T) (3 x 10 minutes) on a flatbed shaker to remove any 
unbound primary antibody. Appropriate labelled secondary antibodies were diluted in 
blocking solution (refer to Table 5.5 for antibody concentrations) and applied onto the 
membranes and left to incubate for 1 hour at RT on a flatbed shaker (in the dark). 
Membranes were finally washed with TBS-T (3 x 10 minutes) and visualised using the 
LICOR Odyssey® imaging system.  
5.3.5.5 Statistical analysis of western blots 
Data was normalised with respect to the loading control used, β-actin. Densitometric 
data was analysed using a non-parametric Mann-Whitney U test and comparisons 




Table 5.5 Details of the primary and secondary antibodies used in western blotting 
for the analysis of protein expression in MS NAWM and control WM tissue                                 
The optimal antibody concentration was determined through optimisation experiments, 
with the optimum concentration in bold.  
Key: FTL: Ferritin light chain, MT: Metallothionein.
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5.3.6 An introduction to mass spectrometry 
Mass spectrometry is an analytical technique allowing the molecular weight of a wide 
range of molecules and biomolecules to be determined. It is a highly sensitive 
technique, capable of generating data within seconds to measure analytes in the 
femtomole range (So et al 2013). Mass spectrometry works on the principle of 
generating ions from molecules that are measured on the basis of their mass-to-charge 
(m/z) and can also be used to determine the chemical structure of molecules such as 
peptides by fragmenting larger proteins and determining their amino acidic sequence 
through the m/z of the fragments (Domon & Aebersold 2006).  
 
There are three main components to a mass spectrometer namely: (i) the ionisation 
source in which molecules are ionised, (ii) a mass analyser in which ions are separated 
based on their m/z, (iii) the detector by which ions are revealed (Figure 5.5). Each part 
of a mass spectrometer can be altered depending on the species/molecules being 
investigated, whether these be lipids, peptide, drugs, metabolites, or proteins.  
 
Ionisation techniques such as electron ionisation (EI) and chemical ionisation (CI) allow 
for the ionisation of small molecules, (mass range up to 1000 Da) that are volatile and 
thermally stable (Glish & Vachet 2003). However, with larger biomolecules, such as 
proteins and peptides, these two methods of ionisation are not suitable, due to the use of 
harsh conditions causing analyte fragmentation (Domon & Aebersold 2006). 
Electrospray ionisation (ESI), exploitable mass range less than 200 kDa (Fenn et al 
1989) and MALDI, exploitable mass range less than 500 kDa (Hillenkamp et al 1991), 
are considered ‘soft’ ionisation techniques. Both ionisation methods allow the transfer 
of the analyte into the gas phase, with little or no sample fragmentation, and are 
typically the ionisation methods of choice when investigating protein/peptides via mass 
spectrometry, though the research reported throughout this chapter has been undertaken 
exclusively via MALDI-MS. 
5.3.7  Matrix Assisted Laser Desorption Ionisation (MALDI) 
MALDI is a versatile soft ionisation technique that has been employed to investigate a 
wide range of molecules including, besides proteins and peptides, other involatile and 
thermally labile compounds such as organic drugs (Dong et al 2010, Galano et al 2012), 









Figure 5.5 Block scheme diagram of a mass spectrometer  
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(Halinski & Stepnowski 2013) polymers (Barrere et al 2012) and nucleic acids (Joyner 
et al 2013).  In MALDI, the ionisation of the analyte is supported by a compound 
known as the matrix. This is in general a small organic acid with an extended 
conjugation of double bonds capable of absorbing UV light. The matrix absorbs the 
energy from a laser firing in the UV region and transfers it to the analyte (Kafka et al 
2011). The matrix composition is vital for the optimal ionisation of the analyte and its 
optimisation is required for the specific compound being investigated. 
After mixing the matrix with the sample and depositing onto a MALDI plate, co-
crystallisation occurs upon evaporation of the solvent component of the matrix. Under 
vacuum, a laser is pulsed over the sample, and the heat generated causes desorption of 
the matrix and analyte ion clusters into the gas phase (Yates et al 2009). A number of 
different lasers have been used in MALDI, which operate at different wavelengths and 
emit different levels of energy (Hoffmann 2007). Commonly used lasers in MALDI 
operate in the UV region such as a nitrogen (N2) laser at wavelength of 337 nm, or 
neodymium-doped:yttrium aluminum garnet (Nd:YAG) lasers at wavelength of  335 
nm. Due to the longer lifespan of Nd:YAG lasers these tend to be used more so than N2 
lasers (Trim et al 2012).  
 
The ionisation mechanism in MALDI is not fully understood, however it is generally 
accepted that as the laser is fired onto the co-crystallised matrix/analyte complex, a 
desorption process occurs by which clusters of matrix and analyte are transferred into 
the gas phase. At the same time, the matrix absorbs the laser energy thus reaching an 
excited state. The matrix is stabilised by transferring a proton to the analyte. This 
generates mostly monoprotonated ions, thus minimising spectral complexity and 
enabling easier interpretation of m/z values. The matrix is used in great excess thus 
protecting the analyte from the direct impact of the laser and minimising analyte 
fragmentation (Figure 5.6). 
5.3.7.1 MALDI coupled mass analysers  
There are a number of mass analysers available that separate ions based on their m/z 
ratio, which differ based on their accuracy and mass resolving power. Suitable mass 
analysers coupled to a MALDI source include the time-of-flight (TOF) analyser that 
separates ions based on the time it takes for ions to reach the detector traveling along the 
analyser (the drift tube). An alternative mass analyser is the quadrupole (Q), separating 




Figure 5.6 The mechanism of matrix assisted laser desorption ionisation (MALDI)                
In MALDI analysis a matrix solution is deposited onto the sample and left to co-
crystallise. The laser firing heats and excites the matrix and analyte crystallised species, 
causing both molecules to expand and enter into a gas phase. Excited matrix ions are 
stabilised by the transfer of protons to analyte molecules in the process known as 
ionisation, the analyte ions are then accelerated under vacuum into the mass analyser.
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not generally coupled to a MALDI source unless they are followed by a second mass 
analyser; hybrid mass analysers can be employed, which offer the advantages of both 
TOF and Q with higher sensitivity and mass accuracy allowing for mass spectrometry 
and tandem mass spectrometry (MS/MS) acquisition on the same samples.   
In the TOF analysers formed ions are accelerated through the drift tube at a suitable 
potential (20-25 kV) (Andersson et al 2010). The TOF depends on the m/z of the ions, 
with lower m/z ions having a higher kinetic energy and reaching the detector more 
quickly than higher m/z ions with lower kinetic energy (Hoffmann 2007). Mass 
resolution can be improved by using a reflectron, which helps the focussing of high 
energy ions thus improving mass accuracy.  A reflectron consists of a decelerating and 
reflecting field, which work by altering the flight direction of the ions. Ions with the 
same m/z but differing velocities will enter the reflectron and those with higher kinetic 
energy and velocity will penetrate the decelerating component of the reflectron further 
than ions with lower kinetic energy and velocity. Consequently, the faster ions will 
spend more time in the reflecting field and catch up with the slower ions on release from 
the reflectron (Hoffmann 2007). Changing the direction of the ions to the detector 
compensates for small differences in velocities of ions with the same m/z values (Glish 
& Vachet 2003). Molecules up to 3000 Da including peptides benefit from the use of 
the analysis in reflectron mode. 
Q analysers are generally popular due to their low cost, small size and lower voltage 
used to accelerate ions from the source to the analyser (V compared to kV) (Glish & 
Vachet 2003). Q are an arrangement of four metal rods in a cylindrical shape with 
applied potentials. Separation of ions in a Q is due to the ions motion and stability in an 
electric field dependant on their m/z, not on their velocity, as in the TOF analysers 
(Glish & Vachet 2003, Yates et al 2009). The ratio between the radio frequency (rf) 
voltage and direct current voltage over the Q determines the analysers function. The size 
of the Q and rf are kept constant so that the analyte ions are separated based on their 
m/z, with each ion reaching the detector by alterations of the rf and DC voltages (Glish 
& Vachet 2003). For example, only ions with a particular m/z will reach the detector for 
a given voltage, while the other ions will be unstable, colliding with the rods. 
Hybrid mass analysers include the Q-TOF, in normal mass spectrometry acquisition the 
Q guides the ions to the TOF analyser (Domon & Aebersold 2006) where the whole 
mass spectrum is measured. 
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For MS/MS acquisition a known precursor ion can be selected in the Q and fragmented 
in the collision cell, and the resulting ion products analysed in the TOF section (Loboda 
et al 2000, Shevchenko et al 2000). Q-TOF allows for both peptide fingerprinting (MS 
acquisition) and MS/MS of precursor ions to be acquired from the same sample 
preparation. These devices are highly sensitive, have high resolving power and mass 
accuracy (Loboda et al 2000). 
5.3.7.2 MALDI-mass spectrometry profiling (MALDI-MSP) 
MALDI-mass spectrometry profiling (MALDI-MSP) is the method of choice when one 
is interested in the molecular pattern within specific areas or anatomical regions of a 
tissue section. By depositing matrix in defined spots across the ROI on the tissue MSP 
can be completed in minutes with acquired ion profiles of species confined to that 
specified matrix spot. Within MALDI-MSP the spectra are usually generated from a 
small number of spots at random or from specific areas on the tissue section. For 
example, concerning the work presented in this thesis, MALDI-MSP was employed to 
generate specific regional mass spectral profiles targeting the WM of the brain yet, due 
to the nature of the matrix, spraying was used instead of the conventional spotting of 
matrix for MSP, as discussed later in the chapter (Figure 5.7).  
5.3.7.3 MALDI-mass spectrometry imaging (MALDI-MSI) 
MALDI-mass spectrometry imaging (MALDI-MSI) is advantageous over other 
proteomic methods which require the use of specific antibodies like in IHC and WB. 
Carrying out WB requires sample homogenisation and time consuming protein 
extraction, purification and separation steps which are avoided when using MALDI-
MSI. Furthermore, MALDI-MSI maintains cellular and molecular integrity within a 
tissue section which is lost when investigating protein expression by WB (Wisztorski et 
al 2008). Firstly introduced in 1997 by Caprioli and colleagues, continuing 
developments in MSI have made the technique more sensitive, robust and useful in 
applications such as cancer research, neuroscience and pharmaceutical development 
(Goodwin et al 2008, Reyzer & Caprioli 2007). MALDI-MSI allows the distribution of 
hundreds of species in intact biological tissue sections to be visualised in a single 
measurement (Caprioli et al 1997). The technique has been used to image lipids, 
peptides, proteins or drugs in a range of different biological settings (Carter et al 2011, 
Chaurand et al 2006, Eberlin et al 2011, Hanrieder et al 2013a, Rohner et al 2005, Trim 
et al 2008).  When carrying out MALDI-MSI on tissue sections, the matrix is applied to 







Figure 5.7 Matrix assisted laser desorption ionisation-mass spectrometry profiling 
(MALDI-MSP)                                                                                                                      
Tissue sections can be histologically stained to define specific areas of interest. For 
example in brain tissue, WM and cortex are identified by LFB (a). On a consecutive 
tissue section matrix can be deposited on to the area of interest (WM) (b) and MALDI-
MSP can be carried out for each specified spot (c). Comparisons of mass spectrum can 
be made between disease tissue and control tissue.
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explained in section 5.3.7.4. Matrix coated tissue sections are introduced into the mass 
spectrometer and a laser is delivered onto the section on each point of known x,y 
coordinates in a pre-defined raster. The spatial resolution achievable by MALDI-MSI 
can range between 10-150 µm dependent on the instrument used. From a single analysis 
on one tissue section, a single mass spectrum is generated from each raster point. From 
these mass spectra it is possible to plot the relative intensity of each m/z peak and 
visualise the ion distribution across the tissue section as an image (Goodwin et al 2008). 
A representative example of the MALDI-MSI process is shown in Figure 5.8. 
5.3.7.4 Matrix composition and application 
The success of a MALDI-MS study is associated with: sample preparation, the type of 
matrix used and method of matrix deposition. The choice of the matrix depends on the 
type of compound being investigated by MALDI-MS (Table 5.6). There are a number 
of different methods of matrix delivery to biological tissue sections, according to 
whether MSP or MSI is employed, with the ultimate aim of maximising analyte 
extraction, while minimising analyte delocalisation. MALDI matrix can be delivered as 
individual droplets (spotted) or as a homogenous layer (coated) onto biological tissue 
sections. Spotting matrix can be completed manually using a pipette or using specific 
automated matrix spotter instruments such as the Potrait® 630 Spotter (LABCYTETM, 
Ireland). This instrument automatically spots matrix across a tissue section using 
acoustic droplet ejection (ADE) (Aerni et al 2006). Advantages of matrix spotting over 
spray coating is that the reproducibility between samples is higher because the analyte 
extraction is more efficient. The instrument is able to alter spot size deposited, with 
smaller closer packed matrix spots preferred for higher resolution MSI, while larger 
matrix spots spread and have the possibility to delocalise the samples and tend to be 
better for MSP (Aerni et al 2006). Coating sections can be undertaken manually or 
using automatic matrix depositors; such automated instrumentation include the 
ImagePrep (Bruker  Daltonics, UK) a robotic matrix deposition system. 
 
Alternatively the SunCollectTM automater sprayer (SunChrom, Friedrichdorf, Germany) 
and the automated TM Sprayer (HTX Technologies, USA) can be used, as in the current 
research. Both these systems use pneumatic atomisation to spray matrix uniformly onto 
MALDI sample plates or glass slides, the pressurised air ensures the constant spray 
conditions, regardless of surrounding environmental factors, such as temperature and 
humidity. The advantage of automated sprayers is that under pressure the spray is very 





Figure 5.8 Matrix assisted laser desorption ionisation-mass spectrometry imaging 
(MALDI-MSI) work flow                                                                                                     
Tissue sections are cut and mounted on to a glass slide or MALDI plate (a), and matrix 
deposited onto the section (b). A laser is fired at set raster points across the tissue 
section (the black arrow showing direction of laser movement across the tissue section) 
(c), at each raster point, a mass spectra is generated (d). Specific m/z ions can be 
identified from the mass spectra and their distribution identified in the tissue section (e). 





Table 5.6 Common matrices used in MALDI-MS                                                                 










As well the ability to optimise parameters that control the level of protein extraction and 
matrix crystallisation, automated spraying systems prevent sample delocalisation. For 
example, the distance between the spraying nozzle and the tissue section can be 
controlled (SunCollect), while nozzle velocity and gas flow can control the matrix 
drying time (TM Sprayer/SunCollect), while a faster rate of solvent evaporation through 
the use of heat prevent the formation of large matrix crystals, known to create heat spots 
(TM Sprayer). Throughout this study, application of matrices was completed using the 
TM Sprayer, while trypsin was delivered using the SunCollect. 
5.3.7.5 MALDI-MS – tissue preparation 
From the validation patient cohort (5 MS NAWM and 5 control cases – refer to 
Appendix III) 10 µm tissue serial sections were cut on the cryostat (Leica, UK) and 
mounted on to poly-lysine glass slides (Leica, UK). All prepared tissue sections were 
used immediately or stored in an airtight slide box at -80°C until use. One section from 
each case was stained with LFB (refer to section 2.3.5 for method) to differentiate 
between the WM and cortex within each case. Whether profiling for proteins or imaging 
for peptides, sections were removed from -80°C and placed in a vacuum dessicator for 
15 minutes to allow the tissue to come to RT and remove any excess moisture. Tissue 
sections were washed sequentially with 80% ethanol, 90% ethanol and chloroform for 
30 seconds in each and left to dry in a vacuum dessicator for 10 minutes prior to 
matrix/trypsin deposition.                                                                                                                                                        
5.3.8 Intact protein profiling (MALDI-MSP) 
For each of the cases investigated (5 MS NAWM and 5 controls), protein profiling was 
completed on six biological repeats with six mass spectra (technical repeats) generated 
from six random ROIs on each biological repeat. 
5.3.8.1 MALDI matrix preparation and deposition 
In this study a range of different matrices were trialled at various concentrations and 
solvent compositions (Table 5.7). For final MALDI-MSP of intact proteins, the 
optimum matrix composition was 5mg/ml ferulic acid (FA) in 50/33/17 (%v/v) 
d.H20/acetone/formic acid. FA matrix was sprayed onto the tissue sections using the 
automated TM Sprayer (HTX Technologies, USA), block temperature: 80ºC, velocity: 
1300 mm/minute, matrix flow rate: 100 µl/minute, line spacing: 1.5 mm, matrix layers 







Table 5.7 Details of the different matrices and solvent compositions trialled for 
intact protein profiling                                                                                                         
Final optimised conditions in red.                                                                                                  
Key: ACN: acetonitrile, TFA: trifluoroacetic acid. 
*Equimolar amounts of aniline were added to the SA solution, therefore 1 ml 5mg/ml 
SA solution contained 2.4 ml of aniline.
198 
 
5.3.8.2 MALDI-MSP Instrumentation 
The mass spectrometer used in the intact protein profiling work was a Voyager De Pro 
MALDI-TOF (Applied Biosystems/MDS Sciex, USA) with a Nd:YAG laser. The 
instrument was operated in linear mode, using a delay time of 750 nsec, 150 laser shots 
were fired per spectrum, at an intensity of 2900 (arbitrary units). For each case, six 
biological repeats were analysed, generating six random technical repeats in the defined 
WM in both the MS cases and control cases (as determined from the LFB stained 
section of each case). The mass spectrometer was calibrated before each sample was 
analysed using a mixed protein calibration standard of insulin (5734 m/z) apomyoglobin 
(MH2+ 8476 m/z, MH+ 16952 m/z), cytochrome C 12361 m/z, using the same parameters 
as stated above. 
5.3.9 Peptide digest imaging (MALDI-MSI) 
For each case investigated (5 MS NAWM and 5 controls), MALDI-MSI was completed 
on five biological repeats. 
5.3.9.1 In situ tissue digestion  
In situ tryptic digests were performed on the tissue sections prior to matrix deposition. 
Trypsin solution was prepared at 20 µg/ml by the addition of 50 mM ammonium 
bicarbonate (NH4HCO3) containing (0.5%) Octyl-α/β-glucoside (OcGlc), all reagents 
supplied by Sigma-Aldrich, UK. The automated pneumatic SunCollect (SunChrom, 
Friedrichdorf, Germany) was used to spray the trypsin solution onto the sections in a 
series of five layers, at a flow rate of 2 μl/min. Trypsin coated sections were incubated 
in a humidity chamber containing d.H2O for 3 hours at 37°C and 5% CO2/95% air. 
5.3.9.2 Matrix preparation and deposition 
For peptide imaging, the matrix α-cyano-4-hydroxycinnamic acid (CHCA) prepared in 
50/0.5 (%v/v) d.H2O/trifluoroacetic acid (TFA) (Fisher, UK) and 25/25 (%v/v) 
ethanol/acetonitrile (ACN) was sprayed using the TM Sprayer (HTX Technologies, 
USA), block temperature: 80ºC, velocity: 1300 mm/minute, matrix flow rate: 100 
µl/minute, line spacing: 1.5 mm, matrix layers (passes): 10, air pressure: 10 psi. 
5.3.9.3 MALDI-MSI instrumentation 
Peptide images were acquired using a Q-Star Pulsar/Q-TOF mass spectrometer 
(Applied Biosystems/MDS Sciex, USA) fitted with a variable rate ND: Yttrium 
vanadate (Nd:YVO4) laser using a continuous raster, imaging at a laser repetition rate of 
5 KHz. Image acquisition was performed at 150 µm spatial resolution. 
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5.3.10 Mass spectrometry data processing 
MSI data was imported into BioMap 3.7.5.5 software (http://www.maldi-msi.org/) for 
image processing. Within BioMap, the WM ROI was manually outlined in each 
biological repeat using the LFB stained section as a guide. The data was normalised 
against the total ion count (TIC) and the same contrast/brightness applied to the images. 
The data list generated from the ROI of each biological repeat was exported from 
BioMap and converted to a text file.  
Prior to statistical analysis, the accumulated text files from each case, representing data 
lists exported from either BioMap 3.7.5.5 (peptide imaging) or from Voyager data 
explorer (intact protein profiling) were imported into SpecAlign (Oxford, UK) to 
undergo data alignment processing. This software generated an average spectrum for 
each case from which all peaks in all spectra being analysed were aligned to, and all 
spectra were normalised against the TIC. Both peptide and protein spectra were then 
processed using mMass (Strohalm et al 2010), an open source mass spectrometry tool, 
to allow for peak selection. 
5.3.11 Statistical analysis 
Post SpecAlign, and peak selection in mMass, a collective group of protein text files 
representing each of the 6 technical repeats of the 6 biological repeats of each of the 10 
cases (5 MS NAWM and 5 controls), or a collective group of peptide text files 
representing each of the 5 biological repeats of the 10 cases (5 MS NAWM and 5 
controls) were imported into Marker View software 1.2 (Applied Biosystems, USA) and 
data were rearranged into a table format. For protein analysis a minimum intensity of 
0.1 was selected, with a maximum number of peaks of 5,000. For peptide analysis a 
minimum intensity of 0.1 was selected, with a maximum number of peaks of 10,000; 
only monoisotopic peaks selected in Marker View were used in the statistical analysis. 
Principal components analysis (PCA) and partial least squares regression discriminant 





5.4.1 Optimised primer concentration and efficiencies 
Initial qPCR optimisation studies determined the optimum concentration of primers. 
The optimum forward and reverse primer concentration for each gene of interest was 
selected based on the lowest Ct value, and the amplification of a single product 
indicating the absence of primer dimers. Initially all 5 primers were optimised by 
Natalie Rounding. MT1X, TF and FTL primers were optimised at 300nM/300nM, and 
gave a single amplified product with no evidence of primer dimer formation (Figure 
5.9). The primers were efficient over a range of cDNA template concentrations, as 
shown by the standard curves for each of the primers and their corresponding efficiency 
scores; MT1X: 105.9%, TF: 99.5%, FTL: 99.8% (Figure 5.9). In comparison, MT1G 
and MT2A primers produced multiple peaks at varying combinations of primer 
concentrations and their efficiency over a range of cDNA concentrations was poor; 
MT1G: 91.4%, MT2A: 106.7%, (Figure 5.10). Consequently these two primers were 
redesigned and after repeated optimisation studies, the optimum concentration of MT1G 
primer pair was  300nM/300nM and MT2A primer pair was 300nM/600nM. Both 
primers gave single products, with good efficiencies over a range of template 
concentrations: MT1G: 106.9%, MT2A: 112.2% (Figure 5.11).  
5.4.2 Housekeeping gene selection 
Based on analysis of the original microarray data, three probe sets for β-actin and three 
probe sets for GAPDH were represented in all seven of the original cases used in the 
microarray study. The signal intensity across these probe sets was relatively high for the 
β-actin probes compared to the GAPDH probes (Table 5.8), therefore β-actin was used 
as the HK control in all subsequent qPCR experiments.  
5.4.3 Opposing gene expression changes in MS NAWM compared to control WM 
From the five candidate genes identified as significantly upregulated in MS NAWM 
astrocytes compared to control WM astrocytes in chapter 4, qPCR validation failed to 
replicate these microarray findings in the validation patient cohort (Figure 5.12). 
However, an additional qPCR carried out on remaining cDNA from a selection of cases 
used in the original microarray study (2 MS cases and 2 control patients) showed  
upregulation in expression of MT1X, TF and FTL in the MS NAWM (Figure 5.13). 
However, due to the study size this expression failed to reach statistical significance, yet 






Figure 5.9 Successful primer pair optimisation for qPCR                                            
Optimisation of MT1X (a), TF (b) and FTL (c). Each primer set gave similar Ct values, 
as indicated by the amplification plots, and single PCR products, as indicated by the 
dissociation curve. The efficiency of the three primers was constant across the range of 





Figure 5.10 Unsuccessful primer pair optimisation for qPCR                                              
Two primer pairs representing MT1G (a) and MT2A (b) were not optimised 
successfully. The presence of variable Ct values from the amplification plots and 
multiple PCR product and primer dimers across the range of primer pair combinations is 
indicative of non-specific primer sets. Also, the efficiency of the two primers was 





Figure 5.11 Redesigned MT1G and MT2A successful primer pair optimisation for 
qPCR                                                                                                                                 
Newly designed primer pair sets representing MT1G (a) and MT2A (b) were optimised 
successfully. The presence of similar Ct values from the amplification plots and single 
PCR product across the range of primer pair combinations is indicative of more specific 
primer sets. However, the efficiency of the two primers was higher in comparison to 
MT1X, TF and FTL (MT1G 106.9%, MT2A 112.9%) which should be considered 





Table 5.8 Housekeeping gene selection for qPCR                                                                 





Figure 5.12 qPCR validation of the selected five candidate genes involved in iron 
homeostasis in an additional validation patient cohort                                                                                                          
No significant difference in gene expression was detected between MS NAWM (6 
cases) and control WM (6 cases).  MT1G p=0.0714, MT2A p= 0.0649, MT1X 
p=0.2944, TF p= 0.9048, FTL p=0.0649 (Mann-Whitney U test). 
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Figure 5.13 qPCR validation for three of the candidate genes in the original 
microarray patient cohort samples                                                                                                       
The same directional upregulatory change for MT1X, TF and FTL was identified in the 




5.4.4 Metallothionein immunoreactivity colocalised with GFAP+ astrocytes 
Dense MT immunoreactivity was a common feature across all MS NAWM and control 
cases investigated. In a qualitative assessment, there was a regular distribution of MT 
throughout the WM, with staining associated with the cell body and extending processes 
of cells with an astrocytic morphology (Figure 5.14).  No apparent differences in the 
pattern of staining were observed between MS NAWM and control WM, with a regular 
distribution of positively stained cells throughout both sample groups. MT 
immunoreactivity colocalised with GFAP+ astrocytes (Figure 5.15, red arrows). 
However it is worth noting that not all GFAP+ astrocytes were MT+ and not all MT+ 
cells were GFAP+ (Figure 5.15, blue arrows). MT IHC was completed by Natalie 
Rounding. 
5.4.5 Ferritin light chain immunoreactivity colocalised with GFAP+ astrocytes 
FTL immunoreactivity was a common feature across all MS NAWM and control WM 
investigated. A regular distribution of FTL staining was associated with cell bodies, but 
was not as extensive as MT immunoreactivity (Figure 5.16a). FTL expression 
colocalised with GFAP+ astrocytes (Figure 5.16b), but was also associated with small 
spherical cells morphologically resembling oligodendrocytes. No qualitative differences 
in staining pattern of FTL was observed between MS NAWM and control WM. 
5.4.6 Transferrin immunoreactivity  
The pattern of staining observed for TF contrasted with MT and FTL, which was clearly 
associated with individual cells. TF immunoreactivity aligned in a tract like pattern, 
suggesting possible associated with axons (Figure 5.17). Upon dual labelling with 
GFAP, there was not an obvious colocalised pattern of staining between TF and GFAP, 
however TF expression may be associated with astrocyte end feet where the processes 
of astrocytes ensheath blood vessels and/or make contact with central synapses within 
the brain (Ventura & Harris 1999). 
5.4.7 Western blot analysis of ferritin light chain in MS NAWM and control WM 
tissue 
Prior to WB, the concentration of each MS and control protein extract was determined 
via the Bradford assay, a representative standard curve is shown in Figure 5.18. FTL 
WB detected a single positive protein band in both the MS and control WM at the 
expected molecular weight  of ~20 kDa (Figure 5.19). Densitometric analysis of FTL 
and β-actin (42 kDa) showed no significant differences in FTL protein expression in 




Figure 5.14 Metallothionein protein expression in MS NAWM and control WM                      
A regular distribution of MT immunoreactivity was detected throughout NAWM (a) 
and control WM (c), and was associated with cells morphologically resembling 
astrocytes. (b) and (d) represent a higher magnification of MT immunopositive cells in 
MS NAWM and control WM respectively, marked with a black box in (a) and (c). Scale 




Figure 5.15 Metallothionein immunoreactivity colocalises with GFAP+ astrocytes 
in MS NAWM                                                                                                                            
MT (brown) immunoreactivity colocalises with GFAP+ astrocytes (red) (b, red arrows). 
MT+ GFAP- cells were also present (b, blue arrows). (b) represents a higher 
magnification of colocalised MT+ astrocytes marked with a black box in (a).  Scale bar 







Figure 5.16 Ferritin light chain protein expression in MS NAWM                                          
FTL immunoreactivity visualised using single label IHC (a) and colocalised with GFAP 
in dual label IHC (b). Colocalised expression of FTL (brown) and GFAP (red) confirm 













Figure 5.17 Transferrin protein expression in axonal tract like pattern in MS 
NAWM                                                                                                                                    
The general expression of TF in MS NAWM and control WM was not distinct to 
individual cell types. The pattern of staining followed a tract like configuration with 
possible colocalised expression with astrocyte endfeet ensheathing blood vessel and/or 
contacting axons within the brain. Expression of TF (brown) and GFAP (red) Scale bar 













Figure 5.18 A representative standard curve used to determine the protein 
concentration of the unknown brain extract using the Bradford protein assay                                          
The above data shows the standard curve of known BSA concentration standards and 
their absorbance at 595nm. The concentration (x) of unknown samples can be 




Figure 5.19 Ponceau S red stain and ferritin light chain western blotting from MS 
and control cases, [30 µg protein/lane]                                                                                     
Ponceau S red indicated the successful transfer of proteins onto the NCM (a). FTL 
immunoprobed WB of separated brain proteins (green, ~20 kDa) (b). Equal loading was 
verified by β-actin probing (red, 42 kDa) (b). FTL western blot completed by Ruth 
Thomas. 
Key: MS: multiple sclerosis case, CO: control case, NCM: nitrocellulose membrane, 
RMM: relative molecular mass, +ve control: positive control, -ve control: negative 
control. 
 











Figure 5.20 Levels of ferritin light chain in MS NAWM and control WM detected 
by WB                                                                                                                          
Densitometric analysis values expressed as the density ratio of target (FTL) to loading 
control (β-actin) in arbitrary units. Data is presented as the mean (n= 5 MS NAWM and 
5 control WM cases). No significant differences in the levels of FTL expression were 
observed between MS NAWM and control WM.
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5.4.8 Western blot analysis of metallothionein in MS NAWM and control WM tissue 
Numerous optimisation attempts to identify the expression of MT through WB were 
completed, and included varying the sample protein concentrations applied to the gels, 
alternative sample buffers, alternative wash steps, varying concentrations of primary 
and secondary antibody, the use of different secondary antibodies and alterations of 
antibody incubation times. However no consistent results for MT expression were 
achieved to enable densitometric analysis to be completed.   
However, throughout the optimisation experiments the presence of a protein band at the 
expected molecular weight of  ~12 kDa for MT was consistently identified on the 
Ponceau S Red stain (Figure 5.21a and Figure 5.22a). Immunoprobing for MT gave 
inconsistent results. Multiple bands were identified (Figure 5.21b - green), or no 
positive stain for MT was identified. Due to the high concentration of secondary 
antibody required to identify MT expression, the α-mouse IR680CW antibody (red) 
originally used was replaced with the α-mouse IR800CW (green) due to the high 
background hue from the IR680CW (red) antibody when visualised on the LiCor 
imaging system. 
MT was firstly probed with an α-mouse IR800CW antibody (green) identifying multiple 
bands as shown in Figure 5.21b, the expected relative molecular mass (RMM) for MT 
was 12 kDa. β-actin (42 kDa) was probed for with an α-rabbit IR800CW antibody 
(green), Figure 5.21c. Multiple bands were detected for both MT and β-actin as seen in 
Figure 5.21b,c, with a particular strong band identified at ~55 kDa in Figure 5.21c. 
In another MT WB optimisation experiment, more concentrated protein samples [40 
µg/lane] were loaded and alternative secondary antibodies were used. The use of two 
separate IR labelled secondary antibodies, (α-mouseIR680CW and α-rabbit IR800CW) 
allowed for the easier distinction between MT (red) and β-actin (green) expression on 
the membrane. The α-mouse IR680CW antibody did not produce the high background 
previously seen. In this experiment a single band for MT was present at ~12 kDa, the 
expected weight for MT, however the bands were unclear and blurred, (Figure 5.22b, 
red). Equal loading was verified by β-actin probing (Figure 5.22b, green) with the 
presence of a single band at 42 kDa. However, attempts to repeat this experiment on the 
full validation cohort failed to reproduce these data and bands at the expected molecular 
weight for MT were not detected. This experiment was repeated on three separate 
occasions and therefore no densitometry analysis could be completed for MT expression 



















Figure 5.21 Ponceau S red stain and metallothionein western blotting of MS and 
control cases [20 µg protein/lane]                                                                                        
Ponceau S red indicated the successful transfer of proteins onto the NCM, a protein 
band at the expected molecular weight (~12 kDa) for MT was present in all samples (a, 
green box). MT immunoprobed of separated brain proteins, identified multiple bands (b, 
green). Equal loading was verified by β-actin probing (c, green 42 kDa), yet additional 
multiple non-specific bands were seen after probing for β-actin in particular a band 
present at ~55 kDa (c, green). 
Key: MS: multiple sclerosis case, CO: control case, NCM: nitrocellulose membrane, 




















Figure 5.22 Ponceau S red stain and metallothionein western blotting of MS and 
control cases [40 µg protein/lane]                                                                                      
Ponceau S red stained the successful transfer of proteins onto the NCM, a protein band 
at the expected molecular weight for MT (~12 kDa) was present in all samples (a, green 
box). MT immunoprobed WB of separated brain proteins, with a single unclear, blurred 
band identified (b, red box ~12 kDa). Equal loading was verified by β-actin probing (b, 
green box 42 kDa).                                                                                                                    
Key: MS: multiple sclerosis case, CO: control case, NCM: nitrocellulose membrane, 




5.4.9 Intact protein profiling (MALDI-MSP) 
Direct tissue profiling was carried out on six serial sections (biological repeats) of each 
MS and control case. Mass spectra were generated from six ROIs (technical repeats) 
and example spectra are shown in Figure 5.23. Each of the spectra shows the presence 
of many species represented by the different protein peaks. The detection of particular 
signals was common to both MS cases and control cases (e.g. the peak at 18.1 kDa, red 
astericks in Figure 5.23 a-d), while other peaks were specific to a particular MS case 
over control cases (e.g. the peak at 22.4 kDa, yellow astericks in Figure 5.23 a,b,). 
Similarly, other peaks were specific to control cases over MS cases (e.g. the peak at 
10.5 kDa, purple astericks Figure 5.23 a-d).  
5.4.9.1 Principal components analysis – intact protein profiling (MALDI-MSP) 
A technically accurate assessment of the differences in protein profiles between control 
and case samples was carried out by multivariate statistical analysis, principal 
component analysis (PCA) via MATLAB®, through the Eigen Vector tool box, to 
produce an unbiased clustering of spectra. PCA turns possibly correlated data linearly 
into uncorrelated data, and allows an unbiased look at all data to identify any specific 
groupings between cases. Initially, a non-discriminant PCA was performed on all 
samples analysed, which included 6 biological repeats of each of the 5 MS NAWM and 
5 control cases, with 6 technical repeats per biological repeat to ensure reproducibility 
of results. From the scores plot, there were no apparent differences between the spectral 
data sets belonging to MS NAWM and control cases respectively (Figure 5.24a). 
although there appeared to be m/z values that were noticeably distant from the centre of 
the loadings plot (18056 m/z, 14444 m/z and 17587m/z) (Figure 5.24b) and therefore 
suggestive as being characteristic of specific cases. However, when the loadings plot 
was compared to the scores plot, the specific species did not correlate with multiple 
repeats of particular samples, and therefore cannot be classed as being meaningful and 
specific to a particular MS or control case. 
In order to try and separate the data into disease and control groups, further PCA was 
carried out on the average spectral data from all biological and technical repeats of each 
case. Mass spectra representing each of the cases’s biological and technical repeats was 
combined into a single average spectra in SpecAlign, the peak lists from each case’s 
averaged mass spectra was statistically assessed in MATLAB® via PCA. As before, no 
clear differences between the MS NAWM cases and control cases depicted from the 









Figure 5.23 Intact protein profiling of MS and control samples                                               
Example mass spectra produced from direct tissue profiling of human PM CNS WM 
material. MS NAWM vs. control cases; MS103 (blue) vs. CO14 (green) (a), MS103 
(blue) vs. CO22 (green) (b), MS235 (blue) vs. CO14 (green) (c), MS235 (blue) vs. 
CO22 (green) (d). Signals common to both MS and control cases (red astericks at 18.1 
kDa, a-d). Signals common to MS103 (yellow astericks at 22.4 kDa, a,b). Signals 





Figure 5.24 PCA score and loadings plot of MS NAWM and control WM tissue 
from intact protein profiling                                                                                                  
There does not appear to be clear separation between MS and control cases from this 
initial PCA. From the score plot (a) there were no clear groupings of the MS NAWM 
and control cases, with the loading plot (b) containing peak information that directly 




Figure 5.25 PCA score plot of averaged mass spectra                                                        
Mass spectra from all biological repeats and technical repeats of each case were 
combined into an average spectra in SpecAlign. Averaged peak lists of each case were 
analysed via PCA, the score plot failed to show any groupings between the spectra 
based on commonalities in m/z ratios of peaks (a). The loading plot (b) contains peak 
information that directly correlates with the scores plot in (a).
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5.4.10 Peptide digest imaging (MALDI-MSI) 
In situ tryptic digest was carried out on 5 serial sections (biological repeats) of each MS 
and control case, and MALDI-MSI performed. The data generated was processed in 
BioMap, where the WM ROIs in each case were isolated and the corresponding mass 
spectra exported. Example spectra from MS NAWM cases are shown in Figure 5.26, 
and control cases in Figure 5.27. 
Each of the spectra show a range of peptides which can be used to identify 
corresponding proteins through peptide mass fingerprinting (PMF) which help to 
identify typically high abundant proteins within MS and control cases. Peak lists from 
these spectra were used to statistically analyse the data. 
Expected proteins within the WM of the brain, such as myelin basic protein (MBP), 
were identified by manual interpretation according to a targeted approach, in which a 
theoretical digest of MBP was carried out. In particular MBP peptide (experimental m/z 
1829.80, monoisotopic theoretical m/z 1829.97) was identified within the WM of all 
cases investigated confirming the specificity of MSI (Figure 5.28). The distribution of 
m/z 1829.80 in the generated mass spectrometric images was restricted to the WM of 
both MS NAWM and control cases (Figure 5.28a, c, e, g). The localised expression was 
confirmed by the complementary LFB stained sections clearly showing the different 
regions of the brain (Figure 5.28b, d, f, h). 
5.4.10.1 Principal components analysis – peptide digest (MALDI-MSI) 
Statistical analysis of the MS NAWM and control WM tryptic digest spectra was 
performed using PCA via MATLABTM through the Eigen Vector tool box. In the same 
approach as for intact protein profiling, PCA provides an unbiased interpretation of the 
data spread and attempts to separate groups of data into clusters. Initially PCA was 
performed on all samples analysed, which included 5 biological repeats of 5 MS 
NAWM and 5 control cases. From the scores plot, there were no apparent differences 
between the spectral data sets belonging to MS NAWM and control cases respectively 
(Figure 5.29a). The scores plot failed to show any firm groupings of MS cases or 
control cases, also confirmed by the loadings plot, where the majority of the m/z values  
overlap and were within the centre of the plot (Figure 5.29b). However, there were 
some m/z values which were spread away from the centre, yet in relation to the scores 




Figure 5.26 Peptide MALDI mass spectra obtained from 5 MS NAWM cases                      
The mass spectra are representative of WM from each MS case analysed; MS103 (a), 





Figure 5.27 Peptide MALDI mass spectra obtained from 5 control cases                               
The mass spectra are representative of WM from each control case analysed; CO14 (a), 




Figure 5.28 MALDI-MS images for the distribution of MBP peptide 1829 m/z 
throughout the WM                                                                                                                 
The localisation of MBP peptide to the WM of both MS NAWM and control WM (a, c, 
e, g). This localisation was confirmed by LFB stained corresponding sections (b, d, f, h) 




Figure 5.29 PCA score and loadings plot of MS NAWM and control WM tissue 
from in situ peptide digest                                                                                                                
From this initial PCA test, there does not appear to be clear separation between MS and 
control cases. However there is broad separation of some cases, such as CO26 cases 
localised to the lower half and MS105 cases to the upper half of the PCA plot. The 




An example of potential case groupings is shown between the MS105 samples located 
in the upper half of the PCA plot and the CO26 samples being grouped in the lower 
half. With this separation between diseased and control samples established in a non-
discriminant manner data was investigated further in a supervised manner. 
5.4.10.2 Partial least squares discriminant analysis – peptide digest (MALDI-MSI) 
PLSDA was performed to provide classification between two sample groups. This is a 
discriminant statistical technique that employs the use of pre-selected groups for 
analysis based on the PCA results. Data was imported into MATLAB to build 
predictive models, to allow for a greater understanding of complex datasets. Regression 
vector plots generated via the use of PLSDA showed the presence of ions specific to 
particular samples. Data imported into MATLAB underwent a range of pre-processing 
steps, but generally throughout this study the data was linearised and the variables 
present in the data set were normalised and the data mean centralised (Eigenvector 
Research Inc. 2012). Choosing a suitable cross validation method when building a 
PLSDA model was important to determine the complexity of data. In this study 
‘contiguous blocks’ was chosen which assesses predictability between repeat sample 
spectra. For example, when CO26 and MS105 were analysed through PLSDA the 2 
groups modelled were showing differences against each other after cross validation 
against the rest of the data (the further 8 cases).  
A number of specific peaks were determined from the PLSDA regression vector plot 
(Figure 5.30), 644 m/z was specific and the largest peptide peak in CO26 cases, other 
CO26 specific peptide peaks included 699 m/z and 727 m/z, which were not identified in 
MS105 cases. Another peptide ion 1099 m/z was increased in MS105 cases when 





Figure 5.30 PLSDA regression vector plot comparing peptide digest data from MS 
NAWM and control WM samples                                                                                         
There are differences in peptide abundances, with 644 m/z only present in CO26 cases 






5.5.1 Iron regulation by astrocytes in MS NAWM  
In this study, four individual experimental approaches were taken, which focussed on 
attempting to validate a key microarray finding, namely the dysregulation of candidate 
genes associated with the regulation of iron homeostasis and oxidative stress in 
astrocytes in MS NAWM. qPCR analysis of the candidate genes performed on patient 
samples from the original microarray cohort and on an additional validation patient 
cohort failed to replicate significantly the increased expression of candidate genes. 
However, qPCR on four of the original microarray samples (2 MS vs. 2 control cases) 
did show the same directional change as seen in the microarray study, demonstrating a 
non-significant upregulation of MT1X, FTL and TF in MS NAWM astrocytes 
compared to control WM astrocytes. Immunohistochemical investigations demonstrated 
colocalisation of MT, FTL and TF with GFAP+ astrocytes in the WM of an additional 
cohort of MS and control patients. However, MALDI-MS and WB quantitation of these 
proteins was unable to demonstrate significant differences in expression between MS 
NAWM and control WM.  
Iron is vitally important in a large number of biological functions including: oxygen 
transport, DNA synthesis and repair, along with mitochondrial energy production 
(Crichton et al 2011, Todorich et al 2009). Within the brain, iron is vital in the synthesis 
of neurotransmitters and myelin (Levenson & Tassabehji 2004, Moos & Morgan 2004). 
Increased levels of iron within the brain are associated with the ageing process, and are 
also linked to several neurodegenerative diseases including AD (Bishop et al 2002, 
Raven et al 2013), PD (Gerlach et al 2006, Gotz et al 2004), epilepsy (Tombini et al 
2013), stroke (Carbonell & Rama 2007) and MS (Hametner et al 2013, Williams et al 
2012). Increased concentrations of iron participate in the Fenton Reaction (Fe2+ + H2O2 
→ Fe3+ + OH• + OH-) with the formation of hydroxyl radicals and anions (Mills et al 
2010). Under physiological conditions, ROS are regulated by antioxidant mechanisms 
that exist in cells to prevent oxidative damage to lipids, proteins and DNA. Antioxidants 
include catalase and glutathione, which convert H2O2 to water (Lillig et al 2008). 
However, in neurodegenerative diseases it is believed that either an increase in ROS 
production (as a result of iron accumulation), an impairment/overload of antioxidant 
defence mechanisms, or a combination of the two leads to iron induced oxidative 




Consequently regulating iron homeostasis in the brain is vitally important and is 
partially dependent on the BBB, which restricts the exchange of iron and iron related 
proteins into the CNS thereby controlling the local environment. Iron homeostasis is 
also controlled by a series of proteins that are expressed in varying amounts depending 
on the cell type, brain region and iron status. TFR1 and DMT1 are responsible for iron 
uptake into cells, while iron is imported into the mitochondria by mitoferrin 1 and/or 
mitoferrin 2 iron importers. FT heavy (H) and light (L) chains store iron, while FPT is 
responsible for exporting iron out of cells. To date, the precise mechanisms of iron 
homeostasis in the brain are not fully understood. Regulation of iron is largely 
controlled by IRPs which control mRNA translation of specific proteins, including 
TFR1, DMT1, FT and FPT. IRPs are capable of sensing iron levels within the CNS 
environment, when iron concentration is reduced IRPs bind to stem loops, known as 
IREs, on mRNAs encoding the regulatory proteins. Binding IRP to IREs located in the 
5’ UTR region of a gene, for example FT and FPT, prevents mRNA stabilisation and 
translation. Whereas binding of IRPs to IREs located at the 3’ UTR region, eg TRF1 
and DMT1, stabilises mRNA resulting in translation and an increased TFR1 and DMT1 
expression, leading to iron uptake into cells, and a decrease in iron export. When iron is 
abundant, IRPs no longer actively bind to IREs thereby stabilising FT and FPT mRNA 
expression and translation and downregulating TFR1 and DMT1 synthesis leading to an 
increase in storage and export of iron (Crichton et al 2011).  
 
Iron accumulation is variable and not uniform across the CNS. In MS, evidence of iron 
accumulation has been identified in deep grey matter structures of the brain including 
the thalamus, caudate and putamen (LeVine et al 2013), while accumulation in the WM 
is associated with areas of inflammation, in particular around venules (Brass et al 
2006a, Brass et al 2006b, Ge et al 2007, Khalil et al 2009, Khalil et al 2011a, Zhang et 
al 2007). A dysregulation of the IRP/IRE regulatory system, resulting in enhanced iron 
storage, has been suggested to increase deposition of iron in vessels of MS brain tissue 
(Williams et al 2012). Whatever the cause of iron accumulation in MS, it is known to 
contribute to disease pathogenesis by amplifying the activated state of microglia thereby 
increasing the production of proinflammatory cytokines (Williams et al 2012). 
Intracellular iron accumulation can also promote mitochondrial dysfunction, whilst 
insufficient management of iron can lead to the production of ROS resulting in 
oxidative stress (Hametner et al 2013, Khalil et al 2011b, Williams et al 2012) leading 
to lipid peroxidation, additional mitochondrial dysfunction, increase in intracellular 
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free-calcium concentration, and the ability to cause cell dysfunction and death 
(Halliwell 2006).  
 
Increasing evidence is beginning to indicate the potential roles of astrocytes in MS 
(Black et al 2010, Brosnan & Raine 2013, Holley et al 2003, Nair et al 2008, Rejdak et 
al 2007, Williams et al 2007), yet the exact role(s) astrocytes play in the pathogenesis of 
the disease remain unknown.  The microarray analysis in chapter 3 identified significant 
upregulation of MT1G, MT1X and MT2A gene expression in MS NAWM astrocytes in 
comparison to control WM. MTs are low molecular weight, cysteine rich proteins 
capable of binding metals, in particular zinc, but also other transition metal such as 
copper, iron, lead etc., (Hidalgo et al 2001). In response to injury or pathology within 
the CNS, increased amounts of MT-I and MT-II, (MT-I+II) mRNA and protein are 
induced (Hidalgo et al 2001, Penkowa et al 2001b). In the CNS, MT-I+II proteins are 
primarily associated with astrocytes, with increased expression forming part of the 
inflammatory and defence responses associated with many neurodegenerative diseases 
(Chung et al 2004, Espejo et al 2005, Penkowa et al 2003a, Penkowa et al 2003b, 
Penkowa et al 2005). Only one study to date has investigated MT-I+II protein 
expression by IHC in MS, with the majority of preceding work on MT expression 
carried out in EAE (Espejo et al 2001, Espejo et al 2005, Penkowa et al 2001a, 
Penkowa & Hidalgo 2001). In support of the current study’s identification of MT-I+II+ 
astrocytes, both of these proteins have previously been linked to astrocytes and 
activated macrophages in MS active lesions, and a noticeably increased expression with 
astrocytes in IA lesions (Penkowa et al 2003c). Furthermore, a transcriptomic study on 
lesions from four individuals with MS (two acute lesions, two silent lesions) confirmed 
this increase in MT gene expression in both lesion types  (Lock et al 2002).  
 
Astrocytes support CNS recovery by secreting antioxidants, growth factors and trophic 
factors, possibly reflecting their increased numbers in IA lesions. Therefore increased 
MT-I+II expression in IA lesions may play an important role in the remission of MS 
(Penkowa et al 2003c). Expression is prolonged even in areas that are relatively 
dormant in active disease, suggesting the same mechanism may occur in the NAWM 
where disease pathology is subtle. Increased astrocytic expression of MT-I+II in 
NAWM may be an attempt to prevent the spread of ROS and ultimately oxidative stress 
that contribute to disease progression. However, it must be acknowledged that our IHC 
findings were not quantitative and multiple attempts to quantify MT expression in MS 
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NAWM by WB proved unsuccessful, most likely reflecting the technical issues and 
antibody supplier as discussed in this chapter.  Nonetheless, the expression of MT in 
EAE has been shown to peak at the highest clinical score and remain elevated 
throughout recovery (Espejo et al 2005). Again, this implies that MT-I+II protein 
expression contributes to disease pathogenesis possibly by downregulating 
inflammation, oxidative stress, demyelination and axonal injury, and/or by upregulating 
repair processes including growth factors and neurotrophic factors.   
 
The precise function of MT-I+II is currently unknown. The literature suggests that MT-
I+II act intracellularly, with increased MT expression in the cytoplasm of astrocytes 
observed following neuronal injury (Chung et al 2004). MT-I+II enable astrocytes to 
handle free radicals and ROS (Chung et al 2008b) and their expression is known to help 
regulate metal homeostasis and promote neuroregeneration (Hidalgo et al 2001). 
Increasing evidence demonstrates MT-I+II may also have extracellular effects on 
neuronal regeneration: injured neuronal cultures treated with MT-I+II display 
regenerative capabilities (Chung et al 2003, Kohler et al 2003). Administered MT-II 
protein in vivo has also been shown to improve clinical symptoms of EAE (Penkowa & 
Hidalgo 2000, Penkowa & Hidalgo 2003) while animals lacking MT-I+II expression go 
on to develop a more severe disease course (Penkowa & Hidalgo 2001). In addition to 
the release of MT-I+II, astrocytes produce an array of other protective proteins in 
response to injury including increased expression of S100B (Businaro et al 2006) (refer 
to Chapter 2). Astrocytes respond to insult/injury with changes in their morphology, 
phenotype and gene expression (West et al 2008), suggesting they are able to respond to 
and reduce the detrimental environment that occurs in MS lesions and in areas 
immediately surrounding lesions, thereby increasing neuronal and oligodendrocyte 
survival supporting remyelination and regeneration (Chung et al 2004, Chung et al 
2008a).  
 
It has been suggested that MT-I+II may promote astrocyte proliferation, or act directly 
as an antioxidant, or indirectly by decreasing oxidative stress by reducing ROS 
production by activated microglia/macrophage (Figure 5.31) (Penkowa 2006). The 
increase in MT expression by astrocytes has been shown to reduce the microglial 
response, reduce neuronal apoptosis and inhibit the apoptosis of autoreactive T cells, 
which are known to be detrimental in MS pathogenesis. These studies, however, failed 




Figure 5.31 Metallothionein-I+II actions in the brain                                                                   
During pathology an increased MT-I+II expression by astrocytes leads to the inhibition 
of apoptosis, oxidative stress, inflammation and cytokine release with downstream 
actions. MT-I+II are involved in anti-inflammatory, antioxidant and anti-apoptotic 
pathways that lead to neuroregeneration, angiogenesis and repair. Figure adapted from 
Penkowa 2006. 
Key: BVEC: blood vessel endothelial cells. 
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recognised through more recent studies (Brosnan & Raine 2013, Nash et al 2011b, 
Sofroniew & Vinters 2010, Williams et al 2007).  
 
Clearly achieving a balance of the astrocyte expression of MT and the beneficial anti-
inflammatory, antioxidant and anti-apoptotic properties of these proteins is crucial.  
However, due to MS heterogeneity and the nature and plasticity of astrocytes, a current 
lack of understanding of MT regulation and its role in MS disease is evident, hence a 
need for further work to elucidate the detailed mechanisms and role in MS are essential.  
 
In general, the physiological level of iron present in astrocytes is relatively low; 
10nmol/mg of cellular protein (Hoepken et al 2004) consistent with the majority of 
research reporting astrocytes in vivo lacking the expression of TF or TFR (Leitner & 
Connor 2012). However, one report demonstrated TF expression associated with 
GFAP+ astrocytes in the aged human brain (Connor et al 1990). Despite the proposed 
lack of TF and TFR expression by astrocytes in vivo, continuing research has 
investigated expression of TFRs by astrocytes in vitro, and their involvement in iron 
metabolism in the brain. This may be a factor that has confounded the understanding of 
iron metabolism within the human brain. 
 
Astrocytes in vitro are capable of binding TF-bound iron (Hoepken et al 2004, Qian et 
al 2000, Qian et al 1999) through their expression of TFR, but also synthesise and 
secrete TF (Espinosa de los Monteros et al 1990), as well as storing large amounts of 
iron as FT (Dringen et al 2007).  Due to the lack of convincing in vivo research 
demonstrating TF and TFR expression by astrocytes it has been suggested  that most 
iron uptake by astrocytes is not bound to TF, with evidence demonstrating that the main 
mechanism of iron uptake in astrocytes involving DMT-1 expression on astrocyte end 
feet (Burdo et al 2003, Dringen et al 2007). However in the current study we failed to 
identify significant expression of DMT-1, instead a significant increase in the iron 
transporter TF was identified in MS NAWM astrocytes.  
 
Whatever the uptake mechanism of iron into astrocytes, iron metabolism involves Cp, a 
ferroxidase enzyme, and FPT, the only known iron exporter in mammalian cells 
(Crichton et al 2011). Cp expression by astrocytes allows the oxidation of ferrous iron 
that enters the brain at the abluminal side of the BBB, while FPT allows the exportation 
of ferric iron from the astrocyte into the extracellular space where it can become bound 
236 
 
to TF in the brain and be taken up by TFR1 expressing cells (Moos et al 2007, Rouault 
& Cooperman 2006). However, in the current microarray study mRNA levels of Cp and 
FPT were not significantly differentially expressed in astrocytes isolated from MS 
NAWM, suggesting the cells attempt to prevent the release of free iron into the CNS. In 
contrast, the current microarray study identified both TF and FTL mRNA expression 
was increased in isolated astrocytes from MS NAWM, and the astrocytic association of 
these candidates with GFAP+ astrocytes demonstrated by IHC. Therefore, based on 
these findings it can be suggested that in response to the depletion of oligodendrocytes 
in MS lesions and the resulting increase in local iron levels, astrocytes in the 
surrounding NAWM increase expression of TF and FTL. Oligodendrocytes are the 
major cell type in the brain that express TF and FT (Hulet et al 1999, Leitner & Connor 
2012). Yet, within MS lesions the loss of oligodendrocytes would lead to a decrease in 
FT causing increased levels of free iron within the CNS (Bagnato et al 2011, LeVine et 
al 1999, van Rensburg et al 2012). Furthermore, oligodendrocyte depletion would result 
in the decreased expression of TF, which is essential in OPC differentiation and myelin 
formation (Hulet et al 1999, Izawa et al 2010b). Increased TF expression in astrocytes, 
would enable the transport of excess iron to OPC, supporting their differentiation into 
mature oligodendrocytes capable of remyelinating areas of demyelination (Hulet et al 
1999). An increase in FTL expression by NAWM astrocytes could also sequester excess 
iron, with FT known to be more efficient at accommodating iron than TF (Harrison & 
Arosio 1996), thereby limiting further ROS production and reducing oxidative stress. 
An increase in FT expression in astrocytes has previously been seen as a response to 
increasing iron toxicity (Izawa et al 2010a). This proposed protective role of NAWM 
astrocytes is also complemented by the astrocyte’s increased expression of antioxidants 
including MT as discussed earlier (Pedersen et al 2009). 
 
Significant upregulation in the expression of FTL in the current microarray study is 
supported by evidence that FTL is the predominant FT subtype in astrocytes in the rat 
brain (Han et al 2002). In vitro studies have shown that FTL has a greater capacity to 
store iron than FTH (Levi et al 1994) which functions as the major ferroxidase 
component of FT. Therefore, in response to the iron accumulation associated with MS, 
astrocytes may increase their expression of FTL to offer an alternative to 
oligodendrocyte storage of iron. The synthesis of FT is controlled by both 
transcriptional and post transcriptional mechanisms, with FT mRNA translation 
increased when iron levels are abundant and repressed when iron levels are depleted 
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(Orino et al 2001). Additional work on the cellular expression, distribution and 
regulation of IRPs in MS is required to identify whether there is a dysregulation of the 
system with respect to iron accumulation in the brain resulting in disease progression. 
To date, very few studies investigating IRPs in the brain have been reported (Connor et 
al 2001). However, improving understanding of IRPs in relation to iron homeostasis in 
the brain is fundamental to understand the impact of dysregulation of these processes in 
neurological diseases, including MS.  
 
Specific cellular responses to oxidative stress are likely the result of several processes. 
For example, at the time of an insult the cellular outcome may depend on FT levels in 
the cell, level of ascorbate (shown to enhance FT translation) and the availability of 
other antioxidant mechanisms such as glutathione, catalase, or MT (Orino et al 2001). 
The current microarray study identified the upregulation of FTL by NAWM astrocytes, 
likely in response to oxidative stress within the WML. Over a period of time this FTL 
expression by astrocytes, as well as other cell types, becomes insufficient at preventing 
ROS formation, thereby contributing to lesion spread. Alternatively, FTL induction by 
astrocytes may be one component of a larger multi-cellular, multi-component anti-
oxidant response, with ultimate limits to their buffering capacity.  Conflicting literature 
on FT expression in response to oxidative insults is probably due to cell-type specific 
responses. As already identified, oligodendrocytes are primarily associated with FT and 
iron storage, yet contain limited antioxidant mechanisms, thereby making these cells 
more susceptible to oxidative damage (Juurlink et al 1998). In comparison astrocytes, 
which generally do not store iron, readily metabolise and traffic iron between cells 
(Dringen et al 2007) while containing high levels of antioxidants including glutathione, 
catalase and MT (Liddell et al 2006a, Liddell et al 2006b, Pedersen et al 2009). 
Consequently astrocytes are highly resistant to ROS and metal induced toxicity in the 
brain. 
 
Further work into the long-term consequences of iron accumulation in astrocytes in MS 
NAWM is required. Studies using genetically modified mice suggest that the sustained 
upregulation of FT in astrocytes may be toxic, although precise mechanisms have yet to 
be identified (Li et al 2009). FT-bound iron in astrocytes in the ageing Cp KO mouse 
are associated with cell loss (Jeong & David 2006). Investigating the effect of 
increasing and prolonged iron accumulation in astrocytes in MS and their subsequent 
expression of antioxidant molecules would enable the extent of the astrocytes’ ability to 
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maintain a neuroprotective role in response to iron accumulation in MS to be 
determined.  
 
During iron accumulation, astrocytes are stimulated to produce FT (Regan et al 2002) 
increasing iron storage in the cells, while TFR is downregulated reducing TF-bound 
iron uptake (Hoepken et al 2004). However, from the current microarray study both TF 
and FTL expression was increased by astrocytes isolated from MS patients, suggesting 
that in response to iron accumulation associated with the disease, astrocytes not only 
increase their iron storage capacity but also transport mechanisms to sequester excess 
iron. It has been suggested that astrocytes in vivo do not express TFR (Leitner & 
Connor 2012), therefore further work is required to demonstrate the expression of TFR 
by astrocytes in MS NAWM as a means of iron entry into the cell. Otherwise, an 
alternative as yet unidentified receptor for TF-bound iron may account for the uptake 
and entry of TF-bound iron into these cells. Alternatively, astrocytes may express TF as 
a means of transporting iron within the cell itself or as a storage molecule for iron which 
has been imported into the cell by other means, such as by DMT-1 or other transporter 
ligands. However, DMT-1 was not significantly expressed in WM astrocytes in the 
current study, reinforcing the possibility that unknown specialised iron regulatory 
mechanism(s) may be occurring in the brain.  
5.5.1.1 Conclusion 
In conclusion, the significant increased mRNA expression of TF, FTL and the different 
isoforms of MT in MS NAWM astrocytes in comparison to control astrocytes was not 
validated in additional qPCR studies. Despite this, through IHC the candidate genes 
showed colocalisation with GFAP+ astrocytes. Even with the lack of validating 
quantitative investigations, the significance of the initial microarray findings and 
corroboration from current literature helps to support the hypothesis that astrocytes in 
MS NAWM are neuroprotective, both in terms of their role in regulating iron 
homeostasis in the CNS and in reducing the spread of oxidative damage associated with 
the disease (Figure 5.32). Expansion of the current study to investigate more MS patient 
samples along with additional iron regulatory proteins would add further weight to these 
findings. This study highlights the complexity and current lack of understanding of iron 
regulation within the brain. Conflicting in vitro and in vivo published research with 
respects to the role of astrocytes in iron regulation adds to this complexity, which must 
be challenged if a better understanding of disease processes with regard to iron and 




Figure 5.32 The proposed role of astrocytes in regulating iron load and oxidative 
stress in MS                                                                                                                                    
An increase in iron load in the CNS as a result of oligodendrocyte damage in MS 
lesions leads to an increased release of iron and subsequent increase in oxidative stress 
and neurotoxicity, 1-4 (red). Astrocytes in NAWM increase their expression of iron 
regulatory and antioxidant genes/proteins to decrease iron load, oxidative stress and 
neurotoxicity, acting in a neuroprotective manner 1-4 (blue). 
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5.5.2 The current advantages and disadvantages of protein identification in 
neurological disease using MALDI-MS 
To date a very limited number of studies have used MALDI-MS to investigate the 
proteome of MS, and no MALDI-MSI study has been conducted on tissue derived from 
MS patients. Although the potential for studying human neurological disease using 
MALDI-MSI is evident from the investigations on peptide and protein expression in 
animal models of PD (Hanrieder et al 2012, Skold et al 2006, Stauber et al 2008) and 
AD (Rohner et al 2005, Stoeckli et al 2006, Stoeckli et al 2002) the use of this 
technique in neuroscience particularly in relation to human CNS tissue is very limited 
(Hanrieder et al 2013b). Only one study to our knowledge has shown the use of 
MALDI-MSI to investigate the protein expression profile of human spinal cord to gain 
an insight into the molecular mechanisms underlying ALS (Hanrieder et al 2013a). 
 
In the current study MALDI-MSP was employed to determine the expression and 
abundance of intact proteins encoded by the candidate genes identified in the microarray 
study, in MS NAWM compared to control WM samples. While MALDI-MSI was used 
to investigate the molecular distribution of trypsin-digested peptides in MS NAWM 
compared to control WM.   
 
Profiling intact proteins in whole tissue sections was carried out for a number of 
reasons: firstly in order to gain an initial insight into the intact protein profile in MS 
NAWM and control WM, secondly, MSP of intact proteins generated data more quickly 
than MSI, which required a considerable amount of instrument time using the Voyager 
De Pro MALDI-TOF to acquire full images of brains sections (~2 days per section). In 
order to help verify the intact proteins identified through MSP, MSI of digested peptides 
was performed in parallel using the Q-Star Pulsar/Q-TOF mass spectrometer. MSI using 
the Q-Star Pulsar/Q-TOF mass spectrometer acquired images at a faster rate (~4 hours 
per section) while also allowing for the distribution of peptides to be distinguished with 
respect to histological features. Overall the two approaches, MSP of intact proteins and 
MSI of digested peptides was designed to complement one another working with the 
currently available instrumentation, resources and time permitted. Additional work is 
needed to confirm exact protein identification using MALDI.   
 
A factor to address in the current study was the choice of matrix and the method of 
matrix application employed. In any MALDI experiment, the choice of matrix depends 
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largely on the targeted substance. A recent study showed that the application of FA on a 
range of tissue samples allowed the detection of proteins upto 125 kDa when 
implementing MALDI-MS (Mainini et al 2013). From the optimisation studies carried 
out investigating varying matrices, along with the desire to acquire high molecular 
weight protein profiles due to our candidate proteins ranging from 6 kDa (MT) to 75 
kDa (TF), FA was chosen as the matrix for use in the current study for MALDI-MSP of 
intact proteins. There are limitations in the different matrices used in MALDI including 
the crystal size, reproducibility, interfering matrix clusters, mass range and signal 
quality (Hanrieder et al 2013b). With FA manual spotting and spraying led to huge 
variability in crystal size and analyte extraction efficiency, resulting in fluctuating signal 
quality/intensity from the analysed samples. However, when using the TM sprayer, 
which provided heat to the matrix solution to accelerate adsorption into the tissue, as 
well as a controlled flow of dry air to focus the spray and control drying time the 
matrix/analyte co-crystallisation proved to be more uniform and homogenous compared 
to manual spotting, which improved reproducibility and signal quality. Worth noting 
despite published literature on the proposed capabilities of profiling proteins up to 125 
kDa and imaging proteins upto 70 kDa with the use of FA (Mainini et al 2013), none of 
the samples investigated in this study using the instrumentation and methods described 
in this chapter detected signals above 25 kDa, a common drawback in many MALDI-
MS systems (Wenzel et al 2005). This has previously been shown to be overcome by 
altering the matrix deposition method from spraying to spotting with proteins upto 200 
kDa being detected in this way (Chaurand et al 2002). Yet with the characteristics of 
FA as a matrix this was shown not to be possible. High molecular weight proteins have 
been identified as failing to reach common mass spectrometry detectors resulting in an 
overall poor representation of high molecular weight species. This has shown to be 
helped in other studies by using an alternative cryogenic detector (Frank et al 1999). 
Clearly, additional work is needed to elucidate exact protein identification using 
MALDI.   
   
To move forward with the current mass spectrometry work would involve specifically 
identifying particular peptide peaks using fragmentation of candidate peptides via 
MS/MS. MS/MS is a routinely used method for peptide sequencing and could be used 
in parallel with MALDI to support protein identification from the in situ tissue sample 
surface. Ions are produced during MS/MS by the breaking of amide bonds along the 
backbone of the peptide. The mass differences between these fragmented ions in the 
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spectra are representative of the amino acid residues within the peptide. Subsequent 
peptide sequences and MS/MS spectra can be entered into bioinformatics programmes 
i.e. MASCOT, allowing for protein identification to be made through searches 
performed against protein databases such as Swiss-Prot and UniProt KB.  For example, 
the peptide ion at 1829.80 Da detected in the WM of all the cases investigated could be 
subjected to MS/MS in order to verify the amino acid sequence provided by the 
database when carrying out the peptide mass fingerprinting, leading to the identification 
of MBP; this in turn would confirm the initial MBP identification. MS/MS could 
therefore be used to confirm the identification of species discriminating the MS NAWM 
and control WM cases. However, the current study was unsuccessful at identifying 
discriminative proteins/peptides between MS and control cases. It is thought that to 
improve statistical significance, additional samples, or technical repeats are needed to 
try and identify any differences between the two groups. As seen in other techniques, 
biomarker discovery in MALDI is hindered by the presence of abundant proteins, which 
may prevent detection of much less abundant species (typically those of interest). For 
example, due to the heterogeneity of whole tissue sections, the expression of candidate 
proteins may be masked by more dominant proteins such as MBP, which would be 
highly abundant in MS NAWM and control WM. 
Evidently a need for the implementation of LCM-ed based techniques to isolate cells or 
ROI from whole tissue sections prior to MALDI-MS would be beneficial at associating 
protein expression to cell type, as was done in the original microarray study 
investigating the astrocyte transcriptome. LCM coupled with MALDI-MS has been 
used to investigate biomolecules specific to cancer cells compared to non-cancerous 
cells. One study identified differences in biomolecules between LCM-ed invasive 
mammary carcinoma and control human breast epithelium cells, (Sanders et al 2008, 
Xu et al 2002). Also in lung cancer, squamous cell carcinoma/adenocarcinoma cells 
were isolated from tissue using LCM and specific biomolecules identified through 
MALDI-MS to differentiate between the two cancers (Bhattacharya et al 2003). With 
this in mind, MALDI-MS could be used to extend the current study to identify 
particular protein peaks that are indicative of isolated MS NAWM astrocytes compared 
to isolated control WM that could be used as a fingerprint that identifies the astrocyte’s 
role in MS development.  
Overall, from the current mass spectrometry work consistent, statistically significant 
differences in the protein profile of MS NAWM and control WM cases used in this 
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study based on the conditions/methods and instrumentation documented in this chapter 
were not detected. That said, with further method development and increasing the 
number of samples investigated, the method of MALDI-MSP and -MSI are promising 
tools for proteomic investigations that have many advantages over traditional proteomic 
approaches such as WB and IHC.  
 
Development of soft ionisation techniques, such as MALDI has enabled the detection 
and analysis of large biomolecules such as peptides and proteins by mass spectrometry. 
Proteomics has developed significantly in the area of mass spectrometry due to its 
capacity to provide information on the protein profile of biological samples, such as 
body fluids and tissue biopsies (Aebersold & Mann 2003, Domon & Aebersold 2006) 
Studies to date investigating the proteomics of MS using mass spectrometry have 
concentrated mainly on patient serum samples (Pieragostino et al 2010) or CSF samples 
(Liu et al 2009, Rajalahti et al 2010, Stoop et al 2008). Due to the heterogeneity of MS 
and complexity of disease mechanisms, there is probably not one specific gene, or 
protein that can act as a biomarker for the disease. However MS patients may express 
different peptides/proteins in comparison to healthy control subjects, which could be 
exploited as a potential biomarker of disease (Stoop et al 2008). Analysis of the proteins 
in CSF samples from patients enables the disease activity to be monitored through life, 
which may help in identifying disease pathways as well as in identifying potential 
biomarkers of disease (Stoop et al 2008). The limitations with using CSF to identify 
peptides/proteins associated with MS is that other factors could be affecting the 
composition of CSF that are not directly related to the disease process, these may be a 
result of some other pathology or therapy and not directly related to MS. Protein 
profiling studies on CSF are carried out using MALDI-TOF-MS with the technique 
used in an array of diseases to identify protein expression without the need for tissue 
localisation (Mikkat et al 2010).  
 
MALDI-TOF-MS studies investigating the proteome of CSF from MS patients 
identified specific proteins compared with CSF taken from patients with other 
neurological disease (Stoop et al 2008). Another MALDI-TOF-MS study detected MS 
specific proteins including a variety of cytokines, chemokines and hormones in CSF 
samples from MS patients compared to control patients (Rajalahti et al 2010). This 
study was the first to use a novel multivariative data modelling approach of sample 
grouping using m/z values collated from the overlap of MALDI peaks, enabling 
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identification patterns that distinguished between MS patients and controls. Further 
work is needed to identify particular proteins/biomarkers of interest found in this study. 
Investigating peptides/proteins in tissue using MALDI-MSP and -MSI is advantageous 
because of the ability to investigate multiple peptides/proteins without the need for 
antibodies as in IHC and WB (Elkabes & Li 2007), while MALDI-MSI maintains 
spatial information within the tissue section. IHC and WB have a limited throughput 
only allowing the detection of one or two proteins per sample, and quantification can 
pose challenging with regards to antibody signal intensity, all fundamental flaws in such 
proteomic techniques which is overcome by using MALDI-MS. Yet to date, no study 
has used MALDI-MSP or -MSI directly on human MS tissue samples due to a number 
of limiting factors. Identifying human material suitable for MALDI-MSP and -MSI is 
difficult due to the uncontrollable practical issues that affect sample quality, a major 
factor determining the success of MALDI-MS. These limiting factors include the 
method of tissue collection and storage, PMI, along with the inevitable inter patient 
variability (Hanrieder et al 2013b).  In a neurobiological setting the use of MALDI-MSI 
is somewhat limited, mainly due to the limited access to the technology, difficulty in 
sample preparation and huge workload to achieve a generally low throughput of 
meaningful data (Hanrieder et al 2013b). In a typical MALDI-MSI study, initial work 
needs to be carried out to optimise and standardise methods for sample preparation, 
choice of suitable matrix, dependant on intended outcome, along with the matrix 
deposition method. With the ability to investigate  hundreds of potential 
peptides/proteins by MALDI-MSI the balance regarding the appropriate number of 
biological and technical repeats needs to be considered and the interpretation of the vast 
array of datasets taken into account. These issues are currently the main focus of 
MALDI-MSI research, with a desire to obtain a more standardised uniform approach to 
allow study comparability. As technology is improving with increasing resolution and 
sensitivity, the implementation of MALDI-MSI to investigate single cell types will be 
made possible. Nonetheless, to date the majority of MADLI-MS studies in neurological 
research have been concluded on whole brain tissue (Hanrieder et al 2013b) with the 
technique still relatively in it’s infancy within this field.  
5.5.2.1 Conclusion 
As a result of carrying out the current MALDI study in reflection of the study aims no 
specific iron regulatory proteins were detected, however there is huge potential in the 
technique especially in relation to MSI with many advantages over the current 
proteomic approaches as discussed. Yet with any developing technologies, a lot of 
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challenges are put forward that need to be addressed in order for MALDI-MS to be 
regularly used in the biological setting, not just in scientific research but also clinically. 
A need for better sample preparation is apparent, standardised protocols according to 
the tissue, molecule, and instrumentation need to be addressed if the technology is to be 
implemented more routinely. As well, the overall workflow from the preparation of 
samples, data acquisition, through to data analysis needs to be more streamlined. The 
development of analysis software that is reliable and able to reduce and filter the vast 
array of MSI data while not jeopardising results is a necessity. A step forward for 
research using MALDI-MS would be to develop databases in which not just 
standardised protocols are stored but also raw data is held, made accessible to 
researchers and clinicians, as is done for transcriptomic microarray data with the gene 
expression omnibus (GEO), a database repository of gene expression data. With 
continuing development, MALDI-MSP and -MSI has the ability to uncover an array of 
proteomic information with regards to diseased tissue compared to healthy tissue, which 
could unveil potential disease mechanisms and processes faster than any traditional 
pathological investigation.  
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6 CHAPTER 6 




MS is a chronic, neuroinflammatory, demyelinating disease of the CNS characterised by 
the infiltration of inflammatory cells, myelin loss, axonal injury and astrogliosis. The 
current project aimed to define the specific astroglial changes that exist in MS NAWM 
compared to control WM that are contributing to the overall WM pathology in MS. This 
involved analysing astrocytes in MS NAWM, areas of WM from which pathology is 
apparently absent, to determine whether specific gene expression and proteomic 
changes exist, which either support lesion development and disease progression or 
inhibit tissue damage, lesion expansion and disease development. In order to establish 
an understanding of astrocyte behaviour and function(s) in MS, initially this project 
characterised the astrocyte phenotype in MS by immunohistologically investigating a 
panel of established astrocyte markers. The study also developed a robust method to 
isolate distinct glial cells from PM CNS tissue combining rapid IHC with LCM to 
enable enriched populations of specific glia to be investigated in downstream 
transcriptomic and proteomic studies. Using this technique, the study employed 
microarray technology to identify significantly differentially expressed genes in 
astrocytes from MS NAWM compared to control WM astrocytes, thereby contributing 
to understanding of the role of astrocytes in MS pathology. The final part of the study 
involved a four-pronged approach to attempt to validate the microarray findings, 
applying qPCR, IHC, WB and MALDI-MS techniques to explore the potential 
neuroprotective role of astrocytes in the regulation of iron and reduction of oxidative 
stress associated with MS.  
Previous studies have discussed the complexity of astrocytes in MS (Brosnan & Raine 
2013, Nair et al 2008, Williams et al 2007) with much emphasis on their dual function: 
on the one hand astrocytes have the ability to enhance immune responses, increase BBB 
permeability and inhibit myelin repair; while on the other these glia have the ability to 
be neuroprotective, supporting oligodendrocyte remyelination and axonal regeneration. 
Astrocytes are dynamic cells capable of adapting to their environment by becoming 
reactive and undergoing astrogliosis with changes in their molecular expression, 
phenotype and function in response to injury or insult (Sofroniew & Vinters 2010). 
Previous studies have identified the upregulation of GFAP within MS lesions as a 
hallmark of reactive astrogliosis, which was also apparent in the current study. Similarly 
an increased expression of S100B, an established marker for astrocyte metabolism and 
suggested indicator of activated astrocytes, was also apparent within MS lesions 
(Rothermundt et al 2003, Sen & Belli 2007). Despite the majority of studies reporting a 
dysregulation of glutamate signalling in MS lesion as indicated by a decreased 
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expression of glutamate transporters and regulatory enzymes (Pampliega et al 2008, 
Vercellino et al 2007). In contrast, in the current study a non-significant increased 
expression of the glutamate transporters EAAT1 and EAAT2 and regulatory enzyme 
GS was identified, despite contrasting qualitative findings. However, overall differences 
in astrocyte morphology and phenotype in MS are clearly demonstrated by each marker, 
indicating that astrocytes consist of a heterogeneous population of cells with many 
different subclasses and possible functions. The need for a specific antibody that labels 
all astrocytes is vital, however, a pan-astrocyte marker is yet to be established, but is 
vitally important to enable the true identity of the astrocyte role to be defined.  
The ability to isolate enriched, specific cell types from human tissue is fundamental to 
defining a particular cell’s role in disease pathogenesis. LCM allows for the accurate 
isolation of a particular ROI or cell(s) from tissue sections and has been commonly used 
to investigate gene expression profiles in both human and animal models of 
neurological disease (Boone et al 2013, Chu et al 2009, Ferraiuolo et al 2011, Pietersen 
et al 2009, Simpson et al 2011, Torres-Munoz et al 2004). With respect to MS, 
currently LCM has only been used to isolate ROI and has not been employed to 
rigorously investigate transcriptomic changes in specific cell types. A combined rapid 
immuno-LCM method was developed in the current study to isolate enriched glial cell 
populations suitable for transcriptomic and proteomic investigations, the enrichment 
being confirmed by RT-PCR. There are many advantages associated with working with 
enriched cell populations over the use of heterogeneous cell populations present in 
whole tissue extracts. Studies on whole tissue may mask important pathological 
mechanisms and prevent mechanisms/functions being linked to specific cell types 
(Waller et al 2012). However it should be noted that not all PM human tissue can be 
considered suitable for LCM to isolate ROI/cells for transcriptomic studies, in particular 
relating to the unavoidable poor RNA quality of human PM material. Factors that have 
been shown to affect RNA integrity include the agonal state of the patient, PMI and 
brain pH (Harrison et al 1991, Kingsbury et al 1995). The additional steps involving 
immunostaining tissue sections and the LCM procedure itself can further affect the 
integrity of RNA (Waller et al 2012). Despite the potential limitations of immuno-LCM 
on PM CNS tissue, the downstream studies completed on isolated cells from human 
tissue are more complementary than working with cell lines or animal models that lack 
full replication of  human disease. As long as strict guidelines are in place for selecting 
suitable cases, then immuno-LCM could pave the way in identifying the role of a 
variety of cells in a range of neurodegenerative disorders. 
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Microarray analysis enables changes in functional pathways and molecular functions to 
be determined between disease and control samples. The majority of current MS 
microarray studies have been completed on either whole tissue (Dutta & Trapp 2010), 
EAE models or PBMC isolated from MS patients. To date, only two microarray studies 
of MS have utilised the use of LCM to isolate ROI prior to microarray analysis (Cunnea 
et al 2010, Mycko et al 2012). In the current study astrocytes were isolated from MS 
NAWM and control WM using immuno-LCM and microarray analysis to interrogate 
changes in the astrocyte transcriptome. Significant differentially expressed genes in 
NAWM astrocytes were associated with the immune response, cell signaling, 
cytoskeletal changes and in the regulation of homeostasis, all classical roles of 
astrocytes (Sofroniew & Vinters 2010). The most significantly upregulated genes in MS 
NAWM astrocytes were related to the regulation of iron and oxidative stress, and 
included the differential expression of FT, TF and varying isoforms of MT, suggesting 
the hypothesis that astrocytes maintain homeostasis in the NAWM by responding to 
increasing iron levels and subsequent oxidative stress (Bagnato et al 2011, Lassmann et 
al 2012). The upregulated expression of iron regulatory mechanisms is most likely one 
aspect of the astrocyte neuroprotective response against accumulating damage within 
MS lesions, whereby astrocytes adapt to protect the NAWM from widespread iron 
induced oxidative damage. Dual labelling IHC confirmed colocalisation of FT, TF and 
MT with GFAP+ astrocytes. Previous studies have shown that MT (Hidalgo et al 2001, 
Penkowa et al 2001a), FT (Dringen et al 2007) and to an extent TF (Connor et al 1990, 
Espinosa de los Monteros et al 1990) are increased in astrocytes in response to insult. 
The increased expression of iron regulatory genes identified in the microarray study was 
not validated in an additional cohort of patients by qPCR. This likely reflects both 
patient variation and limited access to high quality NAWM tissue. The criteria for case 
selection for the validation cohort was based on the histological profile of each case and 
did not follow as stringent criteria as in the original microarray study: measures for 
controlling for age, sex, anatomical location as well as the RNA integrity of each 
sample were not as strictly observed. These cases used in this study had a well-
established disease phenotype, but had no detailed patient history of drug therapy, or 
knowledge of disease activity at time of death. PM samples provide a single snap shot 
of the individuals’ disease, but do not provide an insight into the disease in the years 
before death. Without a thorough history of MRI brain scans for each individual patient 
and regular blood/CSF examinations throughout life, the limitations of working with 
PM CNS material will always be apparent.  Nonetheless, as identified throughout this 
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thesis, the clear advantages of working with this valuable resource are enormous, which 
when working with cell lines and animal models will never be able to fully replicate 
actual human disease mechanisms or processes. 
To determine protein expression quantitatively, WB was employed but failed to identify 
any significant differences in the expression levels of FTL in MS NAWM and control 
WM, likely reflecting the cohort size and human variation, as already discussed. MT 
WB proved very challenging with variable, unreliable results despite numerous attempts 
of optimisation. Obtaining an alternative MT antibody would be the next step, or 
carrying out immunoprecipitation using the MT antibody to isolate the protein from the 
whole tissue protein extracts, prior to analysis via gel electrophoresis, mass 
spectrometry or WB could help. WB was performed on whole tissue extracts, therefore 
relating the expression of any protein to specific cell type(s) was hindered. Any slight 
fold change at the mRNA level, as shown by the candidate genes investigated in this 
study, may not directly relate to proteomic changes. With additional work, LCM could 
be used to isolate astrocytes for proteomic studies, including MALDI-MS and WB. 
Using LCM-ed isolated astrocytes in proteomic studies would also link the expression 
of the candidate proteins or other novel proteins to astrocytes rather than a whole tissue 
extract, as attempted in the current study. Similar approaches using LCM coupled with 
WB have been completed (Koob et al 2012, Martinet et al 2004, Mu et al 2013), but 
without the equivalent protein amplification methods as for RNA, acquiring enough 
protein for WB via LCM may prove challenging (Mu et al 2013). 
In the same way that microarray analysis allows for a non-candidate approach when 
investigating transcriptomic changes between disease and control cases, MALDI is also 
capable of demonstrating the same non-candidate approach when investigating protein 
expression, without the need for specific antibodies. The technique can also be used to 
image the localisation of molecules across a tissue section using MSI, as seen in 
previous investigations on peptide and protein expression in animal models of PD 
(Hanrieder et al 2012, Skold et al 2006, Stauber et al 2008) and AD (Rohner et al 2005, 
Stoeckli et al 2006, Stoeckli et al 2002). In the current study, the identification of 
candidate proteins through MALDI-MS due to time restraints and instrumentation 
issues was not achieved. Conclusions drawn from the mass spectrometry work 
completed, identified no significant differences in the peptide/proteins profiles between 
the MS NAWM and control WM cases used in the current study. Yet with further 
optimisation of techniques, sample preparation and increased number of biological and 
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technical repeats MALDI-MS is a promising tool in proteomic research with many 
advantages. MALDI-MS has also been employed previously to look at the protein 
expression of LCM-ed isolated cells (Bhattacharya et al 2003, Sanders et al 2008, Xu et 
al 2002), which with additional work and optimisation could be employed to extend the 
current study to relate protein expression directly to astrocytes. 
In vitro studies could help to gain a better understanding of the effect of increasing iron 
concentration on astrocytes overtime, and whether increased astrocytic expression of 
FT, TF and MT occurs with increasing levels of iron and oxidative stress. In vitro time 
course experiments could be carried out to see how astrocytes respond to prolonged 
exposure to increased iron and oxidative stress to identify the extent of their iron 
regulating homeostasis capabilities. While the introduction of various metal chelators 
and their effects on levels of iron and oxidative stress in culture could be monitored, 
along with the effects of any potential therapeutic approach on the overall astrocytes 
behaviour. Investigating co-culture systems of astrocytes, neurons and other glial cells 
may further enhance the knowledge of the role of astrocytes in response to increasing 
iron levels, and the effects on surrounding cell types, and is more similar to the in vivo 
setting than studies carried out on pure astrocyte cultures. As well studies investigating 
induced pluripotent stem cells (iPSC) derived from MS and control patients could 
enable researchers to gain a better understanding of iPSC derived glial cells and their 
association and possible role in iron metabolism and oxidative stress in MS 
pathogenesis. These studies must be considered carefully in light of the current lack of 
understanding about iron metabolism and regulation within the CNS and based on the 
current conflicting results of TF/TFR expression in astrocytes in vitro compared to in 
vivo.  
Microarray studies, including those carried out in this thesis are non-hypothesis driven 
approaches to research which lead to the generation of specific scientific questions, 
hypotheses and lines of investigation. Along with the proposed role of astrocytes in 
regulating iron and oxidative stress in MS, other potential areas for further research 
have been postulated. Additional candidate groups of genes derived from the current 
study include the astrocyte’s role in the immune response, regularly associated with MS, 
along with the changes in cytoskeletal genes associated with MS NAWM astrocytes, all 
avenues worthy of further investigation. Additional studies isolating astrocytes by 
immuno-LCM using an alternative astrocyte marker may provide an additional insight 
into the role of astrocytes in the pathogenesis of MS. Again, the necessity for a pan-
252 
 
astrocyte marker to gain a more thorough understanding of astrocytes in relation to 
disease is paramount. Furthermore extending the study to isolate other glial populations 
from PM MS NAWM, including microglia and oligodendrocytes, would enable the 
comparison of their transcriptome to decipher how these cells interact and what role(s) 
they play in driving and/or preventing lesion pathogenesis. Comparison of the current 
gene expression profile of astrocytes in MS to the astrocyte transcriptome in other 
neurological diseases such as AD, ALS and PD would enable identification of any 
common genes and disease specific genes across diverse neurological pathologies. 
6.1 Potential therapeutics 
Developing a clearer understanding of the mechanisms involved in iron-induced 
oxidative stress within the brain in MS is essential in designing novel therapeutic 
agents. Iron dysregulation has been linked to several neurodegenerative diseases such as 
PD, AD and ALS, with current iron chelating therapeutics designed to block the redox-
activity of iron, and its contribution in disease progression (Farina et al 2013). 
Ultimately these types of therapeutics could also help in MS, where increasing evidence 
has identified iron as having a key role in disease pathogenesis (Hametner et al 2013, 
Lassmann et al 2012, Williams et al 2012). There are three currently developed types of 
metal chelator, the chemical iron chelators, natural iron chelators and endogenous iron 
chelators with increasing evidence of their neuroprotective effects in neurodegenerative 
disease (Li et al 2011). For example, the chemical iron chelator desferrioxamine (DFO) 
has been shown to prevent neuronal degeneration in the 6-hydroxydopamine (6-
OHDA)-induced rat experimental model of PD (Zhang et al 2005). Natural iron 
chelators are found in plant material such as epigallocatechin gallate (EGCG) and 
curcumin. In addition, phenols such as quercetin, a key antioxidant and present in a 
variety of Chinese medicines have demonstrated strong iron chelation properties (Perez 
et al 2008). Endogenous iron chelators, such as FT have shown to not only to sequester 
free iron but also convert it into non-toxic ferric iron due to the ferroxidase function of 
such chelators.  
The neuroprotective function of iron chelation may derive from the reduction of 
oxidative stress, alongside iron chelator treatment, therefore antioxidant therapies could 
also help prevent widespread damage caused by oxidative species in MS. Endogenous 
antioxidants include glutathione peroxidase, catalase and SOD, which directly eliminate 
ROS including hydroxyl radicals, superoxide radical and hydrogen peroxide (Guerra-
Araiza et al 2013). The levels of endogenous antioxidants are said to decline in a 
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number of neurodegenerative diseases and with age (Finkel & Holbrook 2000). The 
most widely studied antioxidants are the common dietary type including vitamin C and 
vitamin E (Guerra-Araiza et al 2013). Alongside the traditional vitamins are the 
phytochemicals including flavonoids, which are found in fruits, flowers, seeds, 
medicinal plants and olive oil holding a number of beneficial properties including anti-
inflammatory, anticarcinogenic, antibacterial and antiviral properties (Joseph et al 2007, 
Rossi et al 2008). Flavonoids are also capable of scavenging free radicals and 
modulating intracellular signals to promote cell survival, acting in a neuroprotective 
manner against oxidative stress (Joseph et al 2007, Mercer et al 2005, Rossi et al 2008). 
The most potent flavonoid antioxidant is quercetin capable of scavenging ROS and 
binding transition metal irons, including iron along with its strong anti-inflammatory 
function (Georgetti et al 2003, Nijveldt et al 2001) making it a key potential therapeutic 
in regulating iron toxicity and oxidative damage in MS. Consequently, therapy 
established to limit iron induced oxidative damage in PD, AD and ALS should be 
contemplated in MS, where an increase in iron induced oxidative stress is also apparent.  
6.2 Overall conclusions 
Although the results from this thesis are not entirely conclusive, from the top 20 
significantly upregulated genes observed in the microarray study comparing the 
transcriptome of MS NAWM astrocytes and control WM astrocytes, six were related to 
the regulation of iron and oxidative stress. The role of oxidative stress is widely 
acknowledged in MS (Hametner et al 2013, Lassmann et al 2012, LeVine et al 2013, 
Williams et al 2012) and also in other neurological disorders (Crichton et al 2011, 
Johnstone & Milward 2010, Mills et al 2010, Skjorringe et al 2012) and warrants 
further investigation. Evidently a clear alteration in astrocyte phenotype in MS suggests 
a change in their normal function, with this study demonstrating the protein expression 
of the candidate genes colocalised with GFAP+ astrocytes in MS NAWM. Studying and 
debating the function/role of astrocytes in the different MS lesion types is important but 
fails to address the underlying cause of lesion pathogenesis and the processes by which 
these lesions spread. No other study to date has investigated in detail the role of 
astrocytes with respect to MS NAWM. It is however, extremely important that future 
research focusses on the NAWM and astrocytes to determine the mechanisms/processes 
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